id	sid	tid	token	lemma	pos
cord-313227-6zwkfzab	1	1	key	key	NN
cord-313227-6zwkfzab	1	2	:	:	:
cord-313227-6zwkfzab	2	1	cord-313227	cord-313227	NN
cord-313227-6zwkfzab	2	2	-	-	HYPH
cord-313227-6zwkfzab	2	3	6zwkfzab	6zwkfzab	CD
cord-313227-6zwkfzab	2	4	authors	author	NNS
cord-313227-6zwkfzab	2	5	:	:	:
cord-313227-6zwkfzab	2	6	Scala	Scala	NNP
cord-313227-6zwkfzab	2	7	,	,	,
cord-313227-6zwkfzab	2	8	Stefania	Stefania	NNP
cord-313227-6zwkfzab	2	9	;	;	:
cord-313227-6zwkfzab	2	10	Pacelli	Pacelli	NNP
cord-313227-6zwkfzab	2	11	,	,	,
cord-313227-6zwkfzab	2	12	Roberto	roberto	JJ
cord-313227-6zwkfzab	2	13	title	title	NN
cord-313227-6zwkfzab	2	14	:	:	:
cord-313227-6zwkfzab	2	15	Fighting	fight	VBG
cord-313227-6zwkfzab	2	16	the	the	DT
cord-313227-6zwkfzab	2	17	Host	Host	NNP
cord-313227-6zwkfzab	2	18	Reaction	Reaction	NNP
cord-313227-6zwkfzab	2	19	to	to	IN
cord-313227-6zwkfzab	2	20	SARS	SARS	NNP
cord-313227-6zwkfzab	2	21	-	-	HYPH
cord-313227-6zwkfzab	2	22	COv-2	COv-2	NNP
cord-313227-6zwkfzab	2	23	in	in	IN
cord-313227-6zwkfzab	2	24	Critically	Critically	NNP
cord-313227-6zwkfzab	2	25	Ill	Ill	NNP
cord-313227-6zwkfzab	2	26	Patients	patient	NNS
cord-313227-6zwkfzab	2	27	:	:	:
cord-313227-6zwkfzab	3	1	The	the	DT
cord-313227-6zwkfzab	3	2	Possible	possible	JJ
cord-313227-6zwkfzab	3	3	Contribution	Contribution	NNP
cord-313227-6zwkfzab	3	4	of	of	IN
cord-313227-6zwkfzab	3	5	Off	Off	NNP
cord-313227-6zwkfzab	3	6	-	-	HYPH
cord-313227-6zwkfzab	3	7	Label	label	NN
cord-313227-6zwkfzab	3	8	Drugs	drug	NNS
cord-313227-6zwkfzab	3	9	date	date	NN
cord-313227-6zwkfzab	3	10	:	:	:
cord-313227-6zwkfzab	3	11	2020	2020	CD
cord-313227-6zwkfzab	3	12	-	-	HYPH
cord-313227-6zwkfzab	3	13	05	05	CD
cord-313227-6zwkfzab	3	14	-	-	HYPH
cord-313227-6zwkfzab	3	15	27	27	CD
cord-313227-6zwkfzab	3	16	journal	journal	NN
cord-313227-6zwkfzab	3	17	:	:	:
cord-313227-6zwkfzab	4	1	Front	Front	NNP
cord-313227-6zwkfzab	4	2	Immunol	Immunol	NNP
cord-313227-6zwkfzab	4	3	DOI	doi	NN
cord-313227-6zwkfzab	4	4	:	:	:
cord-313227-6zwkfzab	5	1	10.3389/	10.3389/	CD
cord-313227-6zwkfzab	6	1	fimmu.2020.01201	fimmu.2020.01201	NNS
cord-313227-6zwkfzab	7	1	sha	sha	NNP
cord-313227-6zwkfzab	7	2	:	:	:
cord-313227-6zwkfzab	7	3	e8b7e8a0e867e0815fc9f9e7ec1770b0b9101297	e8b7e8a0e867e0815fc9f9e7ec1770b0b9101297	VB
cord-313227-6zwkfzab	7	4	doc_id	doc_id	CD
cord-313227-6zwkfzab	7	5	:	:	:
cord-313227-6zwkfzab	7	6	313227	313227	CD
cord-313227-6zwkfzab	7	7	cord_uid	cord_uid	NN
cord-313227-6zwkfzab	7	8	:	:	:
cord-313227-6zwkfzab	8	1	6zwkfzab	6zwkfzab	LS
cord-313227-6zwkfzab	8	2	The	the	DT
cord-313227-6zwkfzab	8	3	severe	severe	JJ
cord-313227-6zwkfzab	8	4	acute	acute	JJ
cord-313227-6zwkfzab	8	5	respiratory	respiratory	JJ
cord-313227-6zwkfzab	8	6	syndrome	syndrome	NN
cord-313227-6zwkfzab	8	7	coronavirus	coronavirus	NN
cord-313227-6zwkfzab	8	8	2	2	CD
cord-313227-6zwkfzab	8	9	(	(	-LRB-
cord-313227-6zwkfzab	8	10	SARS	SARS	NNP
cord-313227-6zwkfzab	8	11	-	-	HYPH
cord-313227-6zwkfzab	8	12	COv-2	COv-2	NNP
cord-313227-6zwkfzab	8	13	)	)	-RRB-
cord-313227-6zwkfzab	8	14	is	be	VBZ
cord-313227-6zwkfzab	8	15	the	the	DT
cord-313227-6zwkfzab	8	16	etiologic	etiologic	JJ
cord-313227-6zwkfzab	8	17	agent	agent	NN
cord-313227-6zwkfzab	8	18	of	of	IN
cord-313227-6zwkfzab	8	19	the	the	DT
cord-313227-6zwkfzab	8	20	2019	2019	CD
cord-313227-6zwkfzab	8	21	coronavirus	coronavirus	NN
cord-313227-6zwkfzab	8	22	disease	disease	NN
cord-313227-6zwkfzab	8	23	(	(	-LRB-
cord-313227-6zwkfzab	8	24	COVID19	covid19	NN
cord-313227-6zwkfzab	8	25	)	)	-RRB-
cord-313227-6zwkfzab	8	26	.	.	.
cord-313227-6zwkfzab	9	1	The	the	DT
cord-313227-6zwkfzab	9	2	majority	majority	NN
cord-313227-6zwkfzab	9	3	of	of	IN
cord-313227-6zwkfzab	9	4	infected	infected	JJ
cord-313227-6zwkfzab	9	5	people	people	NNS
cord-313227-6zwkfzab	9	6	presents	present	VBZ
cord-313227-6zwkfzab	9	7	flu	flu	NN
cord-313227-6zwkfzab	9	8	like	like	IN
cord-313227-6zwkfzab	9	9	symptoms	symptom	NNS
cord-313227-6zwkfzab	9	10	and	and	CC
cord-313227-6zwkfzab	10	1	among	among	IN
cord-313227-6zwkfzab	10	2	them	-PRON-	PRP
cord-313227-6zwkfzab	10	3	15–20	15–20	CD
cord-313227-6zwkfzab	10	4	%	%	NN
cord-313227-6zwkfzab	10	5	develops	develop	VBZ
cord-313227-6zwkfzab	10	6	a	a	DT
cord-313227-6zwkfzab	10	7	severe	severe	JJ
cord-313227-6zwkfzab	10	8	interstitial	interstitial	JJ
cord-313227-6zwkfzab	10	9	pneumonitis	pneumonitis	NN
cord-313227-6zwkfzab	10	10	(	(	-LRB-
cord-313227-6zwkfzab	10	11	IP	IP	NNP
cord-313227-6zwkfzab	10	12	)	)	-RRB-
cord-313227-6zwkfzab	10	13	that	that	WDT
cord-313227-6zwkfzab	10	14	may	may	MD
cord-313227-6zwkfzab	10	15	eventually	eventually	RB
cord-313227-6zwkfzab	10	16	evolve	evolve	VB
cord-313227-6zwkfzab	10	17	in	in	IN
cord-313227-6zwkfzab	10	18	acute	acute	JJ
cord-313227-6zwkfzab	10	19	respiratory	respiratory	JJ
cord-313227-6zwkfzab	10	20	distress	distress	NN
cord-313227-6zwkfzab	10	21	syndrome	syndrome	NN
cord-313227-6zwkfzab	10	22	(	(	-LRB-
cord-313227-6zwkfzab	10	23	ARDS	ARDS	NNP
cord-313227-6zwkfzab	10	24	)	)	-RRB-
cord-313227-6zwkfzab	10	25	.	.	.
cord-313227-6zwkfzab	11	1	IP	IP	NNP
cord-313227-6zwkfzab	11	2	is	be	VBZ
cord-313227-6zwkfzab	11	3	caused	cause	VBN
cord-313227-6zwkfzab	11	4	by	by	IN
cord-313227-6zwkfzab	11	5	the	the	DT
cord-313227-6zwkfzab	11	6	viral	viral	JJ
cord-313227-6zwkfzab	11	7	glycoprotein	glycoprotein	NN
cord-313227-6zwkfzab	11	8	spike	spike	NN
cord-313227-6zwkfzab	11	9	(	(	-LRB-
cord-313227-6zwkfzab	11	10	S	s	NN
cord-313227-6zwkfzab	11	11	)	)	-RRB-
cord-313227-6zwkfzab	11	12	binding	bind	VBG
cord-313227-6zwkfzab	11	13	to	to	IN
cord-313227-6zwkfzab	11	14	the	the	DT
cord-313227-6zwkfzab	11	15	angiotensin	angiotensin	NN
cord-313227-6zwkfzab	11	16	converting	convert	VBG
cord-313227-6zwkfzab	11	17	enzyme	enzyme	NN
cord-313227-6zwkfzab	11	18	2	2	CD
cord-313227-6zwkfzab	11	19	(	(	-LRB-
cord-313227-6zwkfzab	11	20	ACE2	ACE2	NNP
cord-313227-6zwkfzab	11	21	)	)	-RRB-
cord-313227-6zwkfzab	11	22	expressed	express	VBD
cord-313227-6zwkfzab	11	23	on	on	IN
cord-313227-6zwkfzab	11	24	the	the	DT
cord-313227-6zwkfzab	11	25	surface	surface	NN
cord-313227-6zwkfzab	11	26	of	of	IN
cord-313227-6zwkfzab	11	27	alveolar	alveolar	NN
cord-313227-6zwkfzab	11	28	pneumocytes	pneumocyte	NNS
cord-313227-6zwkfzab	11	29	.	.	.
cord-313227-6zwkfzab	12	1	The	the	DT
cord-313227-6zwkfzab	12	2	virus	virus	NN
cord-313227-6zwkfzab	12	3	is	be	VBZ
cord-313227-6zwkfzab	12	4	recognized	recognize	VBN
cord-313227-6zwkfzab	12	5	by	by	IN
cord-313227-6zwkfzab	12	6	the	the	DT
cord-313227-6zwkfzab	12	7	“	"	``
cord-313227-6zwkfzab	12	8	pattern	pattern	NN
cord-313227-6zwkfzab	12	9	recognition	recognition	NN
cord-313227-6zwkfzab	12	10	receptors	receptor	NNS
cord-313227-6zwkfzab	12	11	”	"	''
cord-313227-6zwkfzab	12	12	(	(	-LRB-
cord-313227-6zwkfzab	12	13	PRR	PRR	NNP
cord-313227-6zwkfzab	12	14	)	)	-RRB-
cord-313227-6zwkfzab	12	15	of	of	IN
cord-313227-6zwkfzab	12	16	the	the	DT
cord-313227-6zwkfzab	12	17	immune	immune	JJ
cord-313227-6zwkfzab	12	18	cells	cell	NNS
cord-313227-6zwkfzab	12	19	that	that	WDT
cord-313227-6zwkfzab	12	20	release	release	VBP
cord-313227-6zwkfzab	12	21	cytokines	cytokine	NNS
cord-313227-6zwkfzab	12	22	activating	activate	VBG
cord-313227-6zwkfzab	12	23	more	more	JJR
cord-313227-6zwkfzab	12	24	immune	immune	JJ
cord-313227-6zwkfzab	12	25	cells	cell	NNS
cord-313227-6zwkfzab	12	26	that	that	WDT
cord-313227-6zwkfzab	12	27	produce	produce	VBP
cord-313227-6zwkfzab	12	28	a	a	DT
cord-313227-6zwkfzab	12	29	large	large	JJ
cord-313227-6zwkfzab	12	30	number	number	NN
cord-313227-6zwkfzab	12	31	of	of	IN
cord-313227-6zwkfzab	12	32	pro	pro	JJ
cord-313227-6zwkfzab	12	33	-	-	JJ
cord-313227-6zwkfzab	12	34	inflammatory	inflammatory	JJ
cord-313227-6zwkfzab	12	35	cytokines	cytokine	NNS
cord-313227-6zwkfzab	12	36	,	,	,
cord-313227-6zwkfzab	12	37	tissue	tissue	NN
cord-313227-6zwkfzab	12	38	factors	factor	NNS
cord-313227-6zwkfzab	12	39	and	and	CC
cord-313227-6zwkfzab	12	40	vasoactive	vasoactive	JJ
cord-313227-6zwkfzab	12	41	peptides	peptide	NNS
cord-313227-6zwkfzab	12	42	.	.	.
cord-313227-6zwkfzab	13	1	Affected	affected	JJ
cord-313227-6zwkfzab	13	2	patients	patient	NNS
cord-313227-6zwkfzab	13	3	might	may	MD
cord-313227-6zwkfzab	13	4	develop	develop	VB
cord-313227-6zwkfzab	13	5	the	the	DT
cord-313227-6zwkfzab	13	6	“	"	``
cord-313227-6zwkfzab	13	7	cytokine	cytokine	NN
cord-313227-6zwkfzab	13	8	storm	storm	NN
cord-313227-6zwkfzab	13	9	syndrome	syndrome	NN
cord-313227-6zwkfzab	13	10	,	,	,
cord-313227-6zwkfzab	13	11	”	"	''
cord-313227-6zwkfzab	13	12	a	a	DT
cord-313227-6zwkfzab	13	13	fulminant	fulminant	JJ
cord-313227-6zwkfzab	13	14	and	and	CC
cord-313227-6zwkfzab	13	15	fatal	fatal	JJ
cord-313227-6zwkfzab	13	16	hypercytokinaemia	hypercytokinaemia	NN
cord-313227-6zwkfzab	13	17	with	with	IN
cord-313227-6zwkfzab	13	18	multiorgan	multiorgan	NNP
cord-313227-6zwkfzab	13	19	failure	failure	NN
cord-313227-6zwkfzab	13	20	.	.	.
cord-313227-6zwkfzab	14	1	In	in	IN
cord-313227-6zwkfzab	14	2	patients	patient	NNS
cord-313227-6zwkfzab	14	3	infected	infect	VBN
cord-313227-6zwkfzab	14	4	by	by	IN
cord-313227-6zwkfzab	14	5	SARS	SARS	NNP
cord-313227-6zwkfzab	14	6	-	-	HYPH
cord-313227-6zwkfzab	14	7	COv-2	COv-2	NNP
cord-313227-6zwkfzab	14	8	increase	increase	NN
cord-313227-6zwkfzab	14	9	in	in	IN
cord-313227-6zwkfzab	14	10	T	t	NN
cord-313227-6zwkfzab	14	11	-	-	HYPH
cord-313227-6zwkfzab	14	12	helper	helper	NN
cord-313227-6zwkfzab	14	13	2	2	CD
cord-313227-6zwkfzab	15	1	(	(	-LRB-
cord-313227-6zwkfzab	15	2	TH2	TH2	NNP
cord-313227-6zwkfzab	15	3	)	)	-RRB-
cord-313227-6zwkfzab	15	4	cytokines	cytokine	NNS
cord-313227-6zwkfzab	15	5	(	(	-LRB-
cord-313227-6zwkfzab	15	6	IL-4	IL-4	NNP
cord-313227-6zwkfzab	15	7	and	and	CC
cord-313227-6zwkfzab	15	8	IL10	IL10	NNP
cord-313227-6zwkfzab	15	9	)	)	-RRB-
cord-313227-6zwkfzab	15	10	are	be	VBP
cord-313227-6zwkfzab	15	11	reported	report	VBN
cord-313227-6zwkfzab	15	12	in	in	IN
cord-313227-6zwkfzab	15	13	addition	addition	NN
cord-313227-6zwkfzab	15	14	to	to	IN
cord-313227-6zwkfzab	15	15	the	the	DT
cord-313227-6zwkfzab	15	16	T	T	NNP
cord-313227-6zwkfzab	15	17	-	-	HYPH
cord-313227-6zwkfzab	15	18	helper	helper	NN
cord-313227-6zwkfzab	15	19	1	1	CD
cord-313227-6zwkfzab	15	20	(	(	-LRB-
cord-313227-6zwkfzab	15	21	TH1	TH1	NNP
cord-313227-6zwkfzab	15	22	)	)	-RRB-
cord-313227-6zwkfzab	15	23	cytokines	cytokine	NNS
cord-313227-6zwkfzab	15	24	(	(	-LRB-
cord-313227-6zwkfzab	15	25	IL1B	il1b	NN
cord-313227-6zwkfzab	15	26	,	,	,
cord-313227-6zwkfzab	15	27	IFNγ	IFNγ	NNS
cord-313227-6zwkfzab	15	28	,	,	,
cord-313227-6zwkfzab	15	29	IP10	IP10	NNP
cord-313227-6zwkfzab	15	30	,	,	,
cord-313227-6zwkfzab	15	31	and	and	CC
cord-313227-6zwkfzab	15	32	MCP1	MCP1	NNP
cord-313227-6zwkfzab	15	33	)	)	-RRB-
cord-313227-6zwkfzab	15	34	previously	previously	RB
cord-313227-6zwkfzab	15	35	detected	detect	VBN
cord-313227-6zwkfzab	15	36	in	in	IN
cord-313227-6zwkfzab	15	37	other	other	JJ
cord-313227-6zwkfzab	15	38	coronavirus	coronavirus	NN
cord-313227-6zwkfzab	15	39	infections	infection	NNS
cord-313227-6zwkfzab	15	40	.	.	.
cord-313227-6zwkfzab	16	1	Cytokines	cytokine	NNS
cord-313227-6zwkfzab	16	2	and	and	CC
cord-313227-6zwkfzab	16	3	other	other	JJ
cord-313227-6zwkfzab	16	4	molecules	molecule	NNS
cord-313227-6zwkfzab	16	5	involved	involve	VBN
cord-313227-6zwkfzab	16	6	in	in	IN
cord-313227-6zwkfzab	16	7	immune	immune	JJ
cord-313227-6zwkfzab	16	8	response	response	NN
cord-313227-6zwkfzab	16	9	and	and	CC
cord-313227-6zwkfzab	16	10	inflammation	inflammation	NN
cord-313227-6zwkfzab	16	11	are	be	VBP
cord-313227-6zwkfzab	16	12	conceivable	conceivable	JJ
cord-313227-6zwkfzab	16	13	therapeutic	therapeutic	JJ
cord-313227-6zwkfzab	16	14	targets	target	NNS
cord-313227-6zwkfzab	16	15	for	for	IN
cord-313227-6zwkfzab	16	16	IP	IP	NNP
cord-313227-6zwkfzab	16	17	and	and	CC
cord-313227-6zwkfzab	16	18	ARDS	ARDS	NNP
cord-313227-6zwkfzab	16	19	,	,	,
cord-313227-6zwkfzab	16	20	improving	improve	VBG
cord-313227-6zwkfzab	16	21	symptoms	symptom	NNS
cord-313227-6zwkfzab	16	22	and	and	CC
cord-313227-6zwkfzab	16	23	decreasing	decrease	VBG
cord-313227-6zwkfzab	16	24	intensive	intensive	JJ
cord-313227-6zwkfzab	16	25	care	care	NN
cord-313227-6zwkfzab	16	26	unit	unit	NN
cord-313227-6zwkfzab	16	27	admissions	admission	NNS
cord-313227-6zwkfzab	16	28	.	.	.
cord-313227-6zwkfzab	17	1	To	to	IN
cord-313227-6zwkfzab	17	2	this	this	DT
cord-313227-6zwkfzab	17	3	aim	aim	VB
cord-313227-6zwkfzab	17	4	off	off	RP
cord-313227-6zwkfzab	17	5	label	label	NN
cord-313227-6zwkfzab	17	6	drugs	drug	NNS
cord-313227-6zwkfzab	17	7	may	may	MD
cord-313227-6zwkfzab	17	8	be	be	VB
cord-313227-6zwkfzab	17	9	used	use	VBN
cord-313227-6zwkfzab	17	10	taking	take	VBG
cord-313227-6zwkfzab	17	11	into	into	IN
cord-313227-6zwkfzab	17	12	consideration	consideration	NN
cord-313227-6zwkfzab	17	13	the	the	DT
cord-313227-6zwkfzab	17	14	window	window	NN
cord-313227-6zwkfzab	17	15	timing	timing	NN
cord-313227-6zwkfzab	17	16	for	for	IN
cord-313227-6zwkfzab	17	17	immunosuppressive	immunosuppressive	JJ
cord-313227-6zwkfzab	17	18	drugs	drug	NNS
cord-313227-6zwkfzab	17	19	in	in	IN
cord-313227-6zwkfzab	17	20	virus	virus	NN
cord-313227-6zwkfzab	17	21	infected	infect	VBN
cord-313227-6zwkfzab	17	22	patients	patient	NNS
cord-313227-6zwkfzab	17	23	.	.	.
cord-313227-6zwkfzab	18	1	Some	some	DT
cord-313227-6zwkfzab	18	2	off	off	RP
cord-313227-6zwkfzab	18	3	label	label	NN
cord-313227-6zwkfzab	18	4	therapeutic	therapeutic	JJ
cord-313227-6zwkfzab	18	5	options	option	NNS
cord-313227-6zwkfzab	18	6	and	and	CC
cord-313227-6zwkfzab	18	7	preclinical	preclinical	JJ
cord-313227-6zwkfzab	18	8	evidence	evidence	NN
cord-313227-6zwkfzab	18	9	drugs	drug	NNS
cord-313227-6zwkfzab	18	10	are	be	VBP
cord-313227-6zwkfzab	18	11	herein	herein	RB
cord-313227-6zwkfzab	18	12	considered	consider	VBN
cord-313227-6zwkfzab	18	13	.	.	.
cord-313227-6zwkfzab	19	1	In	in	IN
cord-313227-6zwkfzab	19	2	a	a	DT
cord-313227-6zwkfzab	19	3	report	report	NN
cord-313227-6zwkfzab	19	4	on	on	IN
cord-313227-6zwkfzab	19	5	more	more	JJR
cord-313227-6zwkfzab	19	6	than	than	IN
cord-313227-6zwkfzab	19	7	70	70	CD
cord-313227-6zwkfzab	19	8	thousands	thousand	NNS
cord-313227-6zwkfzab	19	9	patients	patient	NNS
cord-313227-6zwkfzab	19	10	of	of	IN
cord-313227-6zwkfzab	19	11	the	the	DT
cord-313227-6zwkfzab	19	12	Chinese	chinese	JJ
cord-313227-6zwkfzab	19	13	province	province	NN
cord-313227-6zwkfzab	19	14	of	of	IN
cord-313227-6zwkfzab	19	15	Hubei	Hubei	NNP
cord-313227-6zwkfzab	19	16	,	,	,
cord-313227-6zwkfzab	19	17	the	the	DT
cord-313227-6zwkfzab	19	18	majority	majority	NN
cord-313227-6zwkfzab	19	19	of	of	IN
cord-313227-6zwkfzab	19	20	infected	infected	JJ
cord-313227-6zwkfzab	19	21	symptomatic	symptomatic	JJ
cord-313227-6zwkfzab	19	22	people	people	NNS
cord-313227-6zwkfzab	19	23	presented	present	VBD
cord-313227-6zwkfzab	19	24	flu	flu	NN
cord-313227-6zwkfzab	19	25	like	like	IN
cord-313227-6zwkfzab	19	26	symptoms	symptom	NNS
cord-313227-6zwkfzab	19	27	(	(	-LRB-
cord-313227-6zwkfzab	19	28	mainly	mainly	RB
cord-313227-6zwkfzab	19	29	fever	fever	NN
cord-313227-6zwkfzab	19	30	and	and	CC
cord-313227-6zwkfzab	19	31	cough	cough	NN
cord-313227-6zwkfzab	19	32	)	)	-RRB-
cord-313227-6zwkfzab	19	33	,	,	,
cord-313227-6zwkfzab	19	34	with	with	IN
cord-313227-6zwkfzab	19	35	15	15	CD
cord-313227-6zwkfzab	19	36	-	-	SYM
cord-313227-6zwkfzab	19	37	20	20	CD
cord-313227-6zwkfzab	19	38	%	%	NN
cord-313227-6zwkfzab	19	39	of	of	IN
cord-313227-6zwkfzab	19	40	patients	patient	NNS
cord-313227-6zwkfzab	19	41	developing	develop	VBG
cord-313227-6zwkfzab	19	42	a	a	DT
cord-313227-6zwkfzab	19	43	severe	severe	JJ
cord-313227-6zwkfzab	19	44	interstitial	interstitial	JJ
cord-313227-6zwkfzab	19	45	pneumonitis	pneumonitis	NN
cord-313227-6zwkfzab	19	46	(	(	-LRB-
cord-313227-6zwkfzab	19	47	IP	IP	NNP
cord-313227-6zwkfzab	19	48	)	)	-RRB-
cord-313227-6zwkfzab	19	49	that	that	WDT
cord-313227-6zwkfzab	19	50	could	could	MD
cord-313227-6zwkfzab	19	51	evolve	evolve	VB
cord-313227-6zwkfzab	19	52	in	in	IN
cord-313227-6zwkfzab	19	53	acute	acute	JJ
cord-313227-6zwkfzab	19	54	respiratory	respiratory	JJ
cord-313227-6zwkfzab	19	55	distress	distress	NN
cord-313227-6zwkfzab	19	56	syndrome	syndrome	NN
cord-313227-6zwkfzab	19	57	(	(	-LRB-
cord-313227-6zwkfzab	19	58	ARDS	ARDS	NNP
cord-313227-6zwkfzab	19	59	)	)	-RRB-
cord-313227-6zwkfzab	19	60	.	.	.
cord-313227-6zwkfzab	20	1	The	the	DT
cord-313227-6zwkfzab	20	2	case	case	NN
cord-313227-6zwkfzab	20	3	fatality	fatality	NN
cord-313227-6zwkfzab	20	4	rate	rate	NN
cord-313227-6zwkfzab	20	5	in	in	IN
cord-313227-6zwkfzab	20	6	the	the	DT
cord-313227-6zwkfzab	20	7	whole	whole	JJ
cord-313227-6zwkfzab	20	8	population	population	NN
cord-313227-6zwkfzab	20	9	resulted	result	VBD
cord-313227-6zwkfzab	20	10	2.3	2.3	CD
cord-313227-6zwkfzab	20	11	%	%	NN
cord-313227-6zwkfzab	20	12	(	(	-LRB-
cord-313227-6zwkfzab	20	13	8	8	CD
cord-313227-6zwkfzab	20	14	and	and	CC
cord-313227-6zwkfzab	20	15	15	15	CD
cord-313227-6zwkfzab	20	16	%	%	NN
cord-313227-6zwkfzab	20	17	,	,	,
cord-313227-6zwkfzab	20	18	for	for	IN
cord-313227-6zwkfzab	20	19	patients	patient	NNS
cord-313227-6zwkfzab	20	20	older	old	JJR
cord-313227-6zwkfzab	20	21	than	than	IN
cord-313227-6zwkfzab	20	22	70	70	CD
cord-313227-6zwkfzab	20	23	and	and	CC
cord-313227-6zwkfzab	20	24	80	80	CD
cord-313227-6zwkfzab	20	25	,	,	,
cord-313227-6zwkfzab	20	26	respectively	respectively	RB
cord-313227-6zwkfzab	20	27	)	)	-RRB-
cord-313227-6zwkfzab	20	28	.	.	.
cord-313227-6zwkfzab	21	1	In	in	IN
cord-313227-6zwkfzab	21	2	critical	critical	JJ
cord-313227-6zwkfzab	21	3	patients	patient	NNS
cord-313227-6zwkfzab	21	4	49	49	CD
cord-313227-6zwkfzab	21	5	%	%	NN
cord-313227-6zwkfzab	21	6	of	of	IN
cord-313227-6zwkfzab	21	7	case	case	NN
cord-313227-6zwkfzab	21	8	fatality	fatality	NN
cord-313227-6zwkfzab	21	9	rate	rate	NN
cord-313227-6zwkfzab	21	10	was	be	VBD
cord-313227-6zwkfzab	21	11	registered	register	VBN
cord-313227-6zwkfzab	21	12	(	(	-LRB-
cord-313227-6zwkfzab	21	13	4	4	CD
cord-313227-6zwkfzab	21	14	)	)	-RRB-
cord-313227-6zwkfzab	21	15	.	.	.
cord-313227-6zwkfzab	22	1	IP	IP	NNP
cord-313227-6zwkfzab	22	2	is	be	VBZ
cord-313227-6zwkfzab	22	3	caused	cause	VBN
cord-313227-6zwkfzab	22	4	by	by	IN
cord-313227-6zwkfzab	22	5	the	the	DT
cord-313227-6zwkfzab	22	6	attack	attack	NN
cord-313227-6zwkfzab	22	7	of	of	IN
cord-313227-6zwkfzab	22	8	the	the	DT
cord-313227-6zwkfzab	22	9	virus	virus	NN
cord-313227-6zwkfzab	22	10	against	against	IN
cord-313227-6zwkfzab	22	11	the	the	DT
cord-313227-6zwkfzab	22	12	alveolar	alveolar	NN
cord-313227-6zwkfzab	22	13	pneumocytes	pneumocyte	NNS
cord-313227-6zwkfzab	22	14	(	(	-LRB-
cord-313227-6zwkfzab	22	15	APs	APs	NNP
cord-313227-6zwkfzab	22	16	)	)	-RRB-
cord-313227-6zwkfzab	22	17	through	through	IN
cord-313227-6zwkfzab	22	18	the	the	DT
cord-313227-6zwkfzab	22	19	binding	binding	NN
cord-313227-6zwkfzab	22	20	of	of	IN
cord-313227-6zwkfzab	22	21	the	the	DT
cord-313227-6zwkfzab	22	22	viral	viral	JJ
cord-313227-6zwkfzab	22	23	glycoprotein	glycoprotein	NN
cord-313227-6zwkfzab	22	24	(	(	-LRB-
cord-313227-6zwkfzab	22	25	spike	spike	NN
cord-313227-6zwkfzab	22	26	,	,	,
cord-313227-6zwkfzab	22	27	S	S	NNP
cord-313227-6zwkfzab	22	28	)	)	-RRB-
cord-313227-6zwkfzab	22	29	to	to	IN
cord-313227-6zwkfzab	22	30	the	the	DT
cord-313227-6zwkfzab	22	31	angiotensin	angiotensin	NN
cord-313227-6zwkfzab	22	32	converting	convert	VBG
cord-313227-6zwkfzab	22	33	enzyme	enzyme	NN
cord-313227-6zwkfzab	22	34	2	2	CD
cord-313227-6zwkfzab	22	35	(	(	-LRB-
cord-313227-6zwkfzab	22	36	ACE2	ACE2	NNP
cord-313227-6zwkfzab	22	37	)	)	-RRB-
cord-313227-6zwkfzab	22	38	expressed	express	VBD
cord-313227-6zwkfzab	22	39	on	on	IN
cord-313227-6zwkfzab	22	40	the	the	DT
cord-313227-6zwkfzab	22	41	surface	surface	NN
cord-313227-6zwkfzab	22	42	of	of	IN
cord-313227-6zwkfzab	22	43	the	the	DT
cord-313227-6zwkfzab	22	44	APs	APs	NNP
cord-313227-6zwkfzab	22	45	(	(	-LRB-
cord-313227-6zwkfzab	22	46	5	5	CD
cord-313227-6zwkfzab	22	47	)	)	-RRB-
cord-313227-6zwkfzab	22	48	.	.	.
cord-313227-6zwkfzab	23	1	The	the	DT
cord-313227-6zwkfzab	23	2	virus	virus	NN
cord-313227-6zwkfzab	23	3	enters	enter	VBZ
cord-313227-6zwkfzab	23	4	in	in	IN
cord-313227-6zwkfzab	23	5	the	the	DT
cord-313227-6zwkfzab	23	6	host	host	NN
cord-313227-6zwkfzab	23	7	target	target	NN
cord-313227-6zwkfzab	23	8	cells	cell	NNS
cord-313227-6zwkfzab	23	9	through	through	IN
cord-313227-6zwkfzab	23	10	receptor	receptor	NN
cord-313227-6zwkfzab	23	11	-	-	HYPH
cord-313227-6zwkfzab	23	12	mediated	mediate	VBN
cord-313227-6zwkfzab	23	13	endocytosis	endocytosis	NN
cord-313227-6zwkfzab	23	14	and	and	CC
cord-313227-6zwkfzab	23	15	quickly	quickly	RB
cord-313227-6zwkfzab	23	16	replicates	replicate	VBZ
cord-313227-6zwkfzab	23	17	;	;	:
cord-313227-6zwkfzab	23	18	virus	virus	NN
cord-313227-6zwkfzab	23	19	release	release	NN
cord-313227-6zwkfzab	23	20	in	in	IN
cord-313227-6zwkfzab	23	21	the	the	DT
cord-313227-6zwkfzab	23	22	extracellular	extracellular	JJ
cord-313227-6zwkfzab	23	23	space	space	NN
cord-313227-6zwkfzab	23	24	occurs	occur	VBZ
cord-313227-6zwkfzab	23	25	through	through	IN
cord-313227-6zwkfzab	23	26	either	either	CC
cord-313227-6zwkfzab	23	27	budding	budding	JJ
cord-313227-6zwkfzab	23	28	or	or	CC
cord-313227-6zwkfzab	23	29	cell	cell	NN
cord-313227-6zwkfzab	23	30	death	death	NN
cord-313227-6zwkfzab	23	31	.	.	.
cord-313227-6zwkfzab	24	1	In	in	IN
cord-313227-6zwkfzab	24	2	the	the	DT
cord-313227-6zwkfzab	24	3	extracellular	extracellular	JJ
cord-313227-6zwkfzab	24	4	space	space	NN
cord-313227-6zwkfzab	24	5	the	the	DT
cord-313227-6zwkfzab	24	6	virus	virus	NN
cord-313227-6zwkfzab	24	7	is	be	VBZ
cord-313227-6zwkfzab	24	8	recognized	recognize	VBN
cord-313227-6zwkfzab	24	9	by	by	IN
cord-313227-6zwkfzab	24	10	the	the	DT
cord-313227-6zwkfzab	24	11	PRR	PRR	NNP
cord-313227-6zwkfzab	24	12	of	of	IN
cord-313227-6zwkfzab	24	13	immune	immune	JJ
cord-313227-6zwkfzab	24	14	cells	cell	NNS
cord-313227-6zwkfzab	24	15	(	(	-LRB-
cord-313227-6zwkfzab	24	16	6	6	CD
cord-313227-6zwkfzab	24	17	)	)	-RRB-
cord-313227-6zwkfzab	24	18	.	.	.
cord-313227-6zwkfzab	25	1	This	this	DT
cord-313227-6zwkfzab	25	2	process	process	NN
cord-313227-6zwkfzab	25	3	contributes	contribute	VBZ
cord-313227-6zwkfzab	25	4	to	to	IN
cord-313227-6zwkfzab	25	5	the	the	DT
cord-313227-6zwkfzab	25	6	virus	virus	NN
cord-313227-6zwkfzab	25	7	elimination	elimination	NN
cord-313227-6zwkfzab	25	8	through	through	IN
cord-313227-6zwkfzab	25	9	an	an	DT
cord-313227-6zwkfzab	25	10	amplification	amplification	NN
cord-313227-6zwkfzab	25	11	cascade	cascade	NN
cord-313227-6zwkfzab	25	12	in	in	IN
cord-313227-6zwkfzab	25	13	which	which	WDT
cord-313227-6zwkfzab	25	14	the	the	DT
cord-313227-6zwkfzab	25	15	immune	immune	JJ
cord-313227-6zwkfzab	25	16	cells	cell	NNS
cord-313227-6zwkfzab	25	17	produce	produce	VBP
cord-313227-6zwkfzab	25	18	a	a	DT
cord-313227-6zwkfzab	25	19	large	large	JJ
cord-313227-6zwkfzab	25	20	number	number	NN
cord-313227-6zwkfzab	25	21	of	of	IN
cord-313227-6zwkfzab	25	22	pro	pro	JJ
cord-313227-6zwkfzab	25	23	-	-	JJ
cord-313227-6zwkfzab	25	24	inflammatory	inflammatory	JJ
cord-313227-6zwkfzab	25	25	cytokines	cytokine	NNS
cord-313227-6zwkfzab	25	26	,	,	,
cord-313227-6zwkfzab	25	27	tissue	tissue	NN
cord-313227-6zwkfzab	25	28	factors	factor	NNS
cord-313227-6zwkfzab	25	29	,	,	,
cord-313227-6zwkfzab	25	30	and	and	CC
cord-313227-6zwkfzab	25	31	vasoactive	vasoactive	JJ
cord-313227-6zwkfzab	25	32	peptides	peptide	NNS
cord-313227-6zwkfzab	25	33	.	.	.
cord-313227-6zwkfzab	26	1	These	these	DT
cord-313227-6zwkfzab	26	2	molecules	molecule	NNS
cord-313227-6zwkfzab	26	3	reach	reach	VBP
cord-313227-6zwkfzab	26	4	the	the	DT
cord-313227-6zwkfzab	26	5	blood	blood	NN
cord-313227-6zwkfzab	26	6	vessel	vessel	NN
cord-313227-6zwkfzab	26	7	wall	wall	NN
cord-313227-6zwkfzab	26	8	causing	cause	VBG
cord-313227-6zwkfzab	26	9	a	a	DT
cord-313227-6zwkfzab	26	10	burst	burst	NN
cord-313227-6zwkfzab	26	11	of	of	IN
cord-313227-6zwkfzab	26	12	nitric	nitric	NN
cord-313227-6zwkfzab	26	13	oxide	oxide	NN
cord-313227-6zwkfzab	26	14	,	,	,
cord-313227-6zwkfzab	26	15	damages	damage	NNS
cord-313227-6zwkfzab	26	16	to	to	IN
cord-313227-6zwkfzab	26	17	the	the	DT
cord-313227-6zwkfzab	26	18	blood	blood	NN
cord-313227-6zwkfzab	26	19	vessels	vessel	NNS
cord-313227-6zwkfzab	26	20	and	and	CC
cord-313227-6zwkfzab	26	21	to	to	IN
cord-313227-6zwkfzab	26	22	the	the	DT
cord-313227-6zwkfzab	26	23	coagulation	coagulation	NN
cord-313227-6zwkfzab	26	24	system	system	NN
cord-313227-6zwkfzab	26	25	(	(	-LRB-
cord-313227-6zwkfzab	26	26	7	7	CD
cord-313227-6zwkfzab	26	27	)	)	-RRB-
cord-313227-6zwkfzab	26	28	.	.	.
cord-313227-6zwkfzab	27	1	Among	among	IN
cord-313227-6zwkfzab	27	2	the	the	DT
cord-313227-6zwkfzab	27	3	most	most	RBS
cord-313227-6zwkfzab	27	4	involved	involved	JJ
cord-313227-6zwkfzab	27	5	cells	cell	NNS
cord-313227-6zwkfzab	27	6	,	,	,
cord-313227-6zwkfzab	27	7	macrophages	macrophage	NNS
cord-313227-6zwkfzab	27	8	play	play	VBP
cord-313227-6zwkfzab	27	9	an	an	DT
cord-313227-6zwkfzab	27	10	important	important	JJ
cord-313227-6zwkfzab	27	11	role	role	NN
cord-313227-6zwkfzab	27	12	in	in	IN
cord-313227-6zwkfzab	27	13	acute	acute	JJ
cord-313227-6zwkfzab	27	14	lung	lung	NN
cord-313227-6zwkfzab	27	15	injury	injury	NN
cord-313227-6zwkfzab	27	16	,	,	,
cord-313227-6zwkfzab	27	17	which	which	WDT
cord-313227-6zwkfzab	27	18	identify	identify	VBP
cord-313227-6zwkfzab	27	19	pathogen	pathogen	NN
cord-313227-6zwkfzab	27	20	-	-	HYPH
cord-313227-6zwkfzab	27	21	associated	associate	VBN
cord-313227-6zwkfzab	27	22	molecular	molecular	JJ
cord-313227-6zwkfzab	27	23	patterns	pattern	NNS
cord-313227-6zwkfzab	27	24	(	(	-LRB-
cord-313227-6zwkfzab	27	25	PAMP	PAMP	NNP
cord-313227-6zwkfzab	27	26	)	)	-RRB-
cord-313227-6zwkfzab	27	27	and	and	CC
cord-313227-6zwkfzab	27	28	trigger	trigger	VB
cord-313227-6zwkfzab	27	29	innate	innate	JJ
cord-313227-6zwkfzab	27	30	immunity	immunity	NN
cord-313227-6zwkfzab	27	31	(	(	-LRB-
cord-313227-6zwkfzab	27	32	8	8	CD
cord-313227-6zwkfzab	27	33	,	,	,
cord-313227-6zwkfzab	27	34	9	9	CD
cord-313227-6zwkfzab	27	35	)	)	-RRB-
cord-313227-6zwkfzab	27	36	.	.	.
cord-313227-6zwkfzab	28	1	Macrophages	macrophage	NNS
cord-313227-6zwkfzab	28	2	secrete	secrete	VBP
cord-313227-6zwkfzab	28	3	a	a	DT
cord-313227-6zwkfzab	28	4	large	large	JJ
cord-313227-6zwkfzab	28	5	number	number	NN
cord-313227-6zwkfzab	28	6	of	of	IN
cord-313227-6zwkfzab	28	7	inflammatory	inflammatory	JJ
cord-313227-6zwkfzab	28	8	mediators	mediator	NNS
cord-313227-6zwkfzab	28	9	and	and	CC
cord-313227-6zwkfzab	28	10	cytokines	cytokine	NNS
cord-313227-6zwkfzab	28	11	,	,	,
cord-313227-6zwkfzab	28	12	such	such	JJ
cord-313227-6zwkfzab	28	13	as	as	IN
cord-313227-6zwkfzab	28	14	tumor	tumor	NN
cord-313227-6zwkfzab	28	15	necrosis	necrosis	NN
cord-313227-6zwkfzab	28	16	factor	factor	NN
cord-313227-6zwkfzab	28	17	-	-	HYPH
cord-313227-6zwkfzab	28	18	alpha	alpha	NN
cord-313227-6zwkfzab	28	19	(	(	-LRB-
cord-313227-6zwkfzab	28	20	TNF	TNF	NNP
cord-313227-6zwkfzab	28	21	-	-	HYPH
cord-313227-6zwkfzab	28	22	α	α	NNP
cord-313227-6zwkfzab	28	23	)	)	-RRB-
cord-313227-6zwkfzab	28	24	,	,	,
cord-313227-6zwkfzab	28	25	interleukin-1beta	interleukin-1beta	JJ
cord-313227-6zwkfzab	28	26	(	(	-LRB-
cord-313227-6zwkfzab	28	27	IL-1β	IL-1β	NNP
cord-313227-6zwkfzab	28	28	)	)	-RRB-
cord-313227-6zwkfzab	28	29	,	,	.
cord-313227-6zwkfzab	29	1	interleukin-6	interleukin-6	NNP
cord-313227-6zwkfzab	29	2	(	(	-LRB-
cord-313227-6zwkfzab	29	3	IL-6	IL-6	NNP
cord-313227-6zwkfzab	29	4	)	)	-RRB-
cord-313227-6zwkfzab	29	5	,	,	,
cord-313227-6zwkfzab	29	6	inducible	inducible	JJ
cord-313227-6zwkfzab	29	7	nitric	nitric	NN
cord-313227-6zwkfzab	29	8	oxide	oxide	NN
cord-313227-6zwkfzab	29	9	synthase	synthase	NN
cord-313227-6zwkfzab	29	10	(	(	-LRB-
cord-313227-6zwkfzab	29	11	iNOS	iNOS	NNP
cord-313227-6zwkfzab	29	12	)	)	-RRB-
cord-313227-6zwkfzab	29	13	,	,	,
cord-313227-6zwkfzab	29	14	and	and	CC
cord-313227-6zwkfzab	29	15	macrophage	macrophage	NN
cord-313227-6zwkfzab	29	16	migration	migration	NN
cord-313227-6zwkfzab	29	17	inhibitory	inhibitory	JJ
cord-313227-6zwkfzab	29	18	factor	factor	NN
cord-313227-6zwkfzab	29	19	(	(	-LRB-
cord-313227-6zwkfzab	29	20	MIF	MIF	NNP
cord-313227-6zwkfzab	29	21	)	)	-RRB-
cord-313227-6zwkfzab	29	22	.	.	.
cord-313227-6zwkfzab	30	1	TNF	TNF	NNP
cord-313227-6zwkfzab	30	2	-	-	HYPH
cord-313227-6zwkfzab	30	3	α	α	NNP
cord-313227-6zwkfzab	30	4	can	can	MD
cord-313227-6zwkfzab	30	5	directly	directly	RB
cord-313227-6zwkfzab	30	6	damage	damage	NN
cord-313227-6zwkfzab	30	7	cells	cell	NNS
cord-313227-6zwkfzab	30	8	of	of	IN
cord-313227-6zwkfzab	30	9	the	the	DT
cord-313227-6zwkfzab	30	10	pulmonary	pulmonary	JJ
cord-313227-6zwkfzab	30	11	vascular	vascular	JJ
cord-313227-6zwkfzab	30	12	endothelium	endothelium	NN
cord-313227-6zwkfzab	30	13	,	,	,
cord-313227-6zwkfzab	30	14	increasing	increase	VBG
cord-313227-6zwkfzab	30	15	capillary	capillary	JJ
cord-313227-6zwkfzab	30	16	endothelial	endothelial	JJ
cord-313227-6zwkfzab	30	17	permeability	permeability	NN
cord-313227-6zwkfzab	30	18	,	,	,
cord-313227-6zwkfzab	30	19	causing	cause	VBG
cord-313227-6zwkfzab	30	20	pulmonary	pulmonary	JJ
cord-313227-6zwkfzab	30	21	edema	edema	NN
cord-313227-6zwkfzab	30	22	,	,	,
cord-313227-6zwkfzab	30	23	predicted	predict	VBN
cord-313227-6zwkfzab	30	24	by	by	IN
cord-313227-6zwkfzab	30	25	IL-6	IL-6	NNP
cord-313227-6zwkfzab	30	26	level	level	NN
cord-313227-6zwkfzab	30	27	(	(	-LRB-
cord-313227-6zwkfzab	30	28	10	10	CD
cord-313227-6zwkfzab	30	29	)	)	-RRB-
cord-313227-6zwkfzab	30	30	.	.	.
cord-313227-6zwkfzab	31	1	Progression	progression	NN
cord-313227-6zwkfzab	31	2	to	to	IN
cord-313227-6zwkfzab	31	3	Acute	acute	JJ
cord-313227-6zwkfzab	31	4	Respiratory	respiratory	JJ
cord-313227-6zwkfzab	31	5	Distress	Distress	NNP
cord-313227-6zwkfzab	31	6	Syndrome	Syndrome	NNP
cord-313227-6zwkfzab	31	7	(	(	-LRB-
cord-313227-6zwkfzab	31	8	ARDS	ARDS	NNP
cord-313227-6zwkfzab	31	9	)	)	-RRB-
cord-313227-6zwkfzab	31	10	is	be	VBZ
cord-313227-6zwkfzab	31	11	based	base	VBN
cord-313227-6zwkfzab	31	12	on	on	IN
cord-313227-6zwkfzab	31	13	the	the	DT
cord-313227-6zwkfzab	31	14	acute	acute	JJ
cord-313227-6zwkfzab	31	15	onset	onset	NN
cord-313227-6zwkfzab	31	16	of	of	IN
cord-313227-6zwkfzab	31	17	lung	lung	NN
cord-313227-6zwkfzab	31	18	inflammation	inflammation	NN
cord-313227-6zwkfzab	31	19	,	,	,
cord-313227-6zwkfzab	31	20	determined	determine	VBN
cord-313227-6zwkfzab	31	21	by	by	IN
cord-313227-6zwkfzab	31	22	monocyte	monocyte	NNP
cord-313227-6zwkfzab	31	23	/	/	SYM
cord-313227-6zwkfzab	31	24	macrophage	macrophage	NN
cord-313227-6zwkfzab	31	25	polarization	polarization	NN
cord-313227-6zwkfzab	31	26	and	and	CC
cord-313227-6zwkfzab	31	27	function	function	NN
cord-313227-6zwkfzab	31	28	.	.	.
cord-313227-6zwkfzab	32	1	During	during	IN
cord-313227-6zwkfzab	32	2	active	active	JJ
cord-313227-6zwkfzab	32	3	infection	infection	NN
cord-313227-6zwkfzab	32	4	,	,	,
cord-313227-6zwkfzab	32	5	inflammatory	inflammatory	JJ
cord-313227-6zwkfzab	32	6	monocytes	monocyte	NNS
cord-313227-6zwkfzab	32	7	/	/	SYM
cord-313227-6zwkfzab	32	8	macrophages	macrophage	NNS
cord-313227-6zwkfzab	32	9	(	(	-LRB-
cord-313227-6zwkfzab	32	10	IMMs	IMMs	NNP
cord-313227-6zwkfzab	32	11	)	)	-RRB-
cord-313227-6zwkfzab	32	12	,	,	,
cord-313227-6zwkfzab	32	13	and	and	CC
cord-313227-6zwkfzab	32	14	resident	resident	NN
cord-313227-6zwkfzab	32	15	macrophages	macrophage	NNS
cord-313227-6zwkfzab	32	16	undergo	undergo	VBP
cord-313227-6zwkfzab	32	17	marked	mark	VBN
cord-313227-6zwkfzab	32	18	phenotypic	phenotypic	JJ
cord-313227-6zwkfzab	32	19	and	and	CC
cord-313227-6zwkfzab	32	20	functional	functional	JJ
cord-313227-6zwkfzab	32	21	changes	change	NNS
cord-313227-6zwkfzab	32	22	,	,	,
cord-313227-6zwkfzab	32	23	from	from	IN
cord-313227-6zwkfzab	32	24	M1	M1	NNP
cord-313227-6zwkfzab	32	25	proinflammatory	proinflammatory	NN
cord-313227-6zwkfzab	32	26	(	(	-LRB-
cord-313227-6zwkfzab	32	27	classically	classically	RB
cord-313227-6zwkfzab	32	28	activated	activate	VBN
cord-313227-6zwkfzab	32	29	)	)	-RRB-
cord-313227-6zwkfzab	32	30	to	to	IN
cord-313227-6zwkfzab	32	31	M2	m2	JJ
cord-313227-6zwkfzab	32	32	inflammatory	inflammatory	NN
cord-313227-6zwkfzab	32	33	-	-	HYPH
cord-313227-6zwkfzab	32	34	resolving	resolve	VBG
cord-313227-6zwkfzab	32	35	macrophages	macrophage	NNS
cord-313227-6zwkfzab	32	36	,	,	,
cord-313227-6zwkfzab	32	37	with	with	IN
cord-313227-6zwkfzab	32	38	a	a	DT
cord-313227-6zwkfzab	32	39	dynamic	dynamic	JJ
cord-313227-6zwkfzab	32	40	continuum	continuum	NN
cord-313227-6zwkfzab	32	41	through	through	IN
cord-313227-6zwkfzab	32	42	discrete	discrete	JJ
cord-313227-6zwkfzab	32	43	categories	category	NNS
cord-313227-6zwkfzab	32	44	.	.	.
cord-313227-6zwkfzab	33	1	During	during	IN
cord-313227-6zwkfzab	33	2	acute	acute	JJ
cord-313227-6zwkfzab	33	3	infection	infection	NN
cord-313227-6zwkfzab	33	4	,	,	,
cord-313227-6zwkfzab	33	5	monocytes	monocyte	NNS
cord-313227-6zwkfzab	33	6	/	/	SYM
cord-313227-6zwkfzab	33	7	macrophages	macrophage	NNS
cord-313227-6zwkfzab	33	8	often	often	RB
cord-313227-6zwkfzab	33	9	display	display	VBP
cord-313227-6zwkfzab	33	10	a	a	DT
cord-313227-6zwkfzab	33	11	phenotype	phenotype	NN
cord-313227-6zwkfzab	33	12	of	of	IN
cord-313227-6zwkfzab	33	13	classically	classically	RB
cord-313227-6zwkfzab	33	14	activated	activate	VBN
cord-313227-6zwkfzab	33	15	macrophages	macrophage	NNS
cord-313227-6zwkfzab	33	16	that	that	WDT
cord-313227-6zwkfzab	33	17	mediate	mediate	VBP
cord-313227-6zwkfzab	33	18	antiviral	antiviral	JJ
cord-313227-6zwkfzab	33	19	host	host	NN
cord-313227-6zwkfzab	33	20	defenses	defense	NNS
cord-313227-6zwkfzab	33	21	but	but	CC
cord-313227-6zwkfzab	33	22	also	also	RB
cord-313227-6zwkfzab	33	23	promote	promote	VB
cord-313227-6zwkfzab	33	24	lung	lung	NN
cord-313227-6zwkfzab	33	25	injury	injury	NN
cord-313227-6zwkfzab	33	26	by	by	IN
cord-313227-6zwkfzab	33	27	producing	produce	VBG
cord-313227-6zwkfzab	33	28	nitric	nitric	NN
cord-313227-6zwkfzab	33	29	oxide	oxide	NN
cord-313227-6zwkfzab	33	30	(	(	-LRB-
cord-313227-6zwkfzab	33	31	NO	no	UH
cord-313227-6zwkfzab	33	32	)	)	-RRB-
cord-313227-6zwkfzab	33	33	,	,	,
cord-313227-6zwkfzab	33	34	Reactive	Reactive	NNP
cord-313227-6zwkfzab	33	35	Oxygen	Oxygen	NNP
cord-313227-6zwkfzab	33	36	Species	Species	NNP
cord-313227-6zwkfzab	33	37	(	(	-LRB-
cord-313227-6zwkfzab	33	38	ROS	ROS	NNP
cord-313227-6zwkfzab	33	39	)	)	-RRB-
cord-313227-6zwkfzab	33	40	,	,	,
cord-313227-6zwkfzab	33	41	IL-1	IL-1	NNP
cord-313227-6zwkfzab	33	42	,	,	,
cord-313227-6zwkfzab	33	43	IL-6	IL-6	NNP
cord-313227-6zwkfzab	33	44	,	,	,
cord-313227-6zwkfzab	33	45	and	and	CC
cord-313227-6zwkfzab	33	46	IL-8	IL-8	NNP
cord-313227-6zwkfzab	33	47	and	and	CC
cord-313227-6zwkfzab	33	48	TNF	TNF	NNP
cord-313227-6zwkfzab	33	49	-	-	HYPH
cord-313227-6zwkfzab	33	50	α	α	NNP
cord-313227-6zwkfzab	33	51	.	.	.
cord-313227-6zwkfzab	34	1	Simultaneously	simultaneously	RB
cord-313227-6zwkfzab	34	2	,	,	,
cord-313227-6zwkfzab	34	3	some	some	DT
cord-313227-6zwkfzab	34	4	macrophages	macrophage	NNS
cord-313227-6zwkfzab	34	5	may	may	MD
cord-313227-6zwkfzab	34	6	become	become	VB
cord-313227-6zwkfzab	34	7	M2	M2	NNP
cord-313227-6zwkfzab	34	8	macrophages	macrophage	NNS
cord-313227-6zwkfzab	34	9	alternatively	alternatively	RB
cord-313227-6zwkfzab	34	10	activated	activate	VBN
cord-313227-6zwkfzab	34	11	,	,	,
cord-313227-6zwkfzab	34	12	exerting	exert	VBG
cord-313227-6zwkfzab	34	13	anti	anti	JJ
cord-313227-6zwkfzab	34	14	-	-	JJ
cord-313227-6zwkfzab	34	15	inflammatory	inflammatory	JJ
cord-313227-6zwkfzab	34	16	function	function	NN
cord-313227-6zwkfzab	34	17	and	and	CC
cord-313227-6zwkfzab	34	18	regulating	regulating	NN
cord-313227-6zwkfzab	34	19	wound	wind	VBN
cord-313227-6zwkfzab	34	20	healing	healing	NN
cord-313227-6zwkfzab	34	21	by	by	IN
cord-313227-6zwkfzab	34	22	producing	produce	VBG
cord-313227-6zwkfzab	34	23	matrix	matrix	NN
cord-313227-6zwkfzab	34	24	metalloproteinases	metalloproteinase	NNS
cord-313227-6zwkfzab	34	25	(	(	-LRB-
cord-313227-6zwkfzab	34	26	MMPs	MMPs	NNP
cord-313227-6zwkfzab	34	27	)	)	-RRB-
cord-313227-6zwkfzab	34	28	,	,	,
cord-313227-6zwkfzab	34	29	growth	growth	NN
cord-313227-6zwkfzab	34	30	factors	factor	NNS
cord-313227-6zwkfzab	34	31	,	,	,
cord-313227-6zwkfzab	34	32	and	and	CC
cord-313227-6zwkfzab	34	33	anti	anti	JJ
cord-313227-6zwkfzab	34	34	-	-	JJ
cord-313227-6zwkfzab	34	35	inflammatory	inflammatory	JJ
cord-313227-6zwkfzab	34	36	cytokines	cytokine	NNS
cord-313227-6zwkfzab	34	37	,	,	,
cord-313227-6zwkfzab	34	38	particularly	particularly	RB
cord-313227-6zwkfzab	34	39	TGF	TGF	NNP
cord-313227-6zwkfzab	34	40	-	-	HYPH
cord-313227-6zwkfzab	34	41	β	β	NNP
cord-313227-6zwkfzab	34	42	.	.	.
cord-313227-6zwkfzab	35	1	Pro	pro	JJ
cord-313227-6zwkfzab	35	2	-	-	JJ
cord-313227-6zwkfzab	35	3	inflammatory	inflammatory	JJ
cord-313227-6zwkfzab	35	4	macrophages	macrophage	NNS
cord-313227-6zwkfzab	35	5	diminish	diminish	VBP
cord-313227-6zwkfzab	35	6	at	at	IN
cord-313227-6zwkfzab	35	7	the	the	DT
cord-313227-6zwkfzab	35	8	removal	removal	NN
cord-313227-6zwkfzab	35	9	of	of	IN
cord-313227-6zwkfzab	35	10	stimulus	stimulus	NN
cord-313227-6zwkfzab	35	11	(	(	-LRB-
cord-313227-6zwkfzab	35	12	11	11	CD
cord-313227-6zwkfzab	35	13	)	)	-RRB-
cord-313227-6zwkfzab	35	14	(	(	-LRB-
cord-313227-6zwkfzab	35	15	12	12	CD
cord-313227-6zwkfzab	35	16	)	)	-RRB-
cord-313227-6zwkfzab	35	17	(	(	-LRB-
cord-313227-6zwkfzab	35	18	13	13	CD
cord-313227-6zwkfzab	35	19	)	)	-RRB-
cord-313227-6zwkfzab	35	20	.	.	.
cord-313227-6zwkfzab	36	1	Evidence	evidence	NN
cord-313227-6zwkfzab	36	2	of	of	IN
cord-313227-6zwkfzab	36	3	a	a	DT
cord-313227-6zwkfzab	36	4	cytokine	cytokine	NN
cord-313227-6zwkfzab	36	5	storm	storm	NN
cord-313227-6zwkfzab	36	6	has	have	VBZ
cord-313227-6zwkfzab	36	7	been	be	VBN
cord-313227-6zwkfzab	36	8	found	find	VBN
cord-313227-6zwkfzab	36	9	in	in	IN
cord-313227-6zwkfzab	36	10	severe	severe	JJ
cord-313227-6zwkfzab	36	11	pneumonitis	pneumonitis	NN
cord-313227-6zwkfzab	36	12	linked	link	VBN
cord-313227-6zwkfzab	36	13	to	to	IN
cord-313227-6zwkfzab	36	14	coronavirus	coronavirus	NN
cord-313227-6zwkfzab	36	15	infection	infection	NN
cord-313227-6zwkfzab	36	16	(	(	-LRB-
cord-313227-6zwkfzab	36	17	14	14	CD
cord-313227-6zwkfzab	36	18	)	)	-RRB-
cord-313227-6zwkfzab	36	19	.	.	.
cord-313227-6zwkfzab	37	1	Previously	previously	RB
cord-313227-6zwkfzab	37	2	,	,	,
cord-313227-6zwkfzab	37	3	in	in	IN
cord-313227-6zwkfzab	37	4	patients	patient	NNS
cord-313227-6zwkfzab	37	5	with	with	IN
cord-313227-6zwkfzab	37	6	SARS	SARS	NNP
cord-313227-6zwkfzab	37	7	,	,	,
cord-313227-6zwkfzab	37	8	IL1B	IL1B	NNP
cord-313227-6zwkfzab	37	9	,	,	,
cord-313227-6zwkfzab	37	10	IL6	IL6	NNP
cord-313227-6zwkfzab	37	11	,	,	,
cord-313227-6zwkfzab	37	12	IL12	IL12	NNP
cord-313227-6zwkfzab	37	13	,	,	,
cord-313227-6zwkfzab	37	14	IFNγ	IFNγ	NNS
cord-313227-6zwkfzab	37	15	,	,	,
cord-313227-6zwkfzab	37	16	IP10	IP10	NNP
cord-313227-6zwkfzab	37	17	,	,	,
cord-313227-6zwkfzab	37	18	and	and	CC
cord-313227-6zwkfzab	37	19	MCP1	MCP1	NNP
cord-313227-6zwkfzab	37	20	were	be	VBD
cord-313227-6zwkfzab	37	21	found	find	VBN
cord-313227-6zwkfzab	37	22	to	to	TO
cord-313227-6zwkfzab	37	23	be	be	VB
cord-313227-6zwkfzab	37	24	increased	increase	VBN
cord-313227-6zwkfzab	37	25	(	(	-LRB-
cord-313227-6zwkfzab	37	26	15	15	CD
cord-313227-6zwkfzab	37	27	)	)	-RRB-
cord-313227-6zwkfzab	37	28	.	.	.
cord-313227-6zwkfzab	38	1	In	in	IN
cord-313227-6zwkfzab	38	2	patients	patient	NNS
cord-313227-6zwkfzab	38	3	with	with	IN
cord-313227-6zwkfzab	38	4	MERS	MERS	NNPS
cord-313227-6zwkfzab	38	5	,	,	,
cord-313227-6zwkfzab	38	6	IFNγ	IFNγ	NNS
cord-313227-6zwkfzab	38	7	,	,	,
cord-313227-6zwkfzab	38	8	TNFα	TNFα	NNP
cord-313227-6zwkfzab	38	9	,	,	,
cord-313227-6zwkfzab	38	10	IL15	IL15	NNP
cord-313227-6zwkfzab	38	11	,	,	,
cord-313227-6zwkfzab	38	12	and	and	CC
cord-313227-6zwkfzab	38	13	IL17	IL17	NNP
cord-313227-6zwkfzab	38	14	were	be	VBD
cord-313227-6zwkfzab	38	15	shown	show	VBN
cord-313227-6zwkfzab	38	16	to	to	TO
cord-313227-6zwkfzab	38	17	participate	participate	VB
cord-313227-6zwkfzab	38	18	in	in	IN
cord-313227-6zwkfzab	38	19	the	the	DT
cord-313227-6zwkfzab	38	20	severity	severity	NN
cord-313227-6zwkfzab	38	21	of	of	IN
cord-313227-6zwkfzab	38	22	the	the	DT
cord-313227-6zwkfzab	38	23	pneumonitis	pneumonitis	NN
cord-313227-6zwkfzab	38	24	(	(	-LRB-
cord-313227-6zwkfzab	38	25	16	16	CD
cord-313227-6zwkfzab	38	26	)	)	-RRB-
cord-313227-6zwkfzab	38	27	,	,	,
cord-313227-6zwkfzab	38	28	and	and	CC
cord-313227-6zwkfzab	38	29	an	an	DT
cord-313227-6zwkfzab	38	30	elevated	elevated	JJ
cord-313227-6zwkfzab	38	31	inflammatory	inflammatory	JJ
cord-313227-6zwkfzab	38	32	innate	innate	JJ
cord-313227-6zwkfzab	38	33	immune	immune	JJ
cord-313227-6zwkfzab	38	34	response	response	NN
cord-313227-6zwkfzab	38	35	has	have	VBZ
cord-313227-6zwkfzab	38	36	been	be	VBN
cord-313227-6zwkfzab	38	37	shown	show	VBN
cord-313227-6zwkfzab	38	38	in	in	IN
cord-313227-6zwkfzab	38	39	the	the	DT
cord-313227-6zwkfzab	38	40	lower	low	JJR
cord-313227-6zwkfzab	38	41	respiratory	respiratory	JJ
cord-313227-6zwkfzab	38	42	tract	tract	NN
cord-313227-6zwkfzab	38	43	.	.	.
cord-313227-6zwkfzab	39	1	Although	although	IN
cord-313227-6zwkfzab	39	2	those	those	DT
cord-313227-6zwkfzab	39	3	cytokines	cytokine	NNS
cord-313227-6zwkfzab	39	4	were	be	VBD
cord-313227-6zwkfzab	39	5	elevated	elevate	VBN
cord-313227-6zwkfzab	39	6	,	,	,
cord-313227-6zwkfzab	39	7	down	down	NN
cord-313227-6zwkfzab	39	8	-	-	HYPH
cord-313227-6zwkfzab	39	9	regulation	regulation	NN
cord-313227-6zwkfzab	39	10	of	of	IN
cord-313227-6zwkfzab	39	11	genes	gene	NNS
cord-313227-6zwkfzab	39	12	encoding	encode	VBG
cord-313227-6zwkfzab	39	13	inflammatory	inflammatory	JJ
cord-313227-6zwkfzab	39	14	TH1	TH1	NNP
cord-313227-6zwkfzab	39	15	and	and	CC
cord-313227-6zwkfzab	39	16	TH2	TH2	NNP
cord-313227-6zwkfzab	39	17	molecules	molecule	NNS
cord-313227-6zwkfzab	39	18	was	be	VBD
cord-313227-6zwkfzab	39	19	noted	note	VBN
cord-313227-6zwkfzab	39	20	(	(	-LRB-
cord-313227-6zwkfzab	39	21	17	17	CD
cord-313227-6zwkfzab	39	22	)	)	-RRB-
cord-313227-6zwkfzab	39	23	.	.	.
cord-313227-6zwkfzab	40	1	Interestingly	interestingly	RB
cord-313227-6zwkfzab	40	2	,	,	,
cord-313227-6zwkfzab	40	3	in	in	IN
cord-313227-6zwkfzab	40	4	patients	patient	NNS
cord-313227-6zwkfzab	40	5	infected	infect	VBN
cord-313227-6zwkfzab	40	6	by	by	IN
cord-313227-6zwkfzab	40	7	SARS	SARS	NNP
cord-313227-6zwkfzab	40	8	-	-	HYPH
cord-313227-6zwkfzab	40	9	COv-2	COv-2	NNP
cord-313227-6zwkfzab	40	10	,	,	,
cord-313227-6zwkfzab	40	11	there	there	EX
cord-313227-6zwkfzab	40	12	is	be	VBZ
cord-313227-6zwkfzab	40	13	an	an	DT
cord-313227-6zwkfzab	40	14	increase	increase	NN
cord-313227-6zwkfzab	40	15	in	in	IN
cord-313227-6zwkfzab	40	16	IL1β	IL1β	NNP
cord-313227-6zwkfzab	40	17	,	,	,
cord-313227-6zwkfzab	40	18	IFNγ	IFNγ	NNS
cord-313227-6zwkfzab	40	19	,	,	,
cord-313227-6zwkfzab	40	20	IP10	IP10	NNP
cord-313227-6zwkfzab	40	21	,	,	,
cord-313227-6zwkfzab	40	22	and	and	CC
cord-313227-6zwkfzab	40	23	MCP1	MCP1	NNP
cord-313227-6zwkfzab	40	24	,	,	,
cord-313227-6zwkfzab	40	25	probably	probably	RB
cord-313227-6zwkfzab	40	26	leading	lead	VBG
cord-313227-6zwkfzab	40	27	to	to	IN
cord-313227-6zwkfzab	40	28	activated	activate	VBN
cord-313227-6zwkfzab	40	29	T	T	NNP
cord-313227-6zwkfzab	40	30	-	-	HYPH
cord-313227-6zwkfzab	40	31	helper-1	helper-1	NNP
cord-313227-6zwkfzab	41	1	(	(	-LRB-
cord-313227-6zwkfzab	41	2	TH1	TH1	NNP
cord-313227-6zwkfzab	41	3	)	)	-RRB-
cord-313227-6zwkfzab	41	4	cell	cell	NN
cord-313227-6zwkfzab	41	5	responses	response	NNS
cord-313227-6zwkfzab	41	6	,	,	,
cord-313227-6zwkfzab	41	7	and	and	CC
cord-313227-6zwkfzab	41	8	increased	increase	VBN
cord-313227-6zwkfzab	41	9	production	production	NN
cord-313227-6zwkfzab	41	10	of	of	IN
cord-313227-6zwkfzab	41	11	T	T	NNP
cord-313227-6zwkfzab	41	12	-	-	HYPH
cord-313227-6zwkfzab	41	13	helper-2	helper-2	NNP
cord-313227-6zwkfzab	41	14	(	(	-LRB-
cord-313227-6zwkfzab	41	15	TH2	TH2	NNP
cord-313227-6zwkfzab	41	16	)	)	-RRB-
cord-313227-6zwkfzab	41	17	immunosuppressive	immunosuppressive	JJ
cord-313227-6zwkfzab	41	18	cytokines	cytokine	NNS
cord-313227-6zwkfzab	41	19	,	,	,
cord-313227-6zwkfzab	41	20	such	such	JJ
cord-313227-6zwkfzab	41	21	as	as	IN
cord-313227-6zwkfzab	41	22	IL4	IL4	NNP
cord-313227-6zwkfzab	41	23	and	and	CC
cord-313227-6zwkfzab	41	24	IL10	IL10	NNP
cord-313227-6zwkfzab	41	25	(	(	-LRB-
cord-313227-6zwkfzab	41	26	18	18	CD
cord-313227-6zwkfzab	41	27	)	)	-RRB-
cord-313227-6zwkfzab	41	28	.	.	.
cord-313227-6zwkfzab	42	1	In	in	IN
cord-313227-6zwkfzab	42	2	particular	particular	JJ
cord-313227-6zwkfzab	42	3	,	,	,
cord-313227-6zwkfzab	42	4	a	a	DT
cord-313227-6zwkfzab	42	5	significant	significant	JJ
cord-313227-6zwkfzab	42	6	increase	increase	NN
cord-313227-6zwkfzab	42	7	in	in	IN
cord-313227-6zwkfzab	42	8	IL2	IL2	NNP
cord-313227-6zwkfzab	42	9	,	,	,
cord-313227-6zwkfzab	42	10	IL7	IL7	NNS
cord-313227-6zwkfzab	42	11	,	,	,
cord-313227-6zwkfzab	42	12	IL10	IL10	NNP
cord-313227-6zwkfzab	42	13	,	,	,
cord-313227-6zwkfzab	42	14	G	G	NNP
cord-313227-6zwkfzab	42	15	-	-	HYPH
cord-313227-6zwkfzab	42	16	CSF	CSF	NNP
cord-313227-6zwkfzab	42	17	,	,	,
cord-313227-6zwkfzab	42	18	IP10	IP10	NNP
cord-313227-6zwkfzab	42	19	,	,	,
cord-313227-6zwkfzab	42	20	MCP1	MCP1	NNP
cord-313227-6zwkfzab	42	21	/	/	SYM
cord-313227-6zwkfzab	42	22	CCL2	CCL2	NNP
cord-313227-6zwkfzab	42	23	,	,	,
cord-313227-6zwkfzab	42	24	MIP1A	mip1a	CD
cord-313227-6zwkfzab	42	25	,	,	,
cord-313227-6zwkfzab	42	26	and	and	CC
cord-313227-6zwkfzab	42	27	TNFα	TNFα	NNS
cord-313227-6zwkfzab	42	28	was	be	VBD
cord-313227-6zwkfzab	42	29	noted	note	VBN
cord-313227-6zwkfzab	42	30	in	in	IN
cord-313227-6zwkfzab	42	31	patients	patient	NNS
cord-313227-6zwkfzab	42	32	requiring	require	VBG
cord-313227-6zwkfzab	42	33	admission	admission	NN
cord-313227-6zwkfzab	42	34	to	to	IN
cord-313227-6zwkfzab	42	35	the	the	DT
cord-313227-6zwkfzab	42	36	intensive	intensive	JJ
cord-313227-6zwkfzab	42	37	care	care	NN
cord-313227-6zwkfzab	42	38	unit	unit	NN
cord-313227-6zwkfzab	42	39	(	(	-LRB-
cord-313227-6zwkfzab	42	40	ICU	ICU	NNP
cord-313227-6zwkfzab	42	41	)	)	-RRB-
cord-313227-6zwkfzab	42	42	compared	compare	VBN
cord-313227-6zwkfzab	42	43	to	to	IN
cord-313227-6zwkfzab	42	44	patients	patient	NNS
cord-313227-6zwkfzab	42	45	with	with	IN
cord-313227-6zwkfzab	42	46	a	a	DT
cord-313227-6zwkfzab	42	47	milder	mild	JJR
cord-313227-6zwkfzab	42	48	disease	disease	NN
cord-313227-6zwkfzab	42	49	.	.	.
cord-313227-6zwkfzab	43	1	As	as	IN
cord-313227-6zwkfzab	43	2	the	the	DT
cord-313227-6zwkfzab	43	3	infiltrate	infiltrate	NN
cord-313227-6zwkfzab	43	4	of	of	IN
cord-313227-6zwkfzab	43	5	monocytes	monocyte	NNS
cord-313227-6zwkfzab	43	6	,	,	,
cord-313227-6zwkfzab	43	7	neutrophils	neutrophil	NNS
cord-313227-6zwkfzab	43	8	,	,	,
cord-313227-6zwkfzab	43	9	lymphocytes	lymphocyte	NNS
cord-313227-6zwkfzab	43	10	,	,	,
cord-313227-6zwkfzab	43	11	and	and	CC
cord-313227-6zwkfzab	43	12	macrophages	macrophage	NNS
cord-313227-6zwkfzab	43	13	are	be	VBP
cord-313227-6zwkfzab	43	14	the	the	DT
cord-313227-6zwkfzab	43	15	cellular	cellular	JJ
cord-313227-6zwkfzab	43	16	actors	actor	NNS
cord-313227-6zwkfzab	43	17	of	of	IN
cord-313227-6zwkfzab	43	18	the	the	DT
cord-313227-6zwkfzab	43	19	inflammatory	inflammatory	JJ
cord-313227-6zwkfzab	43	20	response	response	NN
cord-313227-6zwkfzab	43	21	(	(	-LRB-
cord-313227-6zwkfzab	43	22	14	14	CD
cord-313227-6zwkfzab	43	23	)	)	-RRB-
cord-313227-6zwkfzab	43	24	,	,	,
cord-313227-6zwkfzab	43	25	chemokine	chemokine	NN
cord-313227-6zwkfzab	43	26	ligands	ligand	NNS
cord-313227-6zwkfzab	43	27	and	and	CC
cord-313227-6zwkfzab	43	28	receptors	receptor	NNS
cord-313227-6zwkfzab	43	29	play	play	VBP
cord-313227-6zwkfzab	43	30	an	an	DT
cord-313227-6zwkfzab	43	31	important	important	JJ
cord-313227-6zwkfzab	43	32	role	role	NN
cord-313227-6zwkfzab	43	33	in	in	IN
cord-313227-6zwkfzab	43	34	driving	drive	VBG
cord-313227-6zwkfzab	43	35	immune	immune	JJ
cord-313227-6zwkfzab	43	36	cell	cell	NN
cord-313227-6zwkfzab	43	37	migration	migration	NN
cord-313227-6zwkfzab	43	38	and	and	CC
cord-313227-6zwkfzab	43	39	homing	homing	NN
cord-313227-6zwkfzab	43	40	(	(	-LRB-
cord-313227-6zwkfzab	43	41	19	19	CD
cord-313227-6zwkfzab	43	42	)	)	-RRB-
cord-313227-6zwkfzab	43	43	.	.	.
cord-313227-6zwkfzab	44	1	These	these	DT
cord-313227-6zwkfzab	44	2	cytokines	cytokine	NNS
cord-313227-6zwkfzab	44	3	may	may	MD
cord-313227-6zwkfzab	44	4	explain	explain	VB
cord-313227-6zwkfzab	44	5	the	the	DT
cord-313227-6zwkfzab	44	6	observation	observation	NN
cord-313227-6zwkfzab	44	7	of	of	IN
cord-313227-6zwkfzab	44	8	reduced	reduced	JJ
cord-313227-6zwkfzab	44	9	levels	level	NNS
cord-313227-6zwkfzab	44	10	of	of	IN
cord-313227-6zwkfzab	44	11	circulating	circulate	VBG
cord-313227-6zwkfzab	44	12	lymphocytes	lymphocyte	NNS
cord-313227-6zwkfzab	44	13	.	.	.
cord-313227-6zwkfzab	45	1	Peripheral	peripheral	JJ
cord-313227-6zwkfzab	45	2	blood	blood	NN
cord-313227-6zwkfzab	45	3	examinations	examination	NNS
cord-313227-6zwkfzab	45	4	on	on	IN
cord-313227-6zwkfzab	45	5	admission	admission	NN
cord-313227-6zwkfzab	45	6	in	in	IN
cord-313227-6zwkfzab	45	7	the	the	DT
cord-313227-6zwkfzab	45	8	majority	majority	NN
cord-313227-6zwkfzab	45	9	of	of	IN
cord-313227-6zwkfzab	45	10	patients	patient	NNS
cord-313227-6zwkfzab	45	11	with	with	IN
cord-313227-6zwkfzab	45	12	COVID-19	covid-19	JJ
cord-313227-6zwkfzab	45	13	displayed	display	VBN
cord-313227-6zwkfzab	45	14	lymphopenia	lymphopenia	NNP
cord-313227-6zwkfzab	45	15	,	,	,
cord-313227-6zwkfzab	45	16	elevated	elevated	JJ
cord-313227-6zwkfzab	45	17	infection	infection	NN
cord-313227-6zwkfzab	45	18	-	-	HYPH
cord-313227-6zwkfzab	45	19	related	relate	VBN
cord-313227-6zwkfzab	45	20	biomarkers	biomarker	NNS
cord-313227-6zwkfzab	45	21	(	(	-LRB-
cord-313227-6zwkfzab	45	22	i.e.	i.e.	FW
cord-313227-6zwkfzab	45	23	,	,	,
cord-313227-6zwkfzab	45	24	procalcitonin	procalcitonin	NNS
cord-313227-6zwkfzab	45	25	,	,	,
cord-313227-6zwkfzab	45	26	erythrocyte	erythrocyte	NN
cord-313227-6zwkfzab	45	27	sedimentation	sedimentation	NN
cord-313227-6zwkfzab	45	28	rate	rate	NN
cord-313227-6zwkfzab	45	29	,	,	,
cord-313227-6zwkfzab	45	30	serum	serum	NN
cord-313227-6zwkfzab	45	31	ferritin	ferritin	NN
cord-313227-6zwkfzab	45	32	,	,	,
cord-313227-6zwkfzab	45	33	and	and	CC
cord-313227-6zwkfzab	45	34	C	c	NN
cord-313227-6zwkfzab	45	35	-	-	HYPH
cord-313227-6zwkfzab	45	36	reactive	reactive	JJ
cord-313227-6zwkfzab	45	37	protein	protein	NN
cord-313227-6zwkfzab	45	38	)	)	-RRB-
cord-313227-6zwkfzab	45	39	(	(	-LRB-
cord-313227-6zwkfzab	45	40	20	20	CD
cord-313227-6zwkfzab	45	41	)	)	-RRB-
cord-313227-6zwkfzab	45	42	and	and	CC
cord-313227-6zwkfzab	45	43	several	several	JJ
cord-313227-6zwkfzab	45	44	elevated	elevated	JJ
cord-313227-6zwkfzab	45	45	inflammatory	inflammatory	JJ
cord-313227-6zwkfzab	45	46	cytokines	cytokine	NNS
cord-313227-6zwkfzab	45	47	(	(	-LRB-
cord-313227-6zwkfzab	45	48	i.e.	i.e.	FW
cord-313227-6zwkfzab	45	49	,	,	,
cord-313227-6zwkfzab	45	50	tumor	tumor	NN
cord-313227-6zwkfzab	45	51	necrosis	necrosis	NN
cord-313227-6zwkfzab	45	52	factor	factor	NN
cord-313227-6zwkfzab	45	53	(	(	-LRB-
cord-313227-6zwkfzab	45	54	TNF)-α	tnf)-α	NN
cord-313227-6zwkfzab	45	55	,	,	,
cord-313227-6zwkfzab	45	56	interleukin	interleukin	FW
cord-313227-6zwkfzab	45	57	(	(	-LRB-
cord-313227-6zwkfzab	45	58	IL)-2R	IL)-2R	NNP
cord-313227-6zwkfzab	45	59	and	and	CC
cord-313227-6zwkfzab	45	60	IL-6	IL-6	NNP
cord-313227-6zwkfzab	45	61	)	)	-RRB-
cord-313227-6zwkfzab	45	62	.	.	.
cord-313227-6zwkfzab	46	1	Patients	patient	NNS
cord-313227-6zwkfzab	46	2	with	with	IN
cord-313227-6zwkfzab	46	3	more	more	RBR
cord-313227-6zwkfzab	46	4	severe	severe	JJ
cord-313227-6zwkfzab	46	5	cases	case	NNS
cord-313227-6zwkfzab	46	6	had	have	VBD
cord-313227-6zwkfzab	46	7	higher	high	JJR
cord-313227-6zwkfzab	46	8	leukocyte	leukocyte	NN
cord-313227-6zwkfzab	46	9	and	and	CC
cord-313227-6zwkfzab	46	10	neutrophil	neutrophil	NN
cord-313227-6zwkfzab	46	11	count	count	NN
cord-313227-6zwkfzab	46	12	,	,	,
cord-313227-6zwkfzab	46	13	lower	low	JJR
cord-313227-6zwkfzab	46	14	lymphocyte	lymphocyte	NN
cord-313227-6zwkfzab	46	15	count	count	NN
cord-313227-6zwkfzab	46	16	and	and	CC
cord-313227-6zwkfzab	46	17	higher	high	JJR
cord-313227-6zwkfzab	46	18	neutrophil	neutrophil	NN
cord-313227-6zwkfzab	46	19	-	-	HYPH
cord-313227-6zwkfzab	46	20	to	to	IN
cord-313227-6zwkfzab	46	21	-	-	HYPH
cord-313227-6zwkfzab	46	22	lymphocyte	lymphocyte	NN
cord-313227-6zwkfzab	46	23	ratio	ratio	NN
cord-313227-6zwkfzab	46	24	(	(	-LRB-
cord-313227-6zwkfzab	46	25	NLR	NLR	NNP
cord-313227-6zwkfzab	46	26	)	)	-RRB-
cord-313227-6zwkfzab	46	27	(	(	-LRB-
cord-313227-6zwkfzab	46	28	21	21	CD
cord-313227-6zwkfzab	46	29	)	)	-RRB-
cord-313227-6zwkfzab	46	30	.	.	.
cord-313227-6zwkfzab	47	1	Lymphocyte	lymphocyte	NN
cord-313227-6zwkfzab	47	2	subsets	subset	NNS
cord-313227-6zwkfzab	47	3	showed	show	VBD
cord-313227-6zwkfzab	47	4	that	that	IN
cord-313227-6zwkfzab	47	5	the	the	DT
cord-313227-6zwkfzab	47	6	total	total	JJ
cord-313227-6zwkfzab	47	7	number	number	NN
cord-313227-6zwkfzab	47	8	of	of	IN
cord-313227-6zwkfzab	47	9	B	b	NN
cord-313227-6zwkfzab	47	10	cells	cell	NNS
cord-313227-6zwkfzab	47	11	,	,	,
cord-313227-6zwkfzab	47	12	T	t	NN
cord-313227-6zwkfzab	47	13	cells	cell	NNS
cord-313227-6zwkfzab	47	14	and	and	CC
cord-313227-6zwkfzab	47	15	NK	NK	NNP
cord-313227-6zwkfzab	47	16	cells	cell	NNS
cord-313227-6zwkfzab	47	17	was	be	VBD
cord-313227-6zwkfzab	47	18	significantly	significantly	RB
cord-313227-6zwkfzab	47	19	decreased	decrease	VBN
cord-313227-6zwkfzab	47	20	in	in	IN
cord-313227-6zwkfzab	47	21	patients	patient	NNS
cord-313227-6zwkfzab	47	22	with	with	IN
cord-313227-6zwkfzab	47	23	COVID-19	COVID-19	NNP
cord-313227-6zwkfzab	47	24	,	,	,
cord-313227-6zwkfzab	47	25	more	more	RBR
cord-313227-6zwkfzab	47	26	significantly	significantly	RB
cord-313227-6zwkfzab	47	27	so	so	RB
cord-313227-6zwkfzab	47	28	in	in	IN
cord-313227-6zwkfzab	47	29	severe	severe	JJ
cord-313227-6zwkfzab	47	30	cases	case	NNS
cord-313227-6zwkfzab	47	31	.	.	.
cord-313227-6zwkfzab	48	1	In	in	IN
cord-313227-6zwkfzab	48	2	particular	particular	JJ
cord-313227-6zwkfzab	48	3	,	,	,
cord-313227-6zwkfzab	48	4	T	t	NN
cord-313227-6zwkfzab	48	5	cells	cell	NNS
cord-313227-6zwkfzab	48	6	(	(	-LRB-
cord-313227-6zwkfzab	48	7	T	T	NNP
cord-313227-6zwkfzab	48	8	helper	helper	NN
cord-313227-6zwkfzab	48	9	,	,	,
cord-313227-6zwkfzab	48	10	T	T	NNP
cord-313227-6zwkfzab	48	11	suppressor	suppressor	NN
cord-313227-6zwkfzab	48	12	,	,	,
cord-313227-6zwkfzab	48	13	and	and	CC
cord-313227-6zwkfzab	48	14	Tregs	Tregs	NNP
cord-313227-6zwkfzab	48	15	cells	cell	NNS
cord-313227-6zwkfzab	48	16	)	)	-RRB-
cord-313227-6zwkfzab	48	17	were	be	VBD
cord-313227-6zwkfzab	48	18	mostly	mostly	RB
cord-313227-6zwkfzab	48	19	affected	affect	VBN
cord-313227-6zwkfzab	48	20	by	by	IN
cord-313227-6zwkfzab	48	21	SARS	SARS	NNP
cord-313227-6zwkfzab	48	22	-	-	HYPH
cord-313227-6zwkfzab	48	23	CoV-2	CoV-2	NNP
cord-313227-6zwkfzab	48	24	.	.	.
cord-313227-6zwkfzab	49	1	In	in	IN
cord-313227-6zwkfzab	49	2	addition	addition	NN
cord-313227-6zwkfzab	49	3	,	,	,
cord-313227-6zwkfzab	49	4	recent	recent	JJ
cord-313227-6zwkfzab	49	5	evidence	evidence	NN
cord-313227-6zwkfzab	49	6	in	in	IN
cord-313227-6zwkfzab	49	7	SARS	SARS	NNP
cord-313227-6zwkfzab	49	8	-	-	HYPH
cord-313227-6zwkfzab	49	9	CoV	CoV	NNP
cord-313227-6zwkfzab	49	10	infection	infection	NN
cord-313227-6zwkfzab	49	11	suggests	suggest	VBZ
cord-313227-6zwkfzab	49	12	that	that	IN
cord-313227-6zwkfzab	49	13	seroconversion	seroconversion	NN
cord-313227-6zwkfzab	49	14	may	may	MD
cord-313227-6zwkfzab	49	15	also	also	RB
cord-313227-6zwkfzab	49	16	play	play	VB
cord-313227-6zwkfzab	49	17	a	a	DT
cord-313227-6zwkfzab	49	18	role	role	NN
cord-313227-6zwkfzab	49	19	in	in	IN
cord-313227-6zwkfzab	49	20	lung	lung	NN
cord-313227-6zwkfzab	49	21	injury	injury	NN
cord-313227-6zwkfzab	49	22	.	.	.
cord-313227-6zwkfzab	50	1	A	a	DT
cord-313227-6zwkfzab	50	2	detrimental	detrimental	JJ
cord-313227-6zwkfzab	50	3	role	role	NN
cord-313227-6zwkfzab	50	4	of	of	IN
cord-313227-6zwkfzab	50	5	early	early	JJ
cord-313227-6zwkfzab	50	6	appearance	appearance	NN
cord-313227-6zwkfzab	50	7	of	of	IN
cord-313227-6zwkfzab	50	8	antispike	antispike	NNP
cord-313227-6zwkfzab	50	9	(	(	-LRB-
cord-313227-6zwkfzab	50	10	S)-IgG	S)-IgG	NNP
cord-313227-6zwkfzab	50	11	was	be	VBD
cord-313227-6zwkfzab	50	12	demonstrated	demonstrate	VBN
cord-313227-6zwkfzab	50	13	during	during	IN
cord-313227-6zwkfzab	50	14	SARS	SARS	NNP
cord-313227-6zwkfzab	50	15	-	-	HYPH
cord-313227-6zwkfzab	50	16	CoV	CoV	NNP
cord-313227-6zwkfzab	50	17	infection	infection	NN
cord-313227-6zwkfzab	50	18	in	in	IN
cord-313227-6zwkfzab	50	19	a	a	DT
cord-313227-6zwkfzab	50	20	macaque	macaque	NN
cord-313227-6zwkfzab	50	21	model	model	NN
cord-313227-6zwkfzab	50	22	(	(	-LRB-
cord-313227-6zwkfzab	50	23	22	22	CD
cord-313227-6zwkfzab	50	24	)	)	-RRB-
cord-313227-6zwkfzab	50	25	.	.	.
cord-313227-6zwkfzab	51	1	Despite	despite	IN
cord-313227-6zwkfzab	51	2	markedly	markedly	RB
cord-313227-6zwkfzab	51	3	reducing	reduce	VBG
cord-313227-6zwkfzab	51	4	virus	virus	NN
cord-313227-6zwkfzab	51	5	titers	titer	NNS
cord-313227-6zwkfzab	51	6	,	,	,
cord-313227-6zwkfzab	51	7	anti	anti	JJ
cord-313227-6zwkfzab	51	8	-	-	NNP
cord-313227-6zwkfzab	51	9	S	S	NNP
cord-313227-6zwkfzab	51	10	-	-	HYPH
cord-313227-6zwkfzab	51	11	IgG	IgG	NNP
cord-313227-6zwkfzab	51	12	caused	cause	VBD
cord-313227-6zwkfzab	51	13	lung	lung	NN
cord-313227-6zwkfzab	51	14	injury	injury	NN
cord-313227-6zwkfzab	51	15	during	during	IN
cord-313227-6zwkfzab	51	16	the	the	DT
cord-313227-6zwkfzab	51	17	early	early	JJ
cord-313227-6zwkfzab	51	18	stages	stage	NNS
cord-313227-6zwkfzab	51	19	of	of	IN
cord-313227-6zwkfzab	51	20	infection	infection	NN
cord-313227-6zwkfzab	51	21	,	,	,
cord-313227-6zwkfzab	51	22	impairing	impair	VBG
cord-313227-6zwkfzab	51	23	the	the	DT
cord-313227-6zwkfzab	51	24	wound	wound	NN
cord-313227-6zwkfzab	51	25	-	-	HYPH
cord-313227-6zwkfzab	51	26	healing	heal	VBG
cord-313227-6zwkfzab	51	27	macrophage	macrophage	NN
cord-313227-6zwkfzab	51	28	response	response	NN
cord-313227-6zwkfzab	51	29	and	and	CC
cord-313227-6zwkfzab	51	30	TGF	TGF	NNP
cord-313227-6zwkfzab	51	31	-	-	HYPH
cord-313227-6zwkfzab	51	32	β	β	NN
cord-313227-6zwkfzab	51	33	production	production	NN
cord-313227-6zwkfzab	51	34	,	,	,
cord-313227-6zwkfzab	51	35	while	while	IN
cord-313227-6zwkfzab	51	36	promoting	promote	VBG
cord-313227-6zwkfzab	51	37	pro	pro	JJ
cord-313227-6zwkfzab	51	38	inflammatory	inflammatory	JJ
cord-313227-6zwkfzab	51	39	cytokine	cytokine	NN
cord-313227-6zwkfzab	51	40	IL-8	il-8	NN
cord-313227-6zwkfzab	51	41	,	,	,
cord-313227-6zwkfzab	51	42	MCP1	MCP1	NNP
cord-313227-6zwkfzab	51	43	production	production	NN
cord-313227-6zwkfzab	51	44	,	,	,
cord-313227-6zwkfzab	51	45	and	and	CC
cord-313227-6zwkfzab	51	46	inflammatory	inflammatory	JJ
cord-313227-6zwkfzab	51	47	macrophage	macrophage	NN
cord-313227-6zwkfzab	51	48	accumulation	accumulation	NN
cord-313227-6zwkfzab	51	49	(	(	-LRB-
cord-313227-6zwkfzab	51	50	22	22	CD
cord-313227-6zwkfzab	51	51	)	)	-RRB-
cord-313227-6zwkfzab	51	52	.	.	.
cord-313227-6zwkfzab	52	1	Interestingly	interestingly	RB
cord-313227-6zwkfzab	52	2	,	,	,
cord-313227-6zwkfzab	52	3	in	in	IN
cord-313227-6zwkfzab	52	4	SARS	SARS	NNP
cord-313227-6zwkfzab	52	5	patients	patient	NNS
cord-313227-6zwkfzab	52	6	who	who	WP
cord-313227-6zwkfzab	52	7	died	die	VBD
cord-313227-6zwkfzab	52	8	in	in	IN
cord-313227-6zwkfzab	52	9	Hong	Hong	NNP
cord-313227-6zwkfzab	52	10	Kong	Kong	NNP
cord-313227-6zwkfzab	52	11	during	during	IN
cord-313227-6zwkfzab	52	12	the	the	DT
cord-313227-6zwkfzab	52	13	2002	2002	CD
cord-313227-6zwkfzab	52	14	outbreak	outbreak	NN
cord-313227-6zwkfzab	52	15	,	,	,
cord-313227-6zwkfzab	52	16	the	the	DT
cord-313227-6zwkfzab	52	17	anti	anti	JJ
cord-313227-6zwkfzab	52	18	-	-	JJ
cord-313227-6zwkfzab	52	19	spike	spike	JJ
cord-313227-6zwkfzab	52	20	(	(	-LRB-
cord-313227-6zwkfzab	52	21	S	s	NN
cord-313227-6zwkfzab	52	22	)	)	-RRB-
cord-313227-6zwkfzab	52	23	glycoprotein	glycoprotein	NN
cord-313227-6zwkfzab	52	24	neutralizing	neutralize	VBG
cord-313227-6zwkfzab	52	25	antibodies	antibody	NNS
cord-313227-6zwkfzab	52	26	appeared	appear	VBD
cord-313227-6zwkfzab	52	27	significantly	significantly	RB
cord-313227-6zwkfzab	52	28	before	before	RB
cord-313227-6zwkfzab	52	29	and	and	CC
cord-313227-6zwkfzab	52	30	reached	reach	VBD
cord-313227-6zwkfzab	52	31	a	a	DT
cord-313227-6zwkfzab	52	32	higher	high	JJR
cord-313227-6zwkfzab	52	33	titer	titer	NN
cord-313227-6zwkfzab	52	34	than	than	IN
cord-313227-6zwkfzab	52	35	in	in	IN
cord-313227-6zwkfzab	52	36	patients	patient	NNS
cord-313227-6zwkfzab	52	37	surviving	survive	VBG
cord-313227-6zwkfzab	52	38	(	(	-LRB-
cord-313227-6zwkfzab	52	39	23	23	CD
cord-313227-6zwkfzab	52	40	)	)	-RRB-
cord-313227-6zwkfzab	52	41	.	.	.
cord-313227-6zwkfzab	53	1	Consistently	consistently	RB
cord-313227-6zwkfzab	53	2	,	,	,
cord-313227-6zwkfzab	53	3	preexisting	preexist	VBG
cord-313227-6zwkfzab	53	4	serum	serum	NN
cord-313227-6zwkfzab	53	5	antibodies	antibody	NNS
cord-313227-6zwkfzab	53	6	,	,	,
cord-313227-6zwkfzab	53	7	derived	derive	VBN
cord-313227-6zwkfzab	53	8	by	by	IN
cord-313227-6zwkfzab	53	9	exposition	exposition	NN
cord-313227-6zwkfzab	53	10	to	to	IN
cord-313227-6zwkfzab	53	11	influenza	influenza	JJ
cord-313227-6zwkfzab	53	12	seasonal	seasonal	JJ
cord-313227-6zwkfzab	53	13	strains	strain	NNS
cord-313227-6zwkfzab	53	14	,	,	,
cord-313227-6zwkfzab	53	15	may	may	MD
cord-313227-6zwkfzab	53	16	recognize	recognize	VB
cord-313227-6zwkfzab	53	17	but	but	CC
cord-313227-6zwkfzab	53	18	fail	fail	VB
cord-313227-6zwkfzab	53	19	to	to	TO
cord-313227-6zwkfzab	53	20	neutralize	neutralize	VB
cord-313227-6zwkfzab	53	21	,	,	,
cord-313227-6zwkfzab	53	22	the	the	DT
cord-313227-6zwkfzab	53	23	new	new	JJ
cord-313227-6zwkfzab	53	24	pandemic	pandemic	NN
cord-313227-6zwkfzab	53	25	strain	strain	NN
cord-313227-6zwkfzab	53	26	and	and	CC
cord-313227-6zwkfzab	53	27	were	be	VBD
cord-313227-6zwkfzab	53	28	found	find	VBN
cord-313227-6zwkfzab	53	29	to	to	TO
cord-313227-6zwkfzab	53	30	associate	associate	VB
cord-313227-6zwkfzab	53	31	with	with	IN
cord-313227-6zwkfzab	53	32	worse	bad	JJR
cord-313227-6zwkfzab	53	33	clinical	clinical	JJ
cord-313227-6zwkfzab	53	34	severity	severity	NN
cord-313227-6zwkfzab	53	35	during	during	IN
cord-313227-6zwkfzab	53	36	the	the	DT
cord-313227-6zwkfzab	53	37	2009	2009	CD
cord-313227-6zwkfzab	53	38	influenza	influenza	NN
cord-313227-6zwkfzab	53	39	pandemic	pandemic	NN
cord-313227-6zwkfzab	53	40	(	(	-LRB-
cord-313227-6zwkfzab	53	41	24	24	CD
cord-313227-6zwkfzab	53	42	,	,	,
cord-313227-6zwkfzab	53	43	25	25	CD
cord-313227-6zwkfzab	53	44	)	)	-RRB-
cord-313227-6zwkfzab	53	45	.	.	.
cord-313227-6zwkfzab	54	1	The	the	DT
cord-313227-6zwkfzab	54	2	inflammatory	inflammatory	JJ
cord-313227-6zwkfzab	54	3	status	status	NN
cord-313227-6zwkfzab	54	4	together	together	RB
cord-313227-6zwkfzab	54	5	with	with	IN
cord-313227-6zwkfzab	54	6	pulmonary	pulmonary	JJ
cord-313227-6zwkfzab	54	7	edema	edema	NN
cord-313227-6zwkfzab	54	8	and	and	CC
cord-313227-6zwkfzab	54	9	respiratory	respiratory	JJ
cord-313227-6zwkfzab	54	10	failure	failure	NN
cord-313227-6zwkfzab	54	11	define	define	VBP
cord-313227-6zwkfzab	54	12	the	the	DT
cord-313227-6zwkfzab	54	13	clinical	clinical	JJ
cord-313227-6zwkfzab	54	14	picture	picture	NN
cord-313227-6zwkfzab	54	15	of	of	IN
cord-313227-6zwkfzab	54	16	the	the	DT
cord-313227-6zwkfzab	54	17	ARDS	ARDS	NNP
cord-313227-6zwkfzab	54	18	associated	associate	VBN
cord-313227-6zwkfzab	54	19	with	with	IN
cord-313227-6zwkfzab	54	20	COVID-19	COVID-19	NNP
cord-313227-6zwkfzab	54	21	(	(	-LRB-
cord-313227-6zwkfzab	54	22	26	26	CD
cord-313227-6zwkfzab	54	23	)	)	-RRB-
cord-313227-6zwkfzab	54	24	.	.	.
cord-313227-6zwkfzab	55	1	The	the	DT
cord-313227-6zwkfzab	55	2	most	most	RBS
cord-313227-6zwkfzab	55	3	compelling	compelling	JJ
cord-313227-6zwkfzab	55	4	emergency	emergency	NN
cord-313227-6zwkfzab	55	5	that	that	IN
cord-313227-6zwkfzab	55	6	the	the	DT
cord-313227-6zwkfzab	55	7	health	health	NN
cord-313227-6zwkfzab	55	8	system	system	NN
cord-313227-6zwkfzab	55	9	faces	face	VBZ
cord-313227-6zwkfzab	55	10	in	in	IN
cord-313227-6zwkfzab	55	11	this	this	DT
cord-313227-6zwkfzab	55	12	epidemic	epidemic	NN
cord-313227-6zwkfzab	55	13	is	be	VBZ
cord-313227-6zwkfzab	55	14	the	the	DT
cord-313227-6zwkfzab	55	15	shortage	shortage	NN
cord-313227-6zwkfzab	55	16	of	of	IN
cord-313227-6zwkfzab	55	17	critical	critical	JJ
cord-313227-6zwkfzab	55	18	care	care	NN
cord-313227-6zwkfzab	55	19	units	unit	NNS
cord-313227-6zwkfzab	55	20	.	.	.
cord-313227-6zwkfzab	56	1	The	the	DT
cord-313227-6zwkfzab	56	2	saturation	saturation	NN
cord-313227-6zwkfzab	56	3	of	of	IN
cord-313227-6zwkfzab	56	4	intensive	intensive	JJ
cord-313227-6zwkfzab	56	5	care	care	NN
cord-313227-6zwkfzab	56	6	units	unit	NNS
cord-313227-6zwkfzab	56	7	(	(	-LRB-
cord-313227-6zwkfzab	56	8	ICU	ICU	NNP
cord-313227-6zwkfzab	56	9	)	)	-RRB-
cord-313227-6zwkfzab	56	10	precludes	preclude	VBZ
cord-313227-6zwkfzab	56	11	the	the	DT
cord-313227-6zwkfzab	56	12	rescue	rescue	NN
cord-313227-6zwkfzab	56	13	of	of	IN
cord-313227-6zwkfzab	56	14	patients	patient	NNS
cord-313227-6zwkfzab	56	15	who	who	WP
cord-313227-6zwkfzab	56	16	might	may	MD
cord-313227-6zwkfzab	56	17	be	be	VB
cord-313227-6zwkfzab	56	18	saved	save	VBN
cord-313227-6zwkfzab	56	19	,	,	,
cord-313227-6zwkfzab	56	20	increases	increase	VBZ
cord-313227-6zwkfzab	56	21	COVID-19	covid-19	VBP
cord-313227-6zwkfzab	56	22	lethality	lethality	NN
cord-313227-6zwkfzab	56	23	rate	rate	NN
cord-313227-6zwkfzab	56	24	and	and	CC
cord-313227-6zwkfzab	56	25	worsens	worsen	VBZ
cord-313227-6zwkfzab	56	26	the	the	DT
cord-313227-6zwkfzab	56	27	prognosis	prognosis	NN
cord-313227-6zwkfzab	56	28	for	for	IN
cord-313227-6zwkfzab	56	29	other	other	JJ
cord-313227-6zwkfzab	56	30	pathological	pathological	JJ
cord-313227-6zwkfzab	56	31	conditions	condition	NNS
cord-313227-6zwkfzab	56	32	requiring	require	VBG
cord-313227-6zwkfzab	56	33	ICU	ICU	NNP
cord-313227-6zwkfzab	56	34	admission	admission	NN
cord-313227-6zwkfzab	56	35	.	.	.
cord-313227-6zwkfzab	57	1	The	the	DT
cord-313227-6zwkfzab	57	2	severe	severe	JJ
cord-313227-6zwkfzab	57	3	IP	ip	NN
cord-313227-6zwkfzab	57	4	or	or	CC
cord-313227-6zwkfzab	57	5	ARDS	ARDS	NNP
cord-313227-6zwkfzab	57	6	of	of	IN
cord-313227-6zwkfzab	57	7	the	the	DT
cord-313227-6zwkfzab	57	8	COVID-19	COVID-19	NNP
cord-313227-6zwkfzab	57	9	requires	require	VBZ
cord-313227-6zwkfzab	57	10	ventilator	ventilator	NN
cord-313227-6zwkfzab	57	11	support	support	NN
cord-313227-6zwkfzab	57	12	and	and	CC
cord-313227-6zwkfzab	57	13	can	can	MD
cord-313227-6zwkfzab	57	14	kill	kill	VB
cord-313227-6zwkfzab	57	15	infected	infected	JJ
cord-313227-6zwkfzab	57	16	people	people	NNS
cord-313227-6zwkfzab	57	17	averaging	average	VBG
cord-313227-6zwkfzab	57	18	in	in	IN
cord-313227-6zwkfzab	57	19	2	2	CD
cord-313227-6zwkfzab	57	20	weeks	week	NNS
cord-313227-6zwkfzab	57	21	from	from	IN
cord-313227-6zwkfzab	57	22	the	the	DT
cord-313227-6zwkfzab	57	23	appearance	appearance	NN
cord-313227-6zwkfzab	57	24	of	of	IN
cord-313227-6zwkfzab	57	25	the	the	DT
cord-313227-6zwkfzab	57	26	first	first	JJ
cord-313227-6zwkfzab	57	27	symptoms	symptom	NNS
cord-313227-6zwkfzab	57	28	(	(	-LRB-
cord-313227-6zwkfzab	57	29	27	27	CD
cord-313227-6zwkfzab	57	30	,	,	,
cord-313227-6zwkfzab	57	31	28	28	CD
cord-313227-6zwkfzab	57	32	)	)	-RRB-
cord-313227-6zwkfzab	57	33	.	.	.
cord-313227-6zwkfzab	58	1	Therapy	therapy	NN
cord-313227-6zwkfzab	58	2	in	in	IN
cord-313227-6zwkfzab	58	3	use	use	NN
cord-313227-6zwkfzab	58	4	for	for	IN
cord-313227-6zwkfzab	58	5	HIV	HIV	NNP
cord-313227-6zwkfzab	58	6	and	and	CC
cord-313227-6zwkfzab	58	7	other	other	JJ
cord-313227-6zwkfzab	58	8	viral	viral	JJ
cord-313227-6zwkfzab	58	9	disease	disease	NN
cord-313227-6zwkfzab	58	10	have	have	VBP
cord-313227-6zwkfzab	58	11	been	be	VBN
cord-313227-6zwkfzab	58	12	empirically	empirically	RB
cord-313227-6zwkfzab	58	13	administered	administer	VBN
cord-313227-6zwkfzab	58	14	without	without	IN
cord-313227-6zwkfzab	58	15	much	much	JJ
cord-313227-6zwkfzab	58	16	benefit	benefit	NN
cord-313227-6zwkfzab	58	17	(	(	-LRB-
cord-313227-6zwkfzab	58	18	29	29	CD
cord-313227-6zwkfzab	58	19	)	)	-RRB-
cord-313227-6zwkfzab	58	20	,	,	,
cord-313227-6zwkfzab	58	21	while	while	IN
cord-313227-6zwkfzab	58	22	promising	promise	VBG
cord-313227-6zwkfzab	58	23	experimental	experimental	JJ
cord-313227-6zwkfzab	58	24	antiviral	antiviral	JJ
cord-313227-6zwkfzab	58	25	drugs	drug	NNS
cord-313227-6zwkfzab	58	26	such	such	JJ
cord-313227-6zwkfzab	58	27	as	as	IN
cord-313227-6zwkfzab	58	28	remdesivir	remdesivir	NNP
cord-313227-6zwkfzab	58	29	and	and	CC
cord-313227-6zwkfzab	58	30	chloroquine	chloroquine	NNP
cord-313227-6zwkfzab	58	31	,	,	,
cord-313227-6zwkfzab	58	32	an	an	DT
cord-313227-6zwkfzab	58	33	old	old	JJ
cord-313227-6zwkfzab	58	34	antimalarial	antimalarial	JJ
cord-313227-6zwkfzab	58	35	drug	drug	NN
cord-313227-6zwkfzab	58	36	with	with	IN
cord-313227-6zwkfzab	58	37	in	in	FW
cord-313227-6zwkfzab	58	38	vitro	vitro	FW
cord-313227-6zwkfzab	58	39	activity	activity	NN
cord-313227-6zwkfzab	58	40	on	on	IN
cord-313227-6zwkfzab	58	41	the	the	DT
cord-313227-6zwkfzab	58	42	viral	viral	JJ
cord-313227-6zwkfzab	58	43	infection	infection	NN
cord-313227-6zwkfzab	58	44	,	,	,
cord-313227-6zwkfzab	58	45	are	be	VBP
cord-313227-6zwkfzab	58	46	currently	currently	RB
cord-313227-6zwkfzab	58	47	in	in	IN
cord-313227-6zwkfzab	58	48	clinical	clinical	JJ
cord-313227-6zwkfzab	58	49	trials	trial	NNS
cord-313227-6zwkfzab	58	50	(	(	-LRB-
cord-313227-6zwkfzab	58	51	30	30	CD
cord-313227-6zwkfzab	58	52	,	,	,
cord-313227-6zwkfzab	58	53	31	31	CD
cord-313227-6zwkfzab	58	54	)	)	-RRB-
cord-313227-6zwkfzab	58	55	.	.	.
cord-313227-6zwkfzab	59	1	In	in	IN
cord-313227-6zwkfzab	59	2	the	the	DT
cord-313227-6zwkfzab	59	3	absence	absence	NN
cord-313227-6zwkfzab	59	4	of	of	IN
cord-313227-6zwkfzab	59	5	specific	specific	JJ
cord-313227-6zwkfzab	59	6	validated	validate	VBN
cord-313227-6zwkfzab	59	7	approaches	approach	NNS
cord-313227-6zwkfzab	59	8	,	,	,
cord-313227-6zwkfzab	59	9	and	and	CC
cord-313227-6zwkfzab	59	10	waiting	wait	VBG
cord-313227-6zwkfzab	59	11	for	for	IN
cord-313227-6zwkfzab	59	12	a	a	DT
cord-313227-6zwkfzab	59	13	vaccine	vaccine	NN
cord-313227-6zwkfzab	59	14	,	,	,
cord-313227-6zwkfzab	59	15	a	a	DT
cord-313227-6zwkfzab	59	16	clinical	clinical	JJ
cord-313227-6zwkfzab	59	17	empirical	empirical	JJ
cord-313227-6zwkfzab	59	18	rational	rational	JJ
cord-313227-6zwkfzab	59	19	management	management	NN
cord-313227-6zwkfzab	59	20	is	be	VBZ
cord-313227-6zwkfzab	59	21	needed	need	VBN
cord-313227-6zwkfzab	59	22	.	.	.
cord-313227-6zwkfzab	60	1	Another	another	DT
cord-313227-6zwkfzab	60	2	reasonable	reasonable	JJ
cord-313227-6zwkfzab	60	3	approach	approach	NN
cord-313227-6zwkfzab	60	4	would	would	MD
cord-313227-6zwkfzab	60	5	be	be	VB
cord-313227-6zwkfzab	60	6	drugs	drug	NNS
cord-313227-6zwkfzab	60	7	targeting	target	VBG
cord-313227-6zwkfzab	60	8	the	the	DT
cord-313227-6zwkfzab	60	9	host	host	NN
cord-313227-6zwkfzab	60	10	immune	immune	JJ
cord-313227-6zwkfzab	60	11	-	-	HYPH
cord-313227-6zwkfzab	60	12	inflammatory	inflammatory	JJ
cord-313227-6zwkfzab	60	13	reaction	reaction	NN
cord-313227-6zwkfzab	60	14	.	.	.
cord-313227-6zwkfzab	61	1	Methylprednisolone	Methylprednisolone	NNP
cord-313227-6zwkfzab	61	2	,	,	,
cord-313227-6zwkfzab	61	3	although	although	IN
cord-313227-6zwkfzab	61	4	somewhat	somewhat	RB
cord-313227-6zwkfzab	61	5	controversial	controversial	JJ
cord-313227-6zwkfzab	61	6	,	,	,
cord-313227-6zwkfzab	61	7	seems	seem	VBZ
cord-313227-6zwkfzab	61	8	to	to	TO
cord-313227-6zwkfzab	61	9	be	be	VB
cord-313227-6zwkfzab	61	10	overall	overall	RB
cord-313227-6zwkfzab	61	11	useful	useful	JJ
cord-313227-6zwkfzab	61	12	in	in	IN
cord-313227-6zwkfzab	61	13	these	these	DT
cord-313227-6zwkfzab	61	14	patients	patient	NNS
cord-313227-6zwkfzab	61	15	(	(	-LRB-
cord-313227-6zwkfzab	61	16	32	32	CD
cord-313227-6zwkfzab	61	17	)	)	-RRB-
cord-313227-6zwkfzab	61	18	,	,	,
cord-313227-6zwkfzab	61	19	while	while	IN
cord-313227-6zwkfzab	61	20	dexamethasone	dexamethasone	NN
cord-313227-6zwkfzab	61	21	has	have	VBZ
cord-313227-6zwkfzab	61	22	been	be	VBN
cord-313227-6zwkfzab	61	23	shown	show	VBN
cord-313227-6zwkfzab	61	24	to	to	TO
cord-313227-6zwkfzab	61	25	be	be	VB
cord-313227-6zwkfzab	61	26	useful	useful	JJ
cord-313227-6zwkfzab	61	27	in	in	IN
cord-313227-6zwkfzab	61	28	patients	patient	NNS
cord-313227-6zwkfzab	61	29	with	with	IN
cord-313227-6zwkfzab	61	30	ARDS	ARDS	NNP
cord-313227-6zwkfzab	61	31	of	of	IN
cord-313227-6zwkfzab	61	32	different	different	JJ
cord-313227-6zwkfzab	61	33	etiologies	etiology	NNS
cord-313227-6zwkfzab	61	34	(	(	-LRB-
cord-313227-6zwkfzab	61	35	32	32	CD
cord-313227-6zwkfzab	61	36	,	,	,
cord-313227-6zwkfzab	61	37	33	33	CD
cord-313227-6zwkfzab	61	38	)	)	-RRB-
cord-313227-6zwkfzab	61	39	.	.	.
cord-313227-6zwkfzab	62	1	Cytokines	cytokine	NNS
cord-313227-6zwkfzab	62	2	and	and	CC
cord-313227-6zwkfzab	62	3	the	the	DT
cord-313227-6zwkfzab	62	4	other	other	JJ
cord-313227-6zwkfzab	62	5	molecules	molecule	NNS
cord-313227-6zwkfzab	62	6	involved	involve	VBN
cord-313227-6zwkfzab	62	7	in	in	IN
cord-313227-6zwkfzab	62	8	the	the	DT
cord-313227-6zwkfzab	62	9	immune	immune	JJ
cord-313227-6zwkfzab	62	10	response	response	NN
cord-313227-6zwkfzab	62	11	regulation	regulation	NN
cord-313227-6zwkfzab	62	12	and	and	CC
cord-313227-6zwkfzab	62	13	inflammation	inflammation	NN
cord-313227-6zwkfzab	62	14	are	be	VBP
cord-313227-6zwkfzab	62	15	conceivable	conceivable	JJ
cord-313227-6zwkfzab	62	16	targets	target	NNS
cord-313227-6zwkfzab	62	17	to	to	TO
cord-313227-6zwkfzab	62	18	improve	improve	VB
cord-313227-6zwkfzab	62	19	IP	IP	NNP
cord-313227-6zwkfzab	62	20	and	and	CC
cord-313227-6zwkfzab	62	21	ARDS	ARDS	NNP
cord-313227-6zwkfzab	62	22	lung	lung	NNP
cord-313227-6zwkfzab	62	23	injury	injury	NN
cord-313227-6zwkfzab	62	24	.	.	.
cord-313227-6zwkfzab	63	1	To	to	IN
cord-313227-6zwkfzab	63	2	this	this	DT
cord-313227-6zwkfzab	63	3	aim	aim	VB
cord-313227-6zwkfzab	63	4	off	off	RP
cord-313227-6zwkfzab	63	5	label	label	NN
cord-313227-6zwkfzab	63	6	drugs	drug	NNS
cord-313227-6zwkfzab	63	7	may	may	MD
cord-313227-6zwkfzab	63	8	be	be	VB
cord-313227-6zwkfzab	63	9	used	use	VBN
cord-313227-6zwkfzab	63	10	considering	consider	VBG
cord-313227-6zwkfzab	63	11	the	the	DT
cord-313227-6zwkfzab	63	12	timing	timing	NN
cord-313227-6zwkfzab	63	13	for	for	IN
cord-313227-6zwkfzab	63	14	immunosuppressive	immunosuppressive	JJ
cord-313227-6zwkfzab	63	15	drugs	drug	NNS
cord-313227-6zwkfzab	63	16	in	in	IN
cord-313227-6zwkfzab	63	17	virus	virus	NN
cord-313227-6zwkfzab	63	18	infected	infect	VBN
cord-313227-6zwkfzab	63	19	patients	patient	NNS
cord-313227-6zwkfzab	63	20	.	.	.
cord-313227-6zwkfzab	64	1	Unfortunately	unfortunately	RB
cord-313227-6zwkfzab	64	2	,	,	,
cord-313227-6zwkfzab	64	3	the	the	DT
cord-313227-6zwkfzab	64	4	time	time	NN
cord-313227-6zwkfzab	64	5	window	window	NN
cord-313227-6zwkfzab	64	6	is	be	VBZ
cord-313227-6zwkfzab	64	7	not	not	RB
cord-313227-6zwkfzab	64	8	univocally	univocally	RB
cord-313227-6zwkfzab	64	9	defined	define	VBN
cord-313227-6zwkfzab	64	10	and	and	CC
cord-313227-6zwkfzab	64	11	data	datum	NNS
cord-313227-6zwkfzab	64	12	may	may	MD
cord-313227-6zwkfzab	64	13	derive	derive	VB
cord-313227-6zwkfzab	64	14	from	from	IN
cord-313227-6zwkfzab	64	15	clinical	clinical	JJ
cord-313227-6zwkfzab	64	16	studies	study	NNS
cord-313227-6zwkfzab	64	17	.	.	.
cord-313227-6zwkfzab	65	1	Several	several	JJ
cord-313227-6zwkfzab	65	2	therapeutic	therapeutic	JJ
cord-313227-6zwkfzab	65	3	options	option	NNS
cord-313227-6zwkfzab	65	4	that	that	WDT
cord-313227-6zwkfzab	65	5	could	could	MD
cord-313227-6zwkfzab	65	6	be	be	VB
cord-313227-6zwkfzab	65	7	rapidly	rapidly	RB
cord-313227-6zwkfzab	65	8	translated	translate	VBN
cord-313227-6zwkfzab	65	9	to	to	IN
cord-313227-6zwkfzab	65	10	clinical	clinical	JJ
cord-313227-6zwkfzab	65	11	trials	trial	NNS
cord-313227-6zwkfzab	65	12	are	be	VBP
cord-313227-6zwkfzab	65	13	available	available	JJ
cord-313227-6zwkfzab	65	14	.	.	.
cord-313227-6zwkfzab	66	1	Some	some	DT
cord-313227-6zwkfzab	66	2	of	of	IN
cord-313227-6zwkfzab	66	3	them	-PRON-	PRP
cord-313227-6zwkfzab	66	4	are	be	VBP
cord-313227-6zwkfzab	66	5	listed	list	VBN
cord-313227-6zwkfzab	66	6	below	below	RB
cord-313227-6zwkfzab	66	7	.	.	.
cord-313227-6zwkfzab	67	1	Tocilizumab	Tocilizumab	NNP
cord-313227-6zwkfzab	67	2	is	be	VBZ
cord-313227-6zwkfzab	67	3	an	an	DT
cord-313227-6zwkfzab	67	4	anti	anti	JJ
cord-313227-6zwkfzab	67	5	-	-	JJ
cord-313227-6zwkfzab	67	6	IL6	il6	JJ
cord-313227-6zwkfzab	67	7	receptor	receptor	NN
cord-313227-6zwkfzab	67	8	antibody	antibody	NN
cord-313227-6zwkfzab	67	9	(	(	-LRB-
cord-313227-6zwkfzab	67	10	RoActemra	RoActemra	NNP
cord-313227-6zwkfzab	67	11	,	,	,
cord-313227-6zwkfzab	67	12	Roche	Roche	NNP
cord-313227-6zwkfzab	67	13	)	)	-RRB-
cord-313227-6zwkfzab	67	14	approved	approve	VBD
cord-313227-6zwkfzab	67	15	to	to	TO
cord-313227-6zwkfzab	67	16	treat	treat	VB
cord-313227-6zwkfzab	67	17	moderate	moderate	JJ
cord-313227-6zwkfzab	67	18	to	to	IN
cord-313227-6zwkfzab	67	19	severe	severe	JJ
cord-313227-6zwkfzab	67	20	rheumatoid	rheumatoid	NN
cord-313227-6zwkfzab	67	21	arthritis	arthritis	NN
cord-313227-6zwkfzab	67	22	(	(	-LRB-
cord-313227-6zwkfzab	67	23	RA	RA	NNP
cord-313227-6zwkfzab	67	24	)	)	-RRB-
cord-313227-6zwkfzab	67	25	.	.	.
cord-313227-6zwkfzab	68	1	Tocilizumab	Tocilizumab	NNP
cord-313227-6zwkfzab	68	2	has	have	VBZ
cord-313227-6zwkfzab	68	3	been	be	VBN
cord-313227-6zwkfzab	68	4	used	use	VBN
cord-313227-6zwkfzab	68	5	to	to	TO
cord-313227-6zwkfzab	68	6	counteract	counteract	VB
cord-313227-6zwkfzab	68	7	the	the	DT
cord-313227-6zwkfzab	68	8	side	side	NN
cord-313227-6zwkfzab	68	9	effects	effect	NNS
cord-313227-6zwkfzab	68	10	of	of	IN
cord-313227-6zwkfzab	68	11	immune	immune	JJ
cord-313227-6zwkfzab	68	12	checkpoint	checkpoint	NN
cord-313227-6zwkfzab	68	13	inhibitors	inhibitor	NNS
cord-313227-6zwkfzab	68	14	and	and	CC
cord-313227-6zwkfzab	68	15	CAR	car	NN
cord-313227-6zwkfzab	68	16	-	-	HYPH
cord-313227-6zwkfzab	68	17	T	t	NN
cord-313227-6zwkfzab	68	18	therapy	therapy	NN
cord-313227-6zwkfzab	68	19	in	in	IN
cord-313227-6zwkfzab	68	20	cancer	cancer	NN
cord-313227-6zwkfzab	68	21	bearing	bearing	NN
cord-313227-6zwkfzab	68	22	patients	patient	NNS
cord-313227-6zwkfzab	68	23	(	(	-LRB-
cord-313227-6zwkfzab	68	24	34	34	CD
cord-313227-6zwkfzab	68	25	)	)	-RRB-
cord-313227-6zwkfzab	68	26	and	and	CC
cord-313227-6zwkfzab	68	27	,	,	,
cord-313227-6zwkfzab	68	28	recently	recently	RB
cord-313227-6zwkfzab	68	29	,	,	,
cord-313227-6zwkfzab	68	30	to	to	TO
cord-313227-6zwkfzab	68	31	antagonize	antagonize	VB
cord-313227-6zwkfzab	68	32	the	the	DT
cord-313227-6zwkfzab	68	33	host	host	NN
cord-313227-6zwkfzab	68	34	reaction	reaction	NN
cord-313227-6zwkfzab	68	35	in	in	IN
cord-313227-6zwkfzab	68	36	patients	patient	NNS
cord-313227-6zwkfzab	68	37	affected	affect	VBN
cord-313227-6zwkfzab	68	38	by	by	IN
cord-313227-6zwkfzab	68	39	ARDS	ARDS	NNP
cord-313227-6zwkfzab	68	40	linked	link	VBN
cord-313227-6zwkfzab	68	41	to	to	IN
cord-313227-6zwkfzab	68	42	COVID	COVID	NNP
cord-313227-6zwkfzab	68	43	19	19	CD
cord-313227-6zwkfzab	68	44	(	(	-LRB-
cord-313227-6zwkfzab	68	45	35	35	CD
cord-313227-6zwkfzab	68	46	)	)	-RRB-
cord-313227-6zwkfzab	68	47	.	.	.
cord-313227-6zwkfzab	69	1	At	at	IN
cord-313227-6zwkfzab	69	2	today	today	NN
cord-313227-6zwkfzab	69	3	COVID-19	COVID-19	NNP
cord-313227-6zwkfzab	69	4	national	national	JJ
cord-313227-6zwkfzab	69	5	management	management	NN
cord-313227-6zwkfzab	69	6	guidelines	guideline	NNS
cord-313227-6zwkfzab	69	7	of	of	IN
cord-313227-6zwkfzab	69	8	Chinese	chinese	JJ
cord-313227-6zwkfzab	69	9	health	health	NN
cord-313227-6zwkfzab	69	10	authorities	authority	NNS
cord-313227-6zwkfzab	69	11	include	include	VBP
cord-313227-6zwkfzab	69	12	the	the	DT
cord-313227-6zwkfzab	69	13	use	use	NN
cord-313227-6zwkfzab	69	14	of	of	IN
cord-313227-6zwkfzab	69	15	Tocilizumab	Tocilizumab	NNP
cord-313227-6zwkfzab	69	16	for	for	IN
cord-313227-6zwkfzab	69	17	severe	severe	JJ
cord-313227-6zwkfzab	69	18	pneumonia	pneumonia	NN
cord-313227-6zwkfzab	69	19	.	.	.
cord-313227-6zwkfzab	70	1	A	a	DT
cord-313227-6zwkfzab	70	2	preliminary	preliminary	JJ
cord-313227-6zwkfzab	70	3	report	report	NN
cord-313227-6zwkfzab	70	4	on	on	IN
cord-313227-6zwkfzab	70	5	21	21	CD
cord-313227-6zwkfzab	70	6	critical	critical	JJ
cord-313227-6zwkfzab	70	7	cases	case	NNS
cord-313227-6zwkfzab	70	8	of	of	IN
cord-313227-6zwkfzab	70	9	COVID-19	COVID-19	NNP
cord-313227-6zwkfzab	70	10	suggests	suggest	VBZ
cord-313227-6zwkfzab	70	11	efficacy	efficacy	NN
cord-313227-6zwkfzab	70	12	of	of	IN
cord-313227-6zwkfzab	70	13	the	the	DT
cord-313227-6zwkfzab	70	14	treatment	treatment	NN
cord-313227-6zwkfzab	70	15	with	with	IN
cord-313227-6zwkfzab	70	16	faster	fast	JJR
cord-313227-6zwkfzab	70	17	recovery	recovery	NN
cord-313227-6zwkfzab	70	18	and	and	CC
cord-313227-6zwkfzab	70	19	lower	low	JJR
cord-313227-6zwkfzab	70	20	risk	risk	NN
cord-313227-6zwkfzab	70	21	of	of	IN
cord-313227-6zwkfzab	70	22	death	death	NN
cord-313227-6zwkfzab	70	23	for	for	IN
cord-313227-6zwkfzab	70	24	treated	treat	VBN
cord-313227-6zwkfzab	70	25	patients	patient	NNS
cord-313227-6zwkfzab	70	26	,	,	,
cord-313227-6zwkfzab	70	27	while	while	IN
cord-313227-6zwkfzab	70	28	no	no	DT
cord-313227-6zwkfzab	70	29	toxicity	toxicity	NN
cord-313227-6zwkfzab	70	30	was	be	VBD
cord-313227-6zwkfzab	70	31	associated	associate	VBN
cord-313227-6zwkfzab	70	32	with	with	IN
cord-313227-6zwkfzab	70	33	the	the	DT
cord-313227-6zwkfzab	70	34	reported	report	VBN
cord-313227-6zwkfzab	70	35	administration	administration	NN
cord-313227-6zwkfzab	70	36	schedule	schedule	NN
cord-313227-6zwkfzab	70	37	(	(	-LRB-
cord-313227-6zwkfzab	70	38	one	one	CD
cord-313227-6zwkfzab	70	39	or	or	CC
cord-313227-6zwkfzab	70	40	maximum	maximum	VB
cord-313227-6zwkfzab	70	41	two	two	CD
cord-313227-6zwkfzab	70	42	doses	dose	NNS
cord-313227-6zwkfzab	70	43	)	)	-RRB-
cord-313227-6zwkfzab	70	44	(	(	-LRB-
cord-313227-6zwkfzab	70	45	36	36	CD
cord-313227-6zwkfzab	70	46	)	)	-RRB-
cord-313227-6zwkfzab	70	47	.	.	.
cord-313227-6zwkfzab	71	1	Timing	timing	NN
cord-313227-6zwkfzab	71	2	of	of	IN
cord-313227-6zwkfzab	71	3	administration	administration	NN
cord-313227-6zwkfzab	71	4	seems	seem	VBZ
cord-313227-6zwkfzab	71	5	to	to	TO
cord-313227-6zwkfzab	71	6	be	be	VB
cord-313227-6zwkfzab	71	7	crucial	crucial	JJ
cord-313227-6zwkfzab	71	8	as	as	IN
cord-313227-6zwkfzab	71	9	tocilizumab	tocilizumab	NNP
cord-313227-6zwkfzab	71	10	may	may	MD
cord-313227-6zwkfzab	71	11	be	be	VB
cord-313227-6zwkfzab	71	12	more	more	RBR
cord-313227-6zwkfzab	71	13	efficient	efficient	JJ
cord-313227-6zwkfzab	71	14	if	if	IN
cord-313227-6zwkfzab	71	15	administered	administer	VBN
cord-313227-6zwkfzab	71	16	earlier	early	RBR
cord-313227-6zwkfzab	71	17	than	than	IN
cord-313227-6zwkfzab	71	18	actual	actual	JJ
cord-313227-6zwkfzab	71	19	use	use	NN
cord-313227-6zwkfzab	71	20	(	(	-LRB-
cord-313227-6zwkfzab	71	21	37	37	CD
cord-313227-6zwkfzab	71	22	)	)	-RRB-
cord-313227-6zwkfzab	71	23	.	.	.
cord-313227-6zwkfzab	72	1	Anakinra	Anakinra	NNP
cord-313227-6zwkfzab	72	2	is	be	VBZ
cord-313227-6zwkfzab	72	3	an	an	DT
cord-313227-6zwkfzab	72	4	interleukin-1	interleukin-1	NNP
cord-313227-6zwkfzab	72	5	receptor	receptor	NN
cord-313227-6zwkfzab	72	6	antagonist	antagonist	NN
cord-313227-6zwkfzab	72	7	(	(	-LRB-
cord-313227-6zwkfzab	72	8	IL-1RA	IL-1RA	NNP
cord-313227-6zwkfzab	72	9	)	)	-RRB-
cord-313227-6zwkfzab	72	10	previously	previously	RB
cord-313227-6zwkfzab	72	11	evaluated	evaluate	VBN
cord-313227-6zwkfzab	72	12	in	in	IN
cord-313227-6zwkfzab	72	13	clinical	clinical	JJ
cord-313227-6zwkfzab	72	14	trials	trial	NNS
cord-313227-6zwkfzab	72	15	for	for	IN
cord-313227-6zwkfzab	72	16	RA	RA	NNP
cord-313227-6zwkfzab	72	17	patients	patient	NNS
cord-313227-6zwkfzab	72	18	.	.	.
cord-313227-6zwkfzab	73	1	IL-1beta	il-1beta	JJ
cord-313227-6zwkfzab	73	2	/	/	SYM
cord-313227-6zwkfzab	73	3	IL-1alpha	il-1alpha	EX
cord-313227-6zwkfzab	73	4	are	be	VBP
cord-313227-6zwkfzab	73	5	two	two	CD
cord-313227-6zwkfzab	73	6	stimulating	stimulate	VBG
cord-313227-6zwkfzab	73	7	cytokines	cytokine	NNS
cord-313227-6zwkfzab	73	8	of	of	IN
cord-313227-6zwkfzab	73	9	monocyte	monocyte	JJ
cord-313227-6zwkfzab	73	10	-	-	HYPH
cord-313227-6zwkfzab	73	11	macrophage	macrophage	NN
cord-313227-6zwkfzab	73	12	cells	cell	NNS
cord-313227-6zwkfzab	73	13	acting	act	VBG
cord-313227-6zwkfzab	73	14	upstream	upstream	RB
cord-313227-6zwkfzab	73	15	of	of	IN
cord-313227-6zwkfzab	73	16	the	the	DT
cord-313227-6zwkfzab	73	17	inflammatory	inflammatory	JJ
cord-313227-6zwkfzab	73	18	signaling	signal	VBG
cord-313227-6zwkfzab	73	19	pathway	pathway	NN
cord-313227-6zwkfzab	73	20	induced	induce	VBN
cord-313227-6zwkfzab	73	21	by	by	IN
cord-313227-6zwkfzab	73	22	inflammasome	inflammasome	NNP
cord-313227-6zwkfzab	73	23	,	,	,
cord-313227-6zwkfzab	73	24	thus	thus	RB
cord-313227-6zwkfzab	73	25	anakinra	anakinra	NNP
cord-313227-6zwkfzab	73	26	should	should	MD
cord-313227-6zwkfzab	73	27	block	block	VB
cord-313227-6zwkfzab	73	28	the	the	DT
cord-313227-6zwkfzab	73	29	cytokine	cytokine	NN
cord-313227-6zwkfzab	73	30	storm	storm	NN
cord-313227-6zwkfzab	73	31	.	.	.
cord-313227-6zwkfzab	74	1	In	in	IN
cord-313227-6zwkfzab	74	2	a	a	DT
cord-313227-6zwkfzab	74	3	small	small	JJ
cord-313227-6zwkfzab	74	4	open	open	JJ
cord-313227-6zwkfzab	74	5	-	-	HYPH
cord-313227-6zwkfzab	74	6	label	label	NN
cord-313227-6zwkfzab	74	7	study	study	NN
cord-313227-6zwkfzab	74	8	,	,	,
cord-313227-6zwkfzab	74	9	anakinra	anakinra	NNP
cord-313227-6zwkfzab	74	10	has	have	VBZ
cord-313227-6zwkfzab	74	11	been	be	VBN
cord-313227-6zwkfzab	74	12	tested	test	VBN
cord-313227-6zwkfzab	74	13	as	as	IN
cord-313227-6zwkfzab	74	14	agent	agent	NN
cord-313227-6zwkfzab	74	15	preventive	preventive	NN
cord-313227-6zwkfzab	74	16	of	of	IN
cord-313227-6zwkfzab	74	17	mechanic	mechanic	NN
cord-313227-6zwkfzab	74	18	ventilation	ventilation	NN
cord-313227-6zwkfzab	74	19	in	in	IN
cord-313227-6zwkfzab	74	20	9	9	CD
cord-313227-6zwkfzab	74	21	patients	patient	NNS
cord-313227-6zwkfzab	74	22	hospitalized	hospitalize	VBN
cord-313227-6zwkfzab	74	23	for	for	IN
cord-313227-6zwkfzab	74	24	moderate	moderate	JJ
cord-313227-6zwkfzab	74	25	-	-	HYPH
cord-313227-6zwkfzab	74	26	severe	severe	JJ
cord-313227-6zwkfzab	74	27	COVID-19	covid-19	NN
cord-313227-6zwkfzab	74	28	.	.	.
cord-313227-6zwkfzab	75	1	Amelioration	amelioration	NN
cord-313227-6zwkfzab	75	2	of	of	IN
cord-313227-6zwkfzab	75	3	oxygen	oxygen	NN
cord-313227-6zwkfzab	75	4	flow	flow	NN
cord-313227-6zwkfzab	75	5	and	and	CC
cord-313227-6zwkfzab	75	6	blood	blood	NN
cord-313227-6zwkfzab	75	7	inflammation	inflammation	NN
cord-313227-6zwkfzab	75	8	markers	marker	NNS
cord-313227-6zwkfzab	75	9	was	be	VBD
cord-313227-6zwkfzab	75	10	described	describe	VBN
cord-313227-6zwkfzab	75	11	without	without	IN
cord-313227-6zwkfzab	75	12	significant	significant	JJ
cord-313227-6zwkfzab	75	13	toxicity	toxicity	NN
cord-313227-6zwkfzab	75	14	(	(	-LRB-
cord-313227-6zwkfzab	75	15	38	38	CD
cord-313227-6zwkfzab	75	16	)	)	-RRB-
cord-313227-6zwkfzab	75	17	.	.	.
cord-313227-6zwkfzab	76	1	In	in	IN
cord-313227-6zwkfzab	76	2	clinically	clinically	RB
cord-313227-6zwkfzab	76	3	moderate	moderate	JJ
cord-313227-6zwkfzab	76	4	and	and	CC
cord-313227-6zwkfzab	76	5	severe	severe	JJ
cord-313227-6zwkfzab	76	6	COVID-19	covid-19	JJ
cord-313227-6zwkfzab	76	7	patients	patient	NNS
cord-313227-6zwkfzab	76	8	preliminary	preliminary	JJ
cord-313227-6zwkfzab	76	9	evidence	evidence	NN
cord-313227-6zwkfzab	76	10	reported	report	VBD
cord-313227-6zwkfzab	76	11	high	high	JJ
cord-313227-6zwkfzab	76	12	levels	level	NNS
cord-313227-6zwkfzab	76	13	of	of	IN
cord-313227-6zwkfzab	76	14	three	three	CD
cord-313227-6zwkfzab	76	15	cytokines	cytokine	NNS
cord-313227-6zwkfzab	76	16	,	,	,
cord-313227-6zwkfzab	76	17	CXCL10	CXCL10	NNP
cord-313227-6zwkfzab	76	18	,	,	,
cord-313227-6zwkfzab	76	19	CCL7	CCL7	NNP
cord-313227-6zwkfzab	76	20	and	and	CC
cord-313227-6zwkfzab	76	21	IL-1	IL-1	NNP
cord-313227-6zwkfzab	76	22	,	,	,
cord-313227-6zwkfzab	76	23	rather	rather	RB
cord-313227-6zwkfzab	76	24	than	than	IN
cord-313227-6zwkfzab	76	25	IL-6	IL-6	NNP
cord-313227-6zwkfzab	76	26	,	,	,
cord-313227-6zwkfzab	76	27	(	(	-LRB-
cord-313227-6zwkfzab	76	28	39	39	CD
cord-313227-6zwkfzab	76	29	)	)	-RRB-
cord-313227-6zwkfzab	76	30	.	.	.
cord-313227-6zwkfzab	77	1	In	in	IN
cord-313227-6zwkfzab	77	2	chronic	chronic	JJ
cord-313227-6zwkfzab	77	3	use	use	NN
cord-313227-6zwkfzab	77	4	Anakinra	Anakinra	NNP
cord-313227-6zwkfzab	77	5	could	could	MD
cord-313227-6zwkfzab	77	6	determine	determine	VB
cord-313227-6zwkfzab	77	7	reaction	reaction	NN
cord-313227-6zwkfzab	77	8	at	at	IN
cord-313227-6zwkfzab	77	9	the	the	DT
cord-313227-6zwkfzab	77	10	site	site	NN
cord-313227-6zwkfzab	77	11	of	of	IN
cord-313227-6zwkfzab	77	12	injection	injection	NN
cord-313227-6zwkfzab	77	13	and	and	CC
cord-313227-6zwkfzab	77	14	infection	infection	NN
cord-313227-6zwkfzab	77	15	as	as	IN
cord-313227-6zwkfzab	77	16	the	the	DT
cord-313227-6zwkfzab	77	17	main	main	JJ
cord-313227-6zwkfzab	77	18	side	side	NN
cord-313227-6zwkfzab	77	19	effects	effect	NNS
cord-313227-6zwkfzab	77	20	(	(	-LRB-
cord-313227-6zwkfzab	77	21	40	40	CD
cord-313227-6zwkfzab	77	22	)	)	-RRB-
cord-313227-6zwkfzab	77	23	.	.	.
cord-313227-6zwkfzab	78	1	Emapalumab	Emapalumab	NNP
cord-313227-6zwkfzab	78	2	is	be	VBZ
cord-313227-6zwkfzab	78	3	a	a	DT
cord-313227-6zwkfzab	78	4	fully	fully	RB
cord-313227-6zwkfzab	78	5	human	human	JJ
cord-313227-6zwkfzab	78	6	IgG1	IgG1	NNP
cord-313227-6zwkfzab	78	7	monoclonal	monoclonal	JJ
cord-313227-6zwkfzab	78	8	antibody	antibody	NN
cord-313227-6zwkfzab	78	9	that	that	WDT
cord-313227-6zwkfzab	78	10	binds	bind	VBZ
cord-313227-6zwkfzab	78	11	free	free	JJ
cord-313227-6zwkfzab	78	12	and	and	CC
cord-313227-6zwkfzab	78	13	receptor	receptor	NN
cord-313227-6zwkfzab	78	14	-	-	HYPH
cord-313227-6zwkfzab	78	15	bound	bind	VBN
cord-313227-6zwkfzab	78	16	interferon	interferon	NN
cord-313227-6zwkfzab	78	17	-	-	HYPH
cord-313227-6zwkfzab	78	18	γ	γ	NN
cord-313227-6zwkfzab	78	19	.	.	.
cord-313227-6zwkfzab	79	1	Emapalumab	Emapalumab	NNP
cord-313227-6zwkfzab	79	2	is	be	VBZ
cord-313227-6zwkfzab	79	3	approved	approve	VBN
cord-313227-6zwkfzab	79	4	by	by	IN
cord-313227-6zwkfzab	79	5	the	the	DT
cord-313227-6zwkfzab	79	6	US	US	NNP
cord-313227-6zwkfzab	79	7	FDA	FDA	NNP
cord-313227-6zwkfzab	79	8	for	for	IN
cord-313227-6zwkfzab	79	9	the	the	DT
cord-313227-6zwkfzab	79	10	treatment	treatment	NN
cord-313227-6zwkfzab	79	11	of	of	IN
cord-313227-6zwkfzab	79	12	haemophagocytic	haemophagocytic	NNP
cord-313227-6zwkfzab	79	13	(	(	-LRB-
cord-313227-6zwkfzab	79	14	HLH	HLH	NNP
cord-313227-6zwkfzab	79	15	)	)	-RRB-
cord-313227-6zwkfzab	79	16	(	(	-LRB-
cord-313227-6zwkfzab	79	17	41	41	CD
cord-313227-6zwkfzab	79	18	)	)	-RRB-
cord-313227-6zwkfzab	79	19	a	a	DT
cord-313227-6zwkfzab	79	20	rare	rare	JJ
cord-313227-6zwkfzab	79	21	disorder	disorder	NN
cord-313227-6zwkfzab	79	22	characterized	characterize	VBN
cord-313227-6zwkfzab	79	23	by	by	IN
cord-313227-6zwkfzab	79	24	pathologic	pathologic	JJ
cord-313227-6zwkfzab	79	25	immune	immune	JJ
cord-313227-6zwkfzab	79	26	activation	activation	NN
cord-313227-6zwkfzab	79	27	and	and	CC
cord-313227-6zwkfzab	79	28	hyperinflammation	hyperinflammation	NN
cord-313227-6zwkfzab	79	29	that	that	WDT
cord-313227-6zwkfzab	79	30	eventually	eventually	RB
cord-313227-6zwkfzab	79	31	damage	damage	VBP
cord-313227-6zwkfzab	79	32	multiple	multiple	JJ
cord-313227-6zwkfzab	79	33	organs	organ	NNS
cord-313227-6zwkfzab	79	34	.	.	.
cord-313227-6zwkfzab	80	1	A	a	DT
cord-313227-6zwkfzab	80	2	prospective	prospective	JJ
cord-313227-6zwkfzab	80	3	study	study	NN
cord-313227-6zwkfzab	80	4	has	have	VBZ
cord-313227-6zwkfzab	80	5	shown	show	VBN
cord-313227-6zwkfzab	80	6	a	a	DT
cord-313227-6zwkfzab	80	7	good	good	JJ
cord-313227-6zwkfzab	80	8	safety	safety	NN
cord-313227-6zwkfzab	80	9	profile	profile	NN
cord-313227-6zwkfzab	80	10	of	of	IN
cord-313227-6zwkfzab	80	11	emapalumab	emapalumab	NNP
cord-313227-6zwkfzab	80	12	in	in	IN
cord-313227-6zwkfzab	80	13	pediatric	pediatric	JJ
cord-313227-6zwkfzab	80	14	and	and	CC
cord-313227-6zwkfzab	80	15	adolescent	adolescent	JJ
cord-313227-6zwkfzab	80	16	patients	patient	NNS
cord-313227-6zwkfzab	80	17	affected	affect	VBN
cord-313227-6zwkfzab	80	18	by	by	IN
cord-313227-6zwkfzab	80	19	HLH	HLH	NNP
cord-313227-6zwkfzab	80	20	,	,	,
cord-313227-6zwkfzab	80	21	with	with	IN
cord-313227-6zwkfzab	80	22	the	the	DT
cord-313227-6zwkfzab	80	23	infection	infection	NN
cord-313227-6zwkfzab	80	24	susceptibility	susceptibility	NN
cord-313227-6zwkfzab	80	25	being	be	VBG
cord-313227-6zwkfzab	80	26	the	the	DT
cord-313227-6zwkfzab	80	27	major	major	JJ
cord-313227-6zwkfzab	80	28	threat	threat	NN
cord-313227-6zwkfzab	80	29	(	(	-LRB-
cord-313227-6zwkfzab	80	30	42	42	CD
cord-313227-6zwkfzab	80	31	)	)	-RRB-
cord-313227-6zwkfzab	80	32	.	.	.
cord-313227-6zwkfzab	81	1	Blocking	block	VBG
cord-313227-6zwkfzab	81	2	IFN	IFN	NNP
cord-313227-6zwkfzab	81	3	γ	γ	NN
cord-313227-6zwkfzab	81	4	activity	activity	NN
cord-313227-6zwkfzab	81	5	could	could	MD
cord-313227-6zwkfzab	81	6	counteract	counteract	VB
cord-313227-6zwkfzab	81	7	the	the	DT
cord-313227-6zwkfzab	81	8	host	host	NN
cord-313227-6zwkfzab	81	9	immune	immune	JJ
cord-313227-6zwkfzab	81	10	hyper	hyper	JJ
cord-313227-6zwkfzab	81	11	-	-	NN
cord-313227-6zwkfzab	81	12	reaction	reaction	NN
cord-313227-6zwkfzab	81	13	to	to	IN
cord-313227-6zwkfzab	81	14	SARS	SARS	NNP
cord-313227-6zwkfzab	81	15	-	-	HYPH
cord-313227-6zwkfzab	81	16	COv-2	COv-2	NNP
cord-313227-6zwkfzab	81	17	.	.	.
cord-313227-6zwkfzab	82	1	Mycophenolic	Mycophenolic	NNP
cord-313227-6zwkfzab	82	2	acid	acid	NN
cord-313227-6zwkfzab	82	3	has	have	VBZ
cord-313227-6zwkfzab	82	4	been	be	VBN
cord-313227-6zwkfzab	82	5	used	use	VBN
cord-313227-6zwkfzab	82	6	as	as	IN
cord-313227-6zwkfzab	82	7	immunosuppressant	immunosuppressant	JJ
cord-313227-6zwkfzab	82	8	agent	agent	NN
cord-313227-6zwkfzab	82	9	in	in	IN
cord-313227-6zwkfzab	82	10	pemphigus	pemphigus	NNP
cord-313227-6zwkfzab	82	11	as	as	IN
cord-313227-6zwkfzab	82	12	a	a	DT
cord-313227-6zwkfzab	82	13	corticosteroid	corticosteroid	NN
cord-313227-6zwkfzab	82	14	-	-	HYPH
cord-313227-6zwkfzab	82	15	sparing	spare	VBG
cord-313227-6zwkfzab	82	16	agent	agent	NN
cord-313227-6zwkfzab	82	17	and	and	CC
cord-313227-6zwkfzab	82	18	in	in	IN
cord-313227-6zwkfzab	82	19	kidney	kidney	NN
cord-313227-6zwkfzab	82	20	transplant	transplant	NN
cord-313227-6zwkfzab	82	21	patients	patient	NNS
cord-313227-6zwkfzab	82	22	to	to	TO
cord-313227-6zwkfzab	82	23	avoid	avoid	VB
cord-313227-6zwkfzab	82	24	rejection	rejection	NN
cord-313227-6zwkfzab	82	25	.	.	.
cord-313227-6zwkfzab	83	1	It	-PRON-	PRP
cord-313227-6zwkfzab	83	2	inhibits	inhibit	VBZ
cord-313227-6zwkfzab	83	3	inositol	inositol	NN
cord-313227-6zwkfzab	83	4	monophosphate	monophosphate	NN
cord-313227-6zwkfzab	83	5	dehydrogenase	dehydrogenase	NN
cord-313227-6zwkfzab	83	6	,	,	,
cord-313227-6zwkfzab	83	7	that	that	WDT
cord-313227-6zwkfzab	83	8	causes	cause	VBZ
cord-313227-6zwkfzab	83	9	depletion	depletion	NN
cord-313227-6zwkfzab	83	10	of	of	IN
cord-313227-6zwkfzab	83	11	guanosine	guanosine	NN
cord-313227-6zwkfzab	83	12	and	and	CC
cord-313227-6zwkfzab	83	13	deoxyguanosine	deoxyguanosine	NN
cord-313227-6zwkfzab	83	14	nucleotide	nucleotide	JJ
cord-313227-6zwkfzab	83	15	pools	pool	NNS
cord-313227-6zwkfzab	83	16	impairing	impair	VBG
cord-313227-6zwkfzab	83	17	the	the	DT
cord-313227-6zwkfzab	83	18	activity	activity	NN
cord-313227-6zwkfzab	83	19	of	of	IN
cord-313227-6zwkfzab	83	20	B	b	NN
cord-313227-6zwkfzab	83	21	and	and	CC
cord-313227-6zwkfzab	83	22	T	t	NN
cord-313227-6zwkfzab	83	23	lymphocytes	lymphocyte	NNS
cord-313227-6zwkfzab	83	24	.	.	.
cord-313227-6zwkfzab	84	1	The	the	DT
cord-313227-6zwkfzab	84	2	drug	drug	NN
cord-313227-6zwkfzab	84	3	has	have	VBZ
cord-313227-6zwkfzab	84	4	also	also	RB
cord-313227-6zwkfzab	84	5	been	be	VBN
cord-313227-6zwkfzab	84	6	demonstrated	demonstrate	VBN
cord-313227-6zwkfzab	84	7	to	to	TO
cord-313227-6zwkfzab	84	8	inhibit	inhibit	VB
cord-313227-6zwkfzab	84	9	mRNA	mrna	NN
cord-313227-6zwkfzab	84	10	expression	expression	NN
cord-313227-6zwkfzab	84	11	of	of	IN
cord-313227-6zwkfzab	84	12	pro	pro	JJ
cord-313227-6zwkfzab	84	13	-	-	JJ
cord-313227-6zwkfzab	84	14	inflammatory	inflammatory	JJ
cord-313227-6zwkfzab	84	15	cytokines	cytokine	NNS
cord-313227-6zwkfzab	85	1	TNF	TNF	NNP
cord-313227-6zwkfzab	85	2	-	-	HYPH
cord-313227-6zwkfzab	85	3	α	α	NNP
cord-313227-6zwkfzab	85	4	,	,	,
cord-313227-6zwkfzab	85	5	IL-6	IL-6	NNP
cord-313227-6zwkfzab	85	6	,	,	,
cord-313227-6zwkfzab	85	7	and	and	CC
cord-313227-6zwkfzab	85	8	IL-1β4	IL-1β4	NNP
cord-313227-6zwkfzab	85	9	(	(	-LRB-
cord-313227-6zwkfzab	85	10	43	43	CD
cord-313227-6zwkfzab	85	11	)	)	-RRB-
cord-313227-6zwkfzab	85	12	.	.	.
cord-313227-6zwkfzab	86	1	Mycophenolic	Mycophenolic	NNP
cord-313227-6zwkfzab	86	2	acid	acid	NN
cord-313227-6zwkfzab	86	3	has	have	VBZ
cord-313227-6zwkfzab	86	4	been	be	VBN
cord-313227-6zwkfzab	86	5	shown	show	VBN
cord-313227-6zwkfzab	86	6	to	to	TO
cord-313227-6zwkfzab	86	7	have	have	VB
cord-313227-6zwkfzab	86	8	activity	activity	NN
cord-313227-6zwkfzab	86	9	in	in	IN
cord-313227-6zwkfzab	86	10	vitro	vitro	FW
cord-313227-6zwkfzab	86	11	against	against	IN
cord-313227-6zwkfzab	86	12	zika	zika	NNP
cord-313227-6zwkfzab	86	13	virus	virus	NN
cord-313227-6zwkfzab	86	14	replication	replication	NN
cord-313227-6zwkfzab	86	15	(	(	-LRB-
cord-313227-6zwkfzab	86	16	44	44	CD
cord-313227-6zwkfzab	86	17	)	)	-RRB-
cord-313227-6zwkfzab	86	18	and	and	CC
cord-313227-6zwkfzab	86	19	coronavirus	coronavirus	NN
cord-313227-6zwkfzab	86	20	through	through	IN
cord-313227-6zwkfzab	86	21	a	a	DT
cord-313227-6zwkfzab	86	22	non	non	JJ
cord-313227-6zwkfzab	86	23	-	-	JJ
cord-313227-6zwkfzab	86	24	competitive	competitive	JJ
cord-313227-6zwkfzab	86	25	inhibition	inhibition	NN
cord-313227-6zwkfzab	86	26	of	of	IN
cord-313227-6zwkfzab	86	27	MERS	MERS	NNP
cord-313227-6zwkfzab	86	28	-	-	HYPH
cord-313227-6zwkfzab	86	29	CoV	CoV	NNP
cord-313227-6zwkfzab	86	30	papain	papain	NN
cord-313227-6zwkfzab	86	31	-	-	HYPH
cord-313227-6zwkfzab	86	32	like	like	JJ
cord-313227-6zwkfzab	86	33	protease	protease	NN
cord-313227-6zwkfzab	86	34	(	(	-LRB-
cord-313227-6zwkfzab	86	35	45	45	CD
cord-313227-6zwkfzab	86	36	)	)	-RRB-
cord-313227-6zwkfzab	86	37	.	.	.
cord-313227-6zwkfzab	87	1	Urinary	urinary	JJ
cord-313227-6zwkfzab	87	2	infections	infection	NNS
cord-313227-6zwkfzab	87	3	,	,	,
cord-313227-6zwkfzab	87	4	diarrhea	diarrhea	NN
cord-313227-6zwkfzab	87	5	,	,	,
cord-313227-6zwkfzab	87	6	and	and	CC
cord-313227-6zwkfzab	87	7	leukopenia	leukopenia	NN
cord-313227-6zwkfzab	87	8	are	be	VBP
cord-313227-6zwkfzab	87	9	the	the	DT
cord-313227-6zwkfzab	87	10	side	side	NN
cord-313227-6zwkfzab	87	11	effects	effect	NNS
cord-313227-6zwkfzab	87	12	more	more	RBR
cord-313227-6zwkfzab	87	13	often	often	RB
cord-313227-6zwkfzab	87	14	described	describe	VBN
cord-313227-6zwkfzab	87	15	(	(	-LRB-
cord-313227-6zwkfzab	87	16	46	46	CD
cord-313227-6zwkfzab	87	17	)	)	-RRB-
cord-313227-6zwkfzab	87	18	.	.	.
cord-313227-6zwkfzab	88	1	Anti	Anti	NNP
cord-313227-6zwkfzab	88	2	-	-	JJ
cord-313227-6zwkfzab	88	3	TNFα	tnfα	JJ
cord-313227-6zwkfzab	88	4	agents	agent	NNS
cord-313227-6zwkfzab	88	5	used	use	VBN
cord-313227-6zwkfzab	88	6	in	in	IN
cord-313227-6zwkfzab	88	7	autoimmune	autoimmune	JJ
cord-313227-6zwkfzab	88	8	diseases	disease	NNS
cord-313227-6zwkfzab	88	9	,	,	,
cord-313227-6zwkfzab	88	10	such	such	JJ
cord-313227-6zwkfzab	88	11	as	as	IN
cord-313227-6zwkfzab	88	12	RA	RA	NNP
cord-313227-6zwkfzab	88	13	and	and	CC
cord-313227-6zwkfzab	88	14	ulcerative	ulcerative	JJ
cord-313227-6zwkfzab	88	15	colitis	colitis	NN
cord-313227-6zwkfzab	88	16	,	,	,
cord-313227-6zwkfzab	88	17	in	in	IN
cord-313227-6zwkfzab	88	18	principle	principle	NN
cord-313227-6zwkfzab	88	19	,	,	,
cord-313227-6zwkfzab	88	20	may	may	MD
cord-313227-6zwkfzab	88	21	have	have	VB
cord-313227-6zwkfzab	88	22	a	a	DT
cord-313227-6zwkfzab	88	23	role	role	NN
cord-313227-6zwkfzab	88	24	in	in	IN
cord-313227-6zwkfzab	88	25	treating	treat	VBG
cord-313227-6zwkfzab	88	26	severe	severe	JJ
cord-313227-6zwkfzab	88	27	respiratory	respiratory	JJ
cord-313227-6zwkfzab	88	28	syndrome	syndrome	NN
cord-313227-6zwkfzab	88	29	of	of	IN
cord-313227-6zwkfzab	88	30	COVID-19	COVID-19	NNP
cord-313227-6zwkfzab	88	31	.	.	.
cord-313227-6zwkfzab	89	1	Infliximab	Infliximab	NNP
cord-313227-6zwkfzab	89	2	is	be	VBZ
cord-313227-6zwkfzab	89	3	a	a	DT
cord-313227-6zwkfzab	89	4	monoclonal	monoclonal	JJ
cord-313227-6zwkfzab	89	5	antibody	antibody	NN
cord-313227-6zwkfzab	89	6	targeting	target	VBG
cord-313227-6zwkfzab	89	7	TNF	TNF	NNP
cord-313227-6zwkfzab	89	8	alpha	alpha	NN
cord-313227-6zwkfzab	89	9	while	while	IN
cord-313227-6zwkfzab	89	10	Etanercept	Etanercept	NNP
cord-313227-6zwkfzab	89	11	is	be	VBZ
cord-313227-6zwkfzab	89	12	a	a	DT
cord-313227-6zwkfzab	89	13	receptor	receptor	NN
cord-313227-6zwkfzab	89	14	fusion	fusion	NN
cord-313227-6zwkfzab	89	15	protein	protein	NN
cord-313227-6zwkfzab	89	16	(	(	-LRB-
cord-313227-6zwkfzab	89	17	Human	Human	NNP
cord-313227-6zwkfzab	89	18	IgG1-Fc	IgG1-Fc	NNP
cord-313227-6zwkfzab	89	19	plus	plus	CC
cord-313227-6zwkfzab	89	20	soluble	soluble	JJ
cord-313227-6zwkfzab	89	21	p75	p75	CD
cord-313227-6zwkfzab	89	22	TNF	TNF	NNP
cord-313227-6zwkfzab	89	23	alpha	alpha	NN
cord-313227-6zwkfzab	89	24	extracellular	extracellular	JJ
cord-313227-6zwkfzab	89	25	domain	domain	NN
cord-313227-6zwkfzab	89	26	)	)	-RRB-
cord-313227-6zwkfzab	89	27	.	.	.
cord-313227-6zwkfzab	90	1	TNF	TNF	NNP
cord-313227-6zwkfzab	90	2	-	-	HYPH
cord-313227-6zwkfzab	90	3	α	α	NNP
cord-313227-6zwkfzab	90	4	is	be	VBZ
cord-313227-6zwkfzab	90	5	a	a	DT
cord-313227-6zwkfzab	90	6	proinflammatory	proinflammatory	JJ
cord-313227-6zwkfzab	90	7	cytokine	cytokine	NN
cord-313227-6zwkfzab	90	8	produced	produce	VBN
cord-313227-6zwkfzab	90	9	by	by	IN
cord-313227-6zwkfzab	90	10	macrophages	macrophage	NNS
cord-313227-6zwkfzab	90	11	,	,	,
cord-313227-6zwkfzab	90	12	lymphoid	lymphoid	JJ
cord-313227-6zwkfzab	90	13	cells	cell	NNS
cord-313227-6zwkfzab	90	14	,	,	,
cord-313227-6zwkfzab	90	15	endothelial	endothelial	JJ
cord-313227-6zwkfzab	90	16	cells	cell	NNS
cord-313227-6zwkfzab	90	17	,	,	,
cord-313227-6zwkfzab	90	18	cardiac	cardiac	NN
cord-313227-6zwkfzab	90	19	myocytes	myocyte	NNS
cord-313227-6zwkfzab	90	20	,	,	,
cord-313227-6zwkfzab	90	21	adipose	adipose	JJ
cord-313227-6zwkfzab	90	22	tissue	tissue	NN
cord-313227-6zwkfzab	90	23	,	,	,
cord-313227-6zwkfzab	90	24	and	and	CC
cord-313227-6zwkfzab	90	25	brain	brain	NN
cord-313227-6zwkfzab	90	26	cells	cell	NNS
cord-313227-6zwkfzab	90	27	such	such	JJ
cord-313227-6zwkfzab	90	28	as	as	IN
cord-313227-6zwkfzab	90	29	microglia	microglia	NN
cord-313227-6zwkfzab	90	30	and	and	CC
cord-313227-6zwkfzab	90	31	astrocytes	astrocyte	NNS
cord-313227-6zwkfzab	90	32	.	.	.
cord-313227-6zwkfzab	91	1	Its	-PRON-	PRP$
cord-313227-6zwkfzab	91	2	receptors	receptor	NNS
cord-313227-6zwkfzab	91	3	are	be	VBP
cord-313227-6zwkfzab	91	4	widely	widely	RB
cord-313227-6zwkfzab	91	5	expressed	express	VBN
cord-313227-6zwkfzab	91	6	and	and	CC
cord-313227-6zwkfzab	91	7	TNF	TNF	NNP
cord-313227-6zwkfzab	91	8	-	-	HYPH
cord-313227-6zwkfzab	91	9	α	α	NNP
cord-313227-6zwkfzab	91	10	plays	play	VBZ
cord-313227-6zwkfzab	91	11	a	a	DT
cord-313227-6zwkfzab	91	12	key	key	JJ
cord-313227-6zwkfzab	91	13	role	role	NN
cord-313227-6zwkfzab	91	14	in	in	IN
cord-313227-6zwkfzab	91	15	immunological	immunological	JJ
cord-313227-6zwkfzab	91	16	defense	defense	NN
cord-313227-6zwkfzab	91	17	processes	process	NNS
cord-313227-6zwkfzab	91	18	such	such	JJ
cord-313227-6zwkfzab	91	19	as	as	IN
cord-313227-6zwkfzab	91	20	inducing	induce	VBG
cord-313227-6zwkfzab	91	21	fever	fever	NN
cord-313227-6zwkfzab	91	22	,	,	,
cord-313227-6zwkfzab	91	23	inhibiting	inhibit	VBG
cord-313227-6zwkfzab	91	24	viral	viral	JJ
cord-313227-6zwkfzab	91	25	replication	replication	NN
cord-313227-6zwkfzab	91	26	during	during	IN
cord-313227-6zwkfzab	91	27	infections	infection	NNS
cord-313227-6zwkfzab	91	28	,	,	,
cord-313227-6zwkfzab	91	29	and	and	CC
cord-313227-6zwkfzab	91	30	leading	lead	VBG
cord-313227-6zwkfzab	91	31	to	to	IN
cord-313227-6zwkfzab	91	32	a	a	DT
cord-313227-6zwkfzab	91	33	permanent	permanent	JJ
cord-313227-6zwkfzab	91	34	growth	growth	NN
cord-313227-6zwkfzab	91	35	arrest	arrest	NN
cord-313227-6zwkfzab	91	36	in	in	IN
cord-313227-6zwkfzab	91	37	cancer	cancer	NN
cord-313227-6zwkfzab	91	38	(	(	-LRB-
cord-313227-6zwkfzab	91	39	47	47	CD
cord-313227-6zwkfzab	91	40	,	,	,
cord-313227-6zwkfzab	91	41	48	48	CD
cord-313227-6zwkfzab	91	42	)	)	-RRB-
cord-313227-6zwkfzab	91	43	.	.	.
cord-313227-6zwkfzab	92	1	Toxicity	toxicity	NN
cord-313227-6zwkfzab	92	2	profile	profile	NN
cord-313227-6zwkfzab	92	3	includes	include	VBZ
cord-313227-6zwkfzab	92	4	augmented	augment	VBN
cord-313227-6zwkfzab	92	5	risk	risk	NN
cord-313227-6zwkfzab	92	6	of	of	IN
cord-313227-6zwkfzab	92	7	infections	infection	NNS
cord-313227-6zwkfzab	92	8	(	(	-LRB-
cord-313227-6zwkfzab	92	9	49	49	CD
cord-313227-6zwkfzab	92	10	)	)	-RRB-
cord-313227-6zwkfzab	92	11	.	.	.
cord-313227-6zwkfzab	93	1	Proteasomal	proteasomal	JJ
cord-313227-6zwkfzab	93	2	system	system	NN
cord-313227-6zwkfzab	93	3	regulates	regulate	VBZ
cord-313227-6zwkfzab	93	4	different	different	JJ
cord-313227-6zwkfzab	93	5	cell	cell	NN
cord-313227-6zwkfzab	93	6	functions	function	NNS
cord-313227-6zwkfzab	93	7	,	,	,
cord-313227-6zwkfzab	93	8	among	among	IN
cord-313227-6zwkfzab	93	9	which	which	WDT
cord-313227-6zwkfzab	93	10	nuclear	nuclear	JJ
cord-313227-6zwkfzab	93	11	factor	factor	NN
cord-313227-6zwkfzab	93	12	kB	kB	NNP
cord-313227-6zwkfzab	93	13	(	(	-LRB-
cord-313227-6zwkfzab	93	14	NF	NF	NNP
cord-313227-6zwkfzab	93	15	-	-	HYPH
cord-313227-6zwkfzab	93	16	kB	kB	NNP
cord-313227-6zwkfzab	93	17	)	)	-RRB-
cord-313227-6zwkfzab	93	18	key	key	JJ
cord-313227-6zwkfzab	93	19	transcription	transcription	NN
cord-313227-6zwkfzab	93	20	factor	factor	NN
cord-313227-6zwkfzab	93	21	for	for	IN
cord-313227-6zwkfzab	93	22	innate	innate	JJ
cord-313227-6zwkfzab	93	23	and	and	CC
cord-313227-6zwkfzab	93	24	adaptive	adaptive	JJ
cord-313227-6zwkfzab	93	25	immunity	immunity	NN
cord-313227-6zwkfzab	93	26	(	(	-LRB-
cord-313227-6zwkfzab	93	27	50	50	CD
cord-313227-6zwkfzab	93	28	)	)	-RRB-
cord-313227-6zwkfzab	93	29	.	.	.
cord-313227-6zwkfzab	94	1	Bortezomib	Bortezomib	NNP
cord-313227-6zwkfzab	94	2	inhibits	inhibit	VBZ
cord-313227-6zwkfzab	94	3	proteasome	proteasome	VBN
cord-313227-6zwkfzab	94	4	and	and	CC
cord-313227-6zwkfzab	94	5	it	-PRON-	PRP
cord-313227-6zwkfzab	94	6	is	be	VBZ
cord-313227-6zwkfzab	94	7	used	use	VBN
cord-313227-6zwkfzab	94	8	in	in	IN
cord-313227-6zwkfzab	94	9	the	the	DT
cord-313227-6zwkfzab	94	10	treatment	treatment	NN
cord-313227-6zwkfzab	94	11	of	of	IN
cord-313227-6zwkfzab	94	12	myeloma	myeloma	NN
cord-313227-6zwkfzab	94	13	and	and	CC
cord-313227-6zwkfzab	94	14	mantle	mantle	NN
cord-313227-6zwkfzab	94	15	cell	cell	NN
cord-313227-6zwkfzab	94	16	lymphoma	lymphoma	NN
cord-313227-6zwkfzab	94	17	.	.	.
cord-313227-6zwkfzab	95	1	It	-PRON-	PRP
cord-313227-6zwkfzab	95	2	has	have	VBZ
cord-313227-6zwkfzab	95	3	been	be	VBN
cord-313227-6zwkfzab	95	4	shown	show	VBN
cord-313227-6zwkfzab	95	5	to	to	TO
cord-313227-6zwkfzab	95	6	have	have	VB
cord-313227-6zwkfzab	95	7	antiviral	antiviral	JJ
cord-313227-6zwkfzab	95	8	activity	activity	NN
cord-313227-6zwkfzab	95	9	against	against	IN
cord-313227-6zwkfzab	95	10	herpes	herpes	NNP
cord-313227-6zwkfzab	95	11	virus	virus	NN
cord-313227-6zwkfzab	95	12	,	,	,
cord-313227-6zwkfzab	95	13	targeting	target	VBG
cord-313227-6zwkfzab	95	14	viral	viral	JJ
cord-313227-6zwkfzab	95	15	entry	entry	NN
cord-313227-6zwkfzab	95	16	,	,	,
cord-313227-6zwkfzab	95	17	replication	replication	NN
cord-313227-6zwkfzab	95	18	,	,	,
cord-313227-6zwkfzab	95	19	and	and	CC
cord-313227-6zwkfzab	95	20	assembly	assembly	NN
cord-313227-6zwkfzab	95	21	(	(	-LRB-
cord-313227-6zwkfzab	95	22	51	51	CD
cord-313227-6zwkfzab	95	23	)	)	-RRB-
cord-313227-6zwkfzab	95	24	.	.	.
cord-313227-6zwkfzab	96	1	Another	another	DT
cord-313227-6zwkfzab	96	2	proteasome	proteasome	JJ
cord-313227-6zwkfzab	96	3	inhibitor	inhibitor	NN
cord-313227-6zwkfzab	96	4	,	,	,
cord-313227-6zwkfzab	96	5	VR23	VR23	NNP
cord-313227-6zwkfzab	96	6	,	,	,
cord-313227-6zwkfzab	96	7	possess	possess	VBP
cord-313227-6zwkfzab	96	8	powerful	powerful	JJ
cord-313227-6zwkfzab	96	9	antiinflammatory	antiinflammatory	JJ
cord-313227-6zwkfzab	96	10	activity	activity	NN
cord-313227-6zwkfzab	96	11	reducing	reduce	VBG
cord-313227-6zwkfzab	96	12	IL-6	IL-6	NNP
cord-313227-6zwkfzab	96	13	in	in	IN
cord-313227-6zwkfzab	96	14	synovial	synovial	JJ
cord-313227-6zwkfzab	96	15	cells	cell	NNS
cord-313227-6zwkfzab	96	16	from	from	IN
cord-313227-6zwkfzab	96	17	RA	RA	NNP
cord-313227-6zwkfzab	96	18	patients	patient	NNS
cord-313227-6zwkfzab	96	19	,	,	,
cord-313227-6zwkfzab	96	20	and	and	CC
cord-313227-6zwkfzab	96	21	improving	improve	VBG
cord-313227-6zwkfzab	96	22	LPS	LPS	NNP
cord-313227-6zwkfzab	96	23	-	-	HYPH
cord-313227-6zwkfzab	96	24	induced	induce	VBN
cord-313227-6zwkfzab	96	25	acute	acute	JJ
cord-313227-6zwkfzab	96	26	lung	lung	NN
cord-313227-6zwkfzab	96	27	injury	injury	NN
cord-313227-6zwkfzab	96	28	by	by	IN
cord-313227-6zwkfzab	96	29	decreasing	decrease	VBG
cord-313227-6zwkfzab	96	30	neutrophil	neutrophil	NN
cord-313227-6zwkfzab	96	31	migration	migration	NN
cord-313227-6zwkfzab	96	32	,	,	,
cord-313227-6zwkfzab	96	33	TNF	TNF	NNP
cord-313227-6zwkfzab	96	34	-	-	HYPH
cord-313227-6zwkfzab	96	35	α	α	NNP
cord-313227-6zwkfzab	96	36	secretion	secretion	NN
cord-313227-6zwkfzab	96	37	,	,	,
cord-313227-6zwkfzab	96	38	and	and	CC
cord-313227-6zwkfzab	96	39	tissue	tissue	NN
cord-313227-6zwkfzab	96	40	inflammation	inflammation	NN
cord-313227-6zwkfzab	96	41	in	in	IN
cord-313227-6zwkfzab	96	42	a	a	DT
cord-313227-6zwkfzab	96	43	mice	mice	NN
cord-313227-6zwkfzab	96	44	model	model	NN
cord-313227-6zwkfzab	96	45	(	(	-LRB-
cord-313227-6zwkfzab	96	46	52	52	CD
cord-313227-6zwkfzab	96	47	)	)	-RRB-
cord-313227-6zwkfzab	96	48	.	.	.
cord-313227-6zwkfzab	97	1	The	the	DT
cord-313227-6zwkfzab	97	2	doselimiting	doselimite	VBG
cord-313227-6zwkfzab	97	3	toxicity	toxicity	NN
cord-313227-6zwkfzab	97	4	of	of	IN
cord-313227-6zwkfzab	97	5	proteasome	proteasome	NN
cord-313227-6zwkfzab	97	6	inhibitors	inhibitor	NNS
cord-313227-6zwkfzab	97	7	is	be	VBZ
cord-313227-6zwkfzab	97	8	the	the	DT
cord-313227-6zwkfzab	97	9	peripheral	peripheral	JJ
cord-313227-6zwkfzab	97	10	neuropathy	neuropathy	NN
cord-313227-6zwkfzab	97	11	(	(	-LRB-
cord-313227-6zwkfzab	97	12	53	53	CD
cord-313227-6zwkfzab	97	13	)	)	-RRB-
cord-313227-6zwkfzab	97	14	a	a	DT
cord-313227-6zwkfzab	97	15	clinically	clinically	RB
cord-313227-6zwkfzab	97	16	relevant	relevant	JJ
cord-313227-6zwkfzab	97	17	complication	complication	NN
cord-313227-6zwkfzab	97	18	,	,	,
cord-313227-6zwkfzab	97	19	which	which	WDT
cord-313227-6zwkfzab	97	20	negatively	negatively	RB
cord-313227-6zwkfzab	97	21	impacts	impact	VBZ
cord-313227-6zwkfzab	97	22	the	the	DT
cord-313227-6zwkfzab	97	23	quality	quality	NN
cord-313227-6zwkfzab	97	24	of	of	IN
cord-313227-6zwkfzab	97	25	life	life	NN
cord-313227-6zwkfzab	97	26	of	of	IN
cord-313227-6zwkfzab	97	27	multiple	multiple	JJ
cord-313227-6zwkfzab	97	28	myeloma	myeloma	NN
cord-313227-6zwkfzab	97	29	survivors	survivor	NNS
cord-313227-6zwkfzab	97	30	(	(	-LRB-
cord-313227-6zwkfzab	97	31	54	54	CD
cord-313227-6zwkfzab	97	32	)	)	-RRB-
cord-313227-6zwkfzab	97	33	.	.	.
cord-313227-6zwkfzab	98	1	Pandemic	pandemic	NN
cord-313227-6zwkfzab	98	2	viruses	virus	NNS
cord-313227-6zwkfzab	98	3	decrease	decrease	VBP
cord-313227-6zwkfzab	98	4	type	type	NN
cord-313227-6zwkfzab	99	1	I	-PRON-	PRP
cord-313227-6zwkfzab	100	1	interferon	interferon	NNP
cord-313227-6zwkfzab	100	2	(	(	-LRB-
cord-313227-6zwkfzab	100	3	IFN	IFN	NNP
cord-313227-6zwkfzab	100	4	)	)	-RRB-
cord-313227-6zwkfzab	100	5	abundance	abundance	NN
cord-313227-6zwkfzab	100	6	(	(	-LRB-
cord-313227-6zwkfzab	100	7	24	24	CD
cord-313227-6zwkfzab	100	8	)	)	-RRB-
cord-313227-6zwkfzab	100	9	.	.	.
cord-313227-6zwkfzab	101	1	In	in	IN
cord-313227-6zwkfzab	101	2	humans	human	NNS
cord-313227-6zwkfzab	101	3	17	17	CD
cord-313227-6zwkfzab	101	4	different	different	JJ
cord-313227-6zwkfzab	101	5	types	type	NNS
cord-313227-6zwkfzab	101	6	of	of	IN
cord-313227-6zwkfzab	101	7	poly	poly	JJ
cord-313227-6zwkfzab	101	8	-	-	HYPH
cord-313227-6zwkfzab	101	9	adenosine	adenosine	NN
cord-313227-6zwkfzab	101	10	5	5	CD
cord-313227-6zwkfzab	101	11	′diphosphate	′diphosphate	NN
cord-313227-6zwkfzab	101	12	(	(	-LRB-
cord-313227-6zwkfzab	101	13	ADP)-ribose	adp)-ribose	DT
cord-313227-6zwkfzab	101	14	polymerase	polymerase	NN
cord-313227-6zwkfzab	101	15	(	(	-LRB-
cord-313227-6zwkfzab	101	16	PARP	PARP	NNP
cord-313227-6zwkfzab	101	17	)	)	-RRB-
cord-313227-6zwkfzab	101	18	are	be	VBP
cord-313227-6zwkfzab	101	19	recognized	recognize	VBN
cord-313227-6zwkfzab	101	20	.	.	.
cord-313227-6zwkfzab	102	1	PARPs	parp	NNS
cord-313227-6zwkfzab	102	2	transfer	transfer	VBP
cord-313227-6zwkfzab	102	3	ADP	ADP	NNP
cord-313227-6zwkfzab	102	4	ribose	ribose	NN
cord-313227-6zwkfzab	102	5	from	from	IN
cord-313227-6zwkfzab	102	6	nicotinamide	nicotinamide	NN
cord-313227-6zwkfzab	102	7	adenine	adenine	NN
cord-313227-6zwkfzab	102	8	dinucleotide	dinucleotide	NN
cord-313227-6zwkfzab	102	9	(	(	-LRB-
cord-313227-6zwkfzab	102	10	NAD+	NAD+	NNP
cord-313227-6zwkfzab	102	11	)	)	-RRB-
cord-313227-6zwkfzab	102	12	to	to	IN
cord-313227-6zwkfzab	102	13	targeted	target	VBN
cord-313227-6zwkfzab	102	14	proteins	protein	NNS
cord-313227-6zwkfzab	102	15	achieving	achieve	VBG
cord-313227-6zwkfzab	102	16	a	a	DT
cord-313227-6zwkfzab	102	17	post	post	JJ
cord-313227-6zwkfzab	102	18	translational	translational	JJ
cord-313227-6zwkfzab	102	19	modification	modification	NN
cord-313227-6zwkfzab	102	20	called	call	VBN
cord-313227-6zwkfzab	102	21	ADP	ADP	NNP
cord-313227-6zwkfzab	102	22	-	-	HYPH
cord-313227-6zwkfzab	102	23	ribosylation	ribosylation	NN
cord-313227-6zwkfzab	102	24	,	,	,
cord-313227-6zwkfzab	102	25	generally	generally	RB
cord-313227-6zwkfzab	102	26	in	in	IN
cord-313227-6zwkfzab	102	27	response	response	NN
cord-313227-6zwkfzab	102	28	to	to	IN
cord-313227-6zwkfzab	102	29	stress	stress	NN
cord-313227-6zwkfzab	102	30	conditions	condition	NNS
cord-313227-6zwkfzab	102	31	such	such	JJ
cord-313227-6zwkfzab	102	32	as	as	IN
cord-313227-6zwkfzab	102	33	DNA	dna	NN
cord-313227-6zwkfzab	102	34	damage	damage	NN
cord-313227-6zwkfzab	102	35	,	,	,
cord-313227-6zwkfzab	102	36	heat	heat	NN
cord-313227-6zwkfzab	102	37	shock	shock	NN
cord-313227-6zwkfzab	102	38	and	and	CC
cord-313227-6zwkfzab	102	39	viral	viral	JJ
cord-313227-6zwkfzab	102	40	attack	attack	NN
cord-313227-6zwkfzab	102	41	(	(	-LRB-
cord-313227-6zwkfzab	102	42	55	55	CD
cord-313227-6zwkfzab	102	43	)	)	-RRB-
cord-313227-6zwkfzab	102	44	.	.	.
cord-313227-6zwkfzab	103	1	PARP11	parp11	NN
cord-313227-6zwkfzab	103	2	is	be	VBZ
cord-313227-6zwkfzab	103	3	an	an	DT
cord-313227-6zwkfzab	103	4	ADP	ADP	NNP
cord-313227-6zwkfzab	103	5	ribosyl	ribosyl	NN
cord-313227-6zwkfzab	103	6	-	-	HYPH
cord-313227-6zwkfzab	103	7	transferase	transferase	NN
cord-313227-6zwkfzab	103	8	that	that	WDT
cord-313227-6zwkfzab	103	9	inhibits	inhibit	VBZ
cord-313227-6zwkfzab	103	10	interferon	interferon	NN
cord-313227-6zwkfzab	103	11	type	type	NN
cord-313227-6zwkfzab	104	1	I	-PRON-	PRP
cord-313227-6zwkfzab	104	2	(	(	-LRB-
cord-313227-6zwkfzab	104	3	IFN	IFN	NNP
cord-313227-6zwkfzab	104	4	-	-	HYPH
cord-313227-6zwkfzab	104	5	I	I	NNP
cord-313227-6zwkfzab	104	6	)	)	-RRB-
cord-313227-6zwkfzab	104	7	antiviral	antiviral	JJ
cord-313227-6zwkfzab	104	8	activity	activity	NN
cord-313227-6zwkfzab	104	9	.	.	.
cord-313227-6zwkfzab	105	1	IFN	IFN	NNP
cord-313227-6zwkfzab	105	2	-	-	HYPH
cord-313227-6zwkfzab	105	3	I	-PRON-	PRP
cord-313227-6zwkfzab	105	4	is	be	VBZ
cord-313227-6zwkfzab	105	5	a	a	DT
cord-313227-6zwkfzab	105	6	key	key	JJ
cord-313227-6zwkfzab	105	7	component	component	NN
cord-313227-6zwkfzab	105	8	of	of	IN
cord-313227-6zwkfzab	105	9	the	the	DT
cord-313227-6zwkfzab	105	10	immune	immune	JJ
cord-313227-6zwkfzab	105	11	response	response	NN
cord-313227-6zwkfzab	105	12	against	against	IN
cord-313227-6zwkfzab	105	13	viral	viral	JJ
cord-313227-6zwkfzab	105	14	pathogens	pathogen	NNS
cord-313227-6zwkfzab	105	15	that	that	WDT
cord-313227-6zwkfzab	105	16	induces	induce	VBZ
cord-313227-6zwkfzab	105	17	the	the	DT
cord-313227-6zwkfzab	105	18	expression	expression	NN
cord-313227-6zwkfzab	105	19	of	of	IN
cord-313227-6zwkfzab	105	20	several	several	JJ
cord-313227-6zwkfzab	105	21	genes	gene	NNS
cord-313227-6zwkfzab	105	22	(	(	-LRB-
cord-313227-6zwkfzab	105	23	Interferon	Interferon	NNP
cord-313227-6zwkfzab	105	24	Stimulated	stimulate	VBD
cord-313227-6zwkfzab	105	25	Genes	Genes	NNP
cord-313227-6zwkfzab	105	26	-ISGs	-isgs	CD
cord-313227-6zwkfzab	105	27	)	)	-RRB-
cord-313227-6zwkfzab	105	28	with	with	IN
cord-313227-6zwkfzab	105	29	diverse	diverse	JJ
cord-313227-6zwkfzab	105	30	antiviral	antiviral	JJ
cord-313227-6zwkfzab	105	31	properties	property	NNS
cord-313227-6zwkfzab	105	32	(	(	-LRB-
cord-313227-6zwkfzab	105	33	56	56	CD
cord-313227-6zwkfzab	105	34	)	)	-RRB-
cord-313227-6zwkfzab	105	35	.	.	.
cord-313227-6zwkfzab	106	1	PARP11	parp11	NN
cord-313227-6zwkfzab	107	1	inhibitor	inhibitor	NN
cord-313227-6zwkfzab	107	2	,	,	,
cord-313227-6zwkfzab	107	3	rucaparib	rucaparib	NNP
cord-313227-6zwkfzab	107	4	has	have	VBZ
cord-313227-6zwkfzab	107	5	been	be	VBN
cord-313227-6zwkfzab	107	6	shown	show	VBN
cord-313227-6zwkfzab	107	7	to	to	TO
cord-313227-6zwkfzab	107	8	restore	restore	VB
cord-313227-6zwkfzab	107	9	the	the	DT
cord-313227-6zwkfzab	107	10	activity	activity	NN
cord-313227-6zwkfzab	107	11	of	of	IN
cord-313227-6zwkfzab	107	12	IFN	IFN	NNP
cord-313227-6zwkfzab	107	13	-	-	HYPH
cord-313227-6zwkfzab	107	14	I	-PRON-	PRP
cord-313227-6zwkfzab	107	15	against	against	IN
cord-313227-6zwkfzab	107	16	different	different	JJ
cord-313227-6zwkfzab	107	17	viruses	virus	NNS
cord-313227-6zwkfzab	107	18	in	in	IN
cord-313227-6zwkfzab	107	19	a	a	DT
cord-313227-6zwkfzab	107	20	murine	murine	JJ
cord-313227-6zwkfzab	107	21	model	model	NN
cord-313227-6zwkfzab	107	22	(	(	-LRB-
cord-313227-6zwkfzab	107	23	57	57	CD
cord-313227-6zwkfzab	107	24	)	)	-RRB-
cord-313227-6zwkfzab	107	25	.	.	.
cord-313227-6zwkfzab	108	1	There	there	EX
cord-313227-6zwkfzab	108	2	is	be	VBZ
cord-313227-6zwkfzab	108	3	evidence	evidence	NN
cord-313227-6zwkfzab	108	4	that	that	IN
cord-313227-6zwkfzab	108	5	ZIKV	ZIKV	NNP
cord-313227-6zwkfzab	108	6	infection	infection	NN
cord-313227-6zwkfzab	108	7	triggers	trigger	VBZ
cord-313227-6zwkfzab	108	8	type	type	NN
cord-313227-6zwkfzab	108	9	I	-PRON-	PRP
cord-313227-6zwkfzab	108	10	IFN	IFN	NNP
cord-313227-6zwkfzab	108	11	production	production	NN
cord-313227-6zwkfzab	108	12	by	by	IN
cord-313227-6zwkfzab	108	13	host	host	NN
cord-313227-6zwkfzab	108	14	cells	cell	NNS
cord-313227-6zwkfzab	108	15	,	,	,
cord-313227-6zwkfzab	108	16	ZIKV	ZIKV	NNP
cord-313227-6zwkfzab	108	17	is	be	VBZ
cord-313227-6zwkfzab	108	18	sensitive	sensitive	JJ
cord-313227-6zwkfzab	108	19	to	to	IN
cord-313227-6zwkfzab	108	20	the	the	DT
cord-313227-6zwkfzab	108	21	antiviral	antiviral	JJ
cord-313227-6zwkfzab	108	22	activity	activity	NN
cord-313227-6zwkfzab	108	23	of	of	IN
cord-313227-6zwkfzab	108	24	IFN	IFN	NNP
cord-313227-6zwkfzab	108	25	and	and	CC
cord-313227-6zwkfzab	108	26	IFN	IFN	NNP
cord-313227-6zwkfzab	108	27	I	-PRON-	PRP
cord-313227-6zwkfzab	108	28	seems	seem	VBZ
cord-313227-6zwkfzab	108	29	crucial	crucial	JJ
cord-313227-6zwkfzab	108	30	also	also	RB
cord-313227-6zwkfzab	108	31	in	in	IN
cord-313227-6zwkfzab	108	32	SARS	SARS	NNP
cord-313227-6zwkfzab	108	33	-	-	HYPH
cord-313227-6zwkfzab	108	34	COv-2	COv-2	NNP
cord-313227-6zwkfzab	108	35	infection	infection	NN
cord-313227-6zwkfzab	108	36	(	(	-LRB-
cord-313227-6zwkfzab	108	37	58	58	CD
cord-313227-6zwkfzab	108	38	,	,	,
cord-313227-6zwkfzab	108	39	59	59	CD
cord-313227-6zwkfzab	108	40	)	)	-RRB-
cord-313227-6zwkfzab	108	41	.	.	.
cord-313227-6zwkfzab	109	1	PARP	PARP	NNP
cord-313227-6zwkfzab	109	2	inhibitors	inhibitor	NNS
cord-313227-6zwkfzab	109	3	are	be	VBP
cord-313227-6zwkfzab	109	4	used	use	VBN
cord-313227-6zwkfzab	109	5	in	in	IN
cord-313227-6zwkfzab	109	6	subgroup	subgroup	NN
cord-313227-6zwkfzab	109	7	of	of	IN
cord-313227-6zwkfzab	109	8	patients	patient	NNS
cord-313227-6zwkfzab	109	9	with	with	IN
cord-313227-6zwkfzab	109	10	breast	breast	NN
cord-313227-6zwkfzab	109	11	or	or	CC
cord-313227-6zwkfzab	109	12	ovarian	ovarian	JJ
cord-313227-6zwkfzab	109	13	cancer	cancer	NN
cord-313227-6zwkfzab	109	14	.	.	.
cord-313227-6zwkfzab	110	1	Toxicity	toxicity	NN
cord-313227-6zwkfzab	110	2	is	be	VBZ
cord-313227-6zwkfzab	110	3	mainly	mainly	RB
cord-313227-6zwkfzab	110	4	hematological	hematological	JJ
cord-313227-6zwkfzab	110	5	(	(	-LRB-
cord-313227-6zwkfzab	110	6	60	60	CD
cord-313227-6zwkfzab	110	7	)	)	-RRB-
cord-313227-6zwkfzab	110	8	.	.	.
cord-313227-6zwkfzab	111	1	Peroxisome	Peroxisome	NNP
cord-313227-6zwkfzab	111	2	proliferator	proliferator	NN
cord-313227-6zwkfzab	111	3	-	-	HYPH
cord-313227-6zwkfzab	111	4	activated	activate	VBN
cord-313227-6zwkfzab	111	5	receptor	receptor	NN
cord-313227-6zwkfzab	111	6	gamma	gamma	NN
cord-313227-6zwkfzab	111	7	(	(	-LRB-
cord-313227-6zwkfzab	111	8	PPARγagonists	pparγagonist	NNS
cord-313227-6zwkfzab	111	9	,	,	,
cord-313227-6zwkfzab	111	10	rosiglitazone	rosiglitazone	NN
cord-313227-6zwkfzab	111	11	and	and	CC
cord-313227-6zwkfzab	111	12	pioglitazone	pioglitazone	NN
cord-313227-6zwkfzab	111	13	,	,	,
cord-313227-6zwkfzab	111	14	are	be	VBP
cord-313227-6zwkfzab	111	15	drugs	drug	NNS
cord-313227-6zwkfzab	111	16	in	in	IN
cord-313227-6zwkfzab	111	17	clinical	clinical	JJ
cord-313227-6zwkfzab	111	18	use	use	NN
cord-313227-6zwkfzab	111	19	for	for	IN
cord-313227-6zwkfzab	111	20	diabetes	diabetes	NN
cord-313227-6zwkfzab	111	21	(	(	-LRB-
cord-313227-6zwkfzab	111	22	61	61	CD
cord-313227-6zwkfzab	111	23	)	)	-RRB-
cord-313227-6zwkfzab	111	24	.	.	.
cord-313227-6zwkfzab	112	1	Insulin	insulin	NN
cord-313227-6zwkfzab	112	2	resistance	resistance	NN
cord-313227-6zwkfzab	112	3	amplifies	amplify	VBZ
cord-313227-6zwkfzab	112	4	inflammation	inflammation	NN
cord-313227-6zwkfzab	112	5	,	,	,
cord-313227-6zwkfzab	112	6	associated	associate	VBN
cord-313227-6zwkfzab	112	7	with	with	IN
cord-313227-6zwkfzab	112	8	an	an	DT
cord-313227-6zwkfzab	112	9	increase	increase	NN
cord-313227-6zwkfzab	112	10	in	in	IN
cord-313227-6zwkfzab	112	11	C	c	NN
cord-313227-6zwkfzab	112	12	-	-	HYPH
cord-313227-6zwkfzab	112	13	reactive	reactive	JJ
cord-313227-6zwkfzab	112	14	protein	protein	NN
cord-313227-6zwkfzab	112	15	,	,	,
cord-313227-6zwkfzab	112	16	IL-6	IL-6	NNP
cord-313227-6zwkfzab	112	17	,	,	,
cord-313227-6zwkfzab	112	18	and	and	CC
cord-313227-6zwkfzab	112	19	TNF	TNF	NNP
cord-313227-6zwkfzab	112	20	-	-	HYPH
cord-313227-6zwkfzab	112	21	α	α	NNP
cord-313227-6zwkfzab	112	22	(	(	-LRB-
cord-313227-6zwkfzab	112	23	62	62	CD
cord-313227-6zwkfzab	112	24	)	)	-RRB-
cord-313227-6zwkfzab	112	25	and	and	CC
cord-313227-6zwkfzab	112	26	produces	produce	VBZ
cord-313227-6zwkfzab	112	27	a	a	DT
cord-313227-6zwkfzab	112	28	pro	pro	JJ
cord-313227-6zwkfzab	112	29	-	-	JJ
cord-313227-6zwkfzab	112	30	coagulant	coagulant	JJ
cord-313227-6zwkfzab	112	31	state	state	NN
cord-313227-6zwkfzab	112	32	with	with	IN
cord-313227-6zwkfzab	112	33	increased	increase	VBN
cord-313227-6zwkfzab	112	34	fibrinogen	fibrinogen	NN
cord-313227-6zwkfzab	112	35	and	and	CC
cord-313227-6zwkfzab	112	36	plasminogen	plasminogen	NN
cord-313227-6zwkfzab	112	37	activator	activator	NN
cord-313227-6zwkfzab	112	38	inhibitor	inhibitor	NN
cord-313227-6zwkfzab	112	39	,	,	,
cord-313227-6zwkfzab	112	40	(	(	-LRB-
cord-313227-6zwkfzab	112	41	PAI-1	PAI-1	NNP
cord-313227-6zwkfzab	112	42	)	)	-RRB-
cord-313227-6zwkfzab	112	43	(	(	-LRB-
cord-313227-6zwkfzab	112	44	63	63	CD
cord-313227-6zwkfzab	112	45	)	)	-RRB-
cord-313227-6zwkfzab	112	46	.	.	.
cord-313227-6zwkfzab	113	1	Pioglitazone	Pioglitazone	NNP
cord-313227-6zwkfzab	113	2	,	,	,
cord-313227-6zwkfzab	113	3	in	in	IN
cord-313227-6zwkfzab	113	4	clinical	clinical	JJ
cord-313227-6zwkfzab	113	5	studies	study	NNS
cord-313227-6zwkfzab	113	6	on	on	IN
cord-313227-6zwkfzab	113	7	diabetic	diabetic	JJ
cord-313227-6zwkfzab	113	8	patients	patient	NNS
cord-313227-6zwkfzab	113	9	,	,	,
cord-313227-6zwkfzab	113	10	was	be	VBD
cord-313227-6zwkfzab	113	11	able	able	JJ
cord-313227-6zwkfzab	113	12	to	to	TO
cord-313227-6zwkfzab	113	13	reduce	reduce	VB
cord-313227-6zwkfzab	113	14	the	the	DT
cord-313227-6zwkfzab	113	15	plasma	plasma	NN
cord-313227-6zwkfzab	113	16	level	level	NN
cord-313227-6zwkfzab	113	17	of	of	IN
cord-313227-6zwkfzab	113	18	different	different	JJ
cord-313227-6zwkfzab	113	19	inflammatory	inflammatory	JJ
cord-313227-6zwkfzab	113	20	factors	factor	NNS
cord-313227-6zwkfzab	113	21	among	among	IN
cord-313227-6zwkfzab	113	22	which	which	WDT
cord-313227-6zwkfzab	113	23	CPR	CPR	NNP
cord-313227-6zwkfzab	113	24	,	,	,
cord-313227-6zwkfzab	113	25	IL-1	IL-1	NNP
cord-313227-6zwkfzab	113	26	,	,	,
cord-313227-6zwkfzab	113	27	IL-6	IL-6	NNP
cord-313227-6zwkfzab	113	28	,	,	,
cord-313227-6zwkfzab	113	29	and	and	CC
cord-313227-6zwkfzab	113	30	TNF	TNF	NNP
cord-313227-6zwkfzab	113	31	-	-	HYPH
cord-313227-6zwkfzab	113	32	α	α	NNP
cord-313227-6zwkfzab	113	33	(	(	-LRB-
cord-313227-6zwkfzab	113	34	64	64	CD
cord-313227-6zwkfzab	113	35	)	)	-RRB-
cord-313227-6zwkfzab	113	36	.	.	.
cord-313227-6zwkfzab	114	1	Thus	thus	RB
cord-313227-6zwkfzab	114	2	,	,	,
cord-313227-6zwkfzab	114	3	it	-PRON-	PRP
cord-313227-6zwkfzab	114	4	is	be	VBZ
cord-313227-6zwkfzab	114	5	of	of	IN
cord-313227-6zwkfzab	114	6	great	great	JJ
cord-313227-6zwkfzab	114	7	interest	interest	NN
cord-313227-6zwkfzab	114	8	that	that	WDT
cord-313227-6zwkfzab	114	9	pioglitazone	pioglitazone	NN
cord-313227-6zwkfzab	114	10	can	can	MD
cord-313227-6zwkfzab	114	11	produce	produce	VB
cord-313227-6zwkfzab	114	12	an	an	DT
cord-313227-6zwkfzab	114	13	anti	anti	JJ
cord-313227-6zwkfzab	114	14	-	-	JJ
cord-313227-6zwkfzab	114	15	inflammatory	inflammatory	JJ
cord-313227-6zwkfzab	114	16	effect	effect	NN
cord-313227-6zwkfzab	114	17	also	also	RB
cord-313227-6zwkfzab	114	18	on	on	IN
cord-313227-6zwkfzab	114	19	lung	lung	NN
cord-313227-6zwkfzab	114	20	inflammation	inflammation	NN
cord-313227-6zwkfzab	114	21	and	and	CC
cord-313227-6zwkfzab	114	22	fibrosis	fibrosis	NN
cord-313227-6zwkfzab	114	23	(	(	-LRB-
cord-313227-6zwkfzab	114	24	65	65	CD
cord-313227-6zwkfzab	114	25	)	)	-RRB-
cord-313227-6zwkfzab	114	26	.	.	.
cord-313227-6zwkfzab	115	1	Considered	consider	VBN
cord-313227-6zwkfzab	115	2	the	the	DT
cord-313227-6zwkfzab	115	3	excellent	excellent	JJ
cord-313227-6zwkfzab	115	4	tolerability	tolerability	NN
cord-313227-6zwkfzab	115	5	,	,	,
cord-313227-6zwkfzab	115	6	PPARγ	PPARγ	NNS
cord-313227-6zwkfzab	115	7	agonists	agonist	NNS
cord-313227-6zwkfzab	115	8	may	may	MD
cord-313227-6zwkfzab	115	9	be	be	VB
cord-313227-6zwkfzab	115	10	tested	test	VBN
cord-313227-6zwkfzab	115	11	for	for	IN
cord-313227-6zwkfzab	115	12	amelioration	amelioration	NN
cord-313227-6zwkfzab	115	13	of	of	IN
cord-313227-6zwkfzab	115	14	virus	virus	NN
cord-313227-6zwkfzab	115	15	induced	induce	VBN
cord-313227-6zwkfzab	115	16	lung	lung	NN
cord-313227-6zwkfzab	115	17	injuries	injury	NNS
cord-313227-6zwkfzab	115	18	.	.	.
cord-313227-6zwkfzab	116	1	Plerixafor	Plerixafor	NNP
cord-313227-6zwkfzab	116	2	is	be	VBZ
cord-313227-6zwkfzab	116	3	a	a	DT
cord-313227-6zwkfzab	116	4	CXCR4	cxcr4	NN
cord-313227-6zwkfzab	116	5	antagonist	antagonist	NN
cord-313227-6zwkfzab	116	6	used	use	VBN
cord-313227-6zwkfzab	116	7	for	for	IN
cord-313227-6zwkfzab	116	8	stem	stem	NN
cord-313227-6zwkfzab	116	9	cell	cell	NN
cord-313227-6zwkfzab	116	10	mobilization	mobilization	NN
cord-313227-6zwkfzab	116	11	in	in	IN
cord-313227-6zwkfzab	116	12	patients	patient	NNS
cord-313227-6zwkfzab	116	13	undergoing	undergo	VBG
cord-313227-6zwkfzab	116	14	autologous	autologous	JJ
cord-313227-6zwkfzab	116	15	stem	stem	NN
cord-313227-6zwkfzab	116	16	cell	cell	NN
cord-313227-6zwkfzab	116	17	transplantation	transplantation	NN
cord-313227-6zwkfzab	116	18	.	.	.
cord-313227-6zwkfzab	117	1	CXCR4-mediated	cxcr4-mediated	CD
cord-313227-6zwkfzab	117	2	inflammatory	inflammatory	JJ
cord-313227-6zwkfzab	117	3	responses	response	NNS
cord-313227-6zwkfzab	117	4	is	be	VBZ
cord-313227-6zwkfzab	117	5	based	base	VBN
cord-313227-6zwkfzab	117	6	on	on	IN
cord-313227-6zwkfzab	117	7	the	the	DT
cord-313227-6zwkfzab	117	8	efficient	efficient	JJ
cord-313227-6zwkfzab	117	9	chemotaxis	chemotaxis	NN
cord-313227-6zwkfzab	117	10	function	function	NN
cord-313227-6zwkfzab	117	11	of	of	IN
cord-313227-6zwkfzab	117	12	inflammatory	inflammatory	JJ
cord-313227-6zwkfzab	117	13	cells	cell	NNS
cord-313227-6zwkfzab	117	14	,	,	,
cord-313227-6zwkfzab	117	15	such	such	JJ
cord-313227-6zwkfzab	117	16	as	as	IN
cord-313227-6zwkfzab	117	17	neutrophils	neutrophil	NNS
cord-313227-6zwkfzab	117	18	,	,	,
cord-313227-6zwkfzab	117	19	lymphocytes	lymphocyte	NNS
cord-313227-6zwkfzab	117	20	,	,	,
cord-313227-6zwkfzab	117	21	and	and	CC
cord-313227-6zwkfzab	117	22	monocytes	monocyte	NNS
cord-313227-6zwkfzab	117	23	(	(	-LRB-
cord-313227-6zwkfzab	117	24	66	66	CD
cord-313227-6zwkfzab	117	25	)	)	-RRB-
cord-313227-6zwkfzab	117	26	.	.	.
cord-313227-6zwkfzab	118	1	In	in	IN
cord-313227-6zwkfzab	118	2	murine	murine	JJ
cord-313227-6zwkfzab	118	3	models	model	NNS
cord-313227-6zwkfzab	118	4	of	of	IN
cord-313227-6zwkfzab	118	5	acute	acute	JJ
cord-313227-6zwkfzab	118	6	lung	lung	NN
cord-313227-6zwkfzab	118	7	insufficiency	insufficiency	NN
cord-313227-6zwkfzab	118	8	CXCR4	CXCR4	NNP
cord-313227-6zwkfzab	118	9	expression	expression	NN
cord-313227-6zwkfzab	118	10	was	be	VBD
cord-313227-6zwkfzab	118	11	significantly	significantly	RB
cord-313227-6zwkfzab	118	12	increased	increase	VBN
cord-313227-6zwkfzab	118	13	in	in	IN
cord-313227-6zwkfzab	118	14	macrophages	macrophage	NNS
cord-313227-6zwkfzab	118	15	sorted	sort	VBN
cord-313227-6zwkfzab	118	16	from	from	IN
cord-313227-6zwkfzab	118	17	bronchoalveolar	bronchoalveolar	NNP
cord-313227-6zwkfzab	118	18	lavage	lavage	NN
cord-313227-6zwkfzab	118	19	fluid	fluid	NN
cord-313227-6zwkfzab	118	20	and	and	CC
cord-313227-6zwkfzab	118	21	receptor	receptor	NN
cord-313227-6zwkfzab	118	22	downregulation	downregulation	NN
cord-313227-6zwkfzab	118	23	reduced	reduce	VBD
cord-313227-6zwkfzab	118	24	IL-6	IL-6	NNP
cord-313227-6zwkfzab	118	25	and	and	CC
cord-313227-6zwkfzab	118	26	TNF	TNF	NNP
cord-313227-6zwkfzab	118	27	-	-	HYPH
cord-313227-6zwkfzab	118	28	α	α	NNP
cord-313227-6zwkfzab	118	29	.	.	.
cord-313227-6zwkfzab	119	1	Administration	administration	NN
cord-313227-6zwkfzab	119	2	of	of	IN
cord-313227-6zwkfzab	119	3	AMD3100	AMD3100	,
cord-313227-6zwkfzab	119	4	significantly	significantly	RB
cord-313227-6zwkfzab	119	5	attenuated	attenuate	VBD
cord-313227-6zwkfzab	119	6	the	the	DT
cord-313227-6zwkfzab	119	7	influx	influx	NN
cord-313227-6zwkfzab	119	8	of	of	IN
cord-313227-6zwkfzab	119	9	inflammatory	inflammatory	JJ
cord-313227-6zwkfzab	119	10	cells	cell	NNS
cord-313227-6zwkfzab	119	11	to	to	IN
cord-313227-6zwkfzab	119	12	the	the	DT
cord-313227-6zwkfzab	119	13	airway	airway	NN
cord-313227-6zwkfzab	119	14	and	and	CC
cord-313227-6zwkfzab	119	15	reduced	reduce	VBD
cord-313227-6zwkfzab	119	16	the	the	DT
cord-313227-6zwkfzab	119	17	levels	level	NNS
cord-313227-6zwkfzab	119	18	of	of	IN
cord-313227-6zwkfzab	119	19	IL-4	IL-4	NNP
cord-313227-6zwkfzab	119	20	,	,	,
cord-313227-6zwkfzab	119	21	IL-5	IL-5	NNP
cord-313227-6zwkfzab	119	22	,	,	,
cord-313227-6zwkfzab	120	1	and	and	CC
cord-313227-6zwkfzab	120	2	IL-13	IL-13	NNP
cord-313227-6zwkfzab	120	3	in	in	IN
cord-313227-6zwkfzab	120	4	an	an	DT
cord-313227-6zwkfzab	120	5	murine	murine	JJ
cord-313227-6zwkfzab	120	6	asthmatic	asthmatic	JJ
cord-313227-6zwkfzab	120	7	model	model	NN
cord-313227-6zwkfzab	120	8	either	either	CC
cord-313227-6zwkfzab	120	9	in	in	IN
cord-313227-6zwkfzab	120	10	the	the	DT
cord-313227-6zwkfzab	120	11	lavage	lavage	NN
cord-313227-6zwkfzab	120	12	fluid	fluid	NN
cord-313227-6zwkfzab	120	13	and	and	CC
cord-313227-6zwkfzab	120	14	lung	lung	NN
cord-313227-6zwkfzab	120	15	homogenate	homogenate	NNP
cord-313227-6zwkfzab	120	16	through	through	IN
cord-313227-6zwkfzab	120	17	attenuation	attenuation	NN
cord-313227-6zwkfzab	120	18	of	of	IN
cord-313227-6zwkfzab	120	19	the	the	DT
cord-313227-6zwkfzab	120	20	Th17	Th17	NNP
cord-313227-6zwkfzab	120	21	(	(	-LRB-
cord-313227-6zwkfzab	120	22	67	67	CD
cord-313227-6zwkfzab	120	23	)	)	-RRB-
cord-313227-6zwkfzab	120	24	,	,	,
cord-313227-6zwkfzab	120	25	cell	cell	NN
cord-313227-6zwkfzab	120	26	population	population	NN
cord-313227-6zwkfzab	120	27	.	.	.
cord-313227-6zwkfzab	121	1	No	no	DT
cord-313227-6zwkfzab	121	2	adverse	adverse	JJ
cord-313227-6zwkfzab	121	3	events	event	NNS
cord-313227-6zwkfzab	121	4	have	have	VBP
cord-313227-6zwkfzab	121	5	been	be	VBN
cord-313227-6zwkfzab	121	6	described	describe	VBN
cord-313227-6zwkfzab	121	7	for	for	IN
cord-313227-6zwkfzab	121	8	a	a	DT
cord-313227-6zwkfzab	121	9	single	single	JJ
cord-313227-6zwkfzab	121	10	injection	injection	NN
cord-313227-6zwkfzab	121	11	of	of	IN
cord-313227-6zwkfzab	121	12	plerixafor	plerixafor	NN
cord-313227-6zwkfzab	121	13	(	(	-LRB-
cord-313227-6zwkfzab	121	14	68	68	CD
cord-313227-6zwkfzab	121	15	)	)	-RRB-
cord-313227-6zwkfzab	121	16	.	.	.
cord-313227-6zwkfzab	122	1	Fingolimod	Fingolimod	NNP
cord-313227-6zwkfzab	122	2	,	,	,
cord-313227-6zwkfzab	122	3	a	a	DT
cord-313227-6zwkfzab	122	4	sphingosine-1-phosphate	sphingosine-1-phosphate	NNP
cord-313227-6zwkfzab	122	5	(	(	-LRB-
cord-313227-6zwkfzab	122	6	S1p	s1p	NN
cord-313227-6zwkfzab	122	7	)	)	-RRB-
cord-313227-6zwkfzab	122	8	receptor	receptor	NN
cord-313227-6zwkfzab	122	9	agonist	agonist	NN
cord-313227-6zwkfzab	122	10	is	be	VBZ
cord-313227-6zwkfzab	122	11	approved	approve	VBN
cord-313227-6zwkfzab	122	12	for	for	IN
cord-313227-6zwkfzab	122	13	the	the	DT
cord-313227-6zwkfzab	122	14	treatment	treatment	NN
cord-313227-6zwkfzab	122	15	of	of	IN
cord-313227-6zwkfzab	122	16	multiple	multiple	JJ
cord-313227-6zwkfzab	122	17	sclerosis	sclerosis	NN
cord-313227-6zwkfzab	122	18	(	(	-LRB-
cord-313227-6zwkfzab	122	19	MS	MS	NNP
cord-313227-6zwkfzab	122	20	)	)	-RRB-
cord-313227-6zwkfzab	122	21	.	.	.
cord-313227-6zwkfzab	123	1	S1p	S1p	NNP
cord-313227-6zwkfzab	123	2	is	be	VBZ
cord-313227-6zwkfzab	123	3	mainly	mainly	RB
cord-313227-6zwkfzab	123	4	expressed	express	VBN
cord-313227-6zwkfzab	123	5	in	in	IN
cord-313227-6zwkfzab	123	6	vascular	vascular	JJ
cord-313227-6zwkfzab	123	7	endothelial	endothelial	JJ
cord-313227-6zwkfzab	123	8	cells	cell	NNS
cord-313227-6zwkfzab	123	9	and	and	CC
cord-313227-6zwkfzab	123	10	lymphocytes	lymphocyte	NNS
cord-313227-6zwkfzab	123	11	in	in	IN
cord-313227-6zwkfzab	123	12	lung	lung	NN
cord-313227-6zwkfzab	123	13	tissue	tissue	NN
cord-313227-6zwkfzab	123	14	.	.	.
cord-313227-6zwkfzab	124	1	S1p1	S1p1	NNP
cord-313227-6zwkfzab	124	2	agonists	agonist	NNS
cord-313227-6zwkfzab	124	3	(	(	-LRB-
cord-313227-6zwkfzab	124	4	CYM-5442	CYM-5442	NNP
cord-313227-6zwkfzab	124	5	and	and	CC
cord-313227-6zwkfzab	124	6	RP-002	RP-002	NNP
cord-313227-6zwkfzab	124	7	)	)	-RRB-
cord-313227-6zwkfzab	124	8	have	have	VBP
cord-313227-6zwkfzab	124	9	been	be	VBN
cord-313227-6zwkfzab	124	10	reported	report	VBN
cord-313227-6zwkfzab	124	11	to	to	TO
cord-313227-6zwkfzab	124	12	protect	protect	VB
cord-313227-6zwkfzab	124	13	mice	mouse	NNS
cord-313227-6zwkfzab	124	14	from	from	IN
cord-313227-6zwkfzab	124	15	death	death	NN
cord-313227-6zwkfzab	124	16	caused	cause	VBN
cord-313227-6zwkfzab	124	17	by	by	IN
cord-313227-6zwkfzab	124	18	severe	severe	JJ
cord-313227-6zwkfzab	124	19	influenza	influenza	NN
cord-313227-6zwkfzab	124	20	infection	infection	NN
cord-313227-6zwkfzab	124	21	,	,	,
cord-313227-6zwkfzab	124	22	attenuating	attenuate	VBG
cord-313227-6zwkfzab	124	23	cytokine	cytokine	NN
cord-313227-6zwkfzab	124	24	production	production	NN
cord-313227-6zwkfzab	124	25	and	and	CC
cord-313227-6zwkfzab	124	26	inhibiting	inhibit	VBG
cord-313227-6zwkfzab	124	27	infiltration	infiltration	NN
cord-313227-6zwkfzab	124	28	of	of	IN
cord-313227-6zwkfzab	124	29	innate	innate	JJ
cord-313227-6zwkfzab	124	30	immune	immune	JJ
cord-313227-6zwkfzab	124	31	cells	cell	NNS
cord-313227-6zwkfzab	124	32	.	.	.
cord-313227-6zwkfzab	125	1	In	in	IN
cord-313227-6zwkfzab	125	2	a	a	DT
cord-313227-6zwkfzab	125	3	mouse	mouse	NN
cord-313227-6zwkfzab	125	4	model	model	NN
cord-313227-6zwkfzab	125	5	of	of	IN
cord-313227-6zwkfzab	125	6	2009	2009	CD
cord-313227-6zwkfzab	125	7	H1N1	H1N1	NNP
cord-313227-6zwkfzab	125	8	pandemic	pandemic	NN
cord-313227-6zwkfzab	125	9	influenza	influenza	NN
cord-313227-6zwkfzab	125	10	,	,	,
cord-313227-6zwkfzab	125	11	the	the	DT
cord-313227-6zwkfzab	125	12	S1p1	S1p1	NNP
cord-313227-6zwkfzab	125	13	receptor	receptor	NN
cord-313227-6zwkfzab	125	14	agonist	agonist	NN
cord-313227-6zwkfzab	125	15	significantly	significantly	RB
cord-313227-6zwkfzab	125	16	inhibited	inhibit	VBD
cord-313227-6zwkfzab	125	17	synthesis	synthesis	NN
cord-313227-6zwkfzab	125	18	of	of	IN
cord-313227-6zwkfzab	125	19	IL-1α	IL-1α	NNP
cord-313227-6zwkfzab	125	20	,	,	,
cord-313227-6zwkfzab	125	21	IL-1β	IL-1β	NNP
cord-313227-6zwkfzab	125	22	,	,	,
cord-313227-6zwkfzab	125	23	IL-6	IL-6	NNP
cord-313227-6zwkfzab	125	24	,	,	,
cord-313227-6zwkfzab	125	25	IL-10	IL-10	NNP
cord-313227-6zwkfzab	125	26	,	,	,
cord-313227-6zwkfzab	125	27	MCP-1	MCP-1	NNP
cord-313227-6zwkfzab	125	28	,	,	,
cord-313227-6zwkfzab	125	29	TNF	TNF	NNP
cord-313227-6zwkfzab	125	30	-	-	HYPH
cord-313227-6zwkfzab	125	31	α	α	NNP
cord-313227-6zwkfzab	125	32	,	,	,
cord-313227-6zwkfzab	125	33	and	and	CC
cord-313227-6zwkfzab	125	34	GM	GM	NNP
cord-313227-6zwkfzab	125	35	-	-	HYPH
cord-313227-6zwkfzab	125	36	CSF	CSF	NNP
cord-313227-6zwkfzab	125	37	,	,	,
cord-313227-6zwkfzab	125	38	and	and	CC
cord-313227-6zwkfzab	125	39	reduced	reduce	VBN
cord-313227-6zwkfzab	125	40	deaths	death	NNS
cord-313227-6zwkfzab	125	41	from	from	IN
cord-313227-6zwkfzab	125	42	lethal	lethal	JJ
cord-313227-6zwkfzab	125	43	infections	infection	NNS
cord-313227-6zwkfzab	125	44	by	by	IN
cord-313227-6zwkfzab	125	45	more	more	JJR
cord-313227-6zwkfzab	125	46	than	than	IN
cord-313227-6zwkfzab	125	47	80	80	CD
cord-313227-6zwkfzab	125	48	%	%	NN
cord-313227-6zwkfzab	125	49	.	.	.
cord-313227-6zwkfzab	126	1	In	in	IN
cord-313227-6zwkfzab	126	2	addition	addition	NN
cord-313227-6zwkfzab	126	3	the	the	DT
cord-313227-6zwkfzab	126	4	combination	combination	NN
cord-313227-6zwkfzab	126	5	of	of	IN
cord-313227-6zwkfzab	126	6	oseltamivir	oseltamivir	NNP
cord-313227-6zwkfzab	126	7	can	can	MD
cord-313227-6zwkfzab	126	8	reduce	reduce	VB
cord-313227-6zwkfzab	126	9	mouse	mouse	NN
cord-313227-6zwkfzab	126	10	mortality	mortality	NN
cord-313227-6zwkfzab	126	11	by	by	IN
cord-313227-6zwkfzab	126	12	96	96	CD
cord-313227-6zwkfzab	126	13	%	%	NN
cord-313227-6zwkfzab	126	14	(	(	-LRB-
cord-313227-6zwkfzab	126	15	69	69	CD
cord-313227-6zwkfzab	126	16	)	)	-RRB-
cord-313227-6zwkfzab	126	17	.	.	.
cord-313227-6zwkfzab	127	1	Recently	recently	RB
cord-313227-6zwkfzab	127	2	a	a	DT
cord-313227-6zwkfzab	127	3	Multiple	multiple	JJ
cord-313227-6zwkfzab	127	4	sclerosis	sclerosis	NN
cord-313227-6zwkfzab	127	5	(	(	-LRB-
cord-313227-6zwkfzab	127	6	MS	MS	NNP
cord-313227-6zwkfzab	127	7	)	)	-RRB-
cord-313227-6zwkfzab	127	8	patient	patient	NN
cord-313227-6zwkfzab	127	9	in	in	IN
cord-313227-6zwkfzab	127	10	treatment	treatment	NN
cord-313227-6zwkfzab	127	11	with	with	IN
cord-313227-6zwkfzab	127	12	fingolimod	fingolimod	NNP
cord-313227-6zwkfzab	127	13	that	that	WDT
cord-313227-6zwkfzab	127	14	was	be	VBD
cord-313227-6zwkfzab	127	15	diagnosed	diagnose	VBN
cord-313227-6zwkfzab	127	16	with	with	IN
cord-313227-6zwkfzab	127	17	COVID-19	COVID-19	NNP
cord-313227-6zwkfzab	127	18	reported	report	VBD
cord-313227-6zwkfzab	127	19	a	a	DT
cord-313227-6zwkfzab	127	20	favorable	favorable	JJ
cord-313227-6zwkfzab	127	21	outcome	outcome	NN
cord-313227-6zwkfzab	127	22	(	(	-LRB-
cord-313227-6zwkfzab	127	23	70	70	CD
cord-313227-6zwkfzab	127	24	)	)	-RRB-
cord-313227-6zwkfzab	127	25	.	.	.
cord-313227-6zwkfzab	128	1	As	as	IN
cord-313227-6zwkfzab	128	2	reported	report	VBN
cord-313227-6zwkfzab	128	3	,	,	,
cord-313227-6zwkfzab	128	4	the	the	DT
cord-313227-6zwkfzab	128	5	toxicity	toxicity	NN
cord-313227-6zwkfzab	128	6	profile	profile	NN
cord-313227-6zwkfzab	128	7	even	even	RB
cord-313227-6zwkfzab	128	8	for	for	IN
cord-313227-6zwkfzab	128	9	long	long	JJ
cord-313227-6zwkfzab	128	10	term	term	NN
cord-313227-6zwkfzab	128	11	use	use	NN
cord-313227-6zwkfzab	128	12	,	,	,
cord-313227-6zwkfzab	128	13	is	be	VBZ
cord-313227-6zwkfzab	128	14	reassuring	reassure	VBG
cord-313227-6zwkfzab	128	15	(	(	-LRB-
cord-313227-6zwkfzab	128	16	71	71	CD
cord-313227-6zwkfzab	128	17	)	)	-RRB-
cord-313227-6zwkfzab	128	18	.	.	.
cord-313227-6zwkfzab	129	1	In	in	IN
cord-313227-6zwkfzab	129	2	conclusion	conclusion	NN
cord-313227-6zwkfzab	129	3	,	,	,
cord-313227-6zwkfzab	129	4	while	while	IN
cord-313227-6zwkfzab	129	5	specific	specific	JJ
cord-313227-6zwkfzab	129	6	antiviral	antiviral	JJ
cord-313227-6zwkfzab	129	7	therapies	therapy	NNS
cord-313227-6zwkfzab	129	8	are	be	VBP
cord-313227-6zwkfzab	129	9	in	in	IN
cord-313227-6zwkfzab	129	10	rapid	rapid	JJ
cord-313227-6zwkfzab	129	11	development	development	NN
cord-313227-6zwkfzab	129	12	(	(	-LRB-
cord-313227-6zwkfzab	129	13	remdesivir	remdesivir	NNP
cord-313227-6zwkfzab	129	14	,	,	,
cord-313227-6zwkfzab	129	15	chloroquine	chloroquine	NN
cord-313227-6zwkfzab	129	16	,	,	,
cord-313227-6zwkfzab	129	17	vaccine	vaccine	NN
cord-313227-6zwkfzab	129	18	)	)	-RRB-
cord-313227-6zwkfzab	129	19	,	,	,
cord-313227-6zwkfzab	129	20	controlling	control	VBG
cord-313227-6zwkfzab	129	21	the	the	DT
cord-313227-6zwkfzab	129	22	powerful	powerful	JJ
cord-313227-6zwkfzab	129	23	inflammatory	inflammatory	JJ
cord-313227-6zwkfzab	129	24	response	response	NN
cord-313227-6zwkfzab	129	25	causing	cause	VBG
cord-313227-6zwkfzab	129	26	severe	severe	JJ
cord-313227-6zwkfzab	129	27	IP	ip	NN
cord-313227-6zwkfzab	129	28	or	or	CC
cord-313227-6zwkfzab	129	29	ARDS	ARDS	NNP
cord-313227-6zwkfzab	129	30	is	be	VBZ
cord-313227-6zwkfzab	129	31	a	a	DT
cord-313227-6zwkfzab	129	32	reasonable	reasonable	JJ
cord-313227-6zwkfzab	129	33	approach	approach	NN
cord-313227-6zwkfzab	129	34	.	.	.
cord-313227-6zwkfzab	130	1	Agents	agent	NNS
cord-313227-6zwkfzab	130	2	that	that	WDT
cord-313227-6zwkfzab	130	3	are	be	VBP
cord-313227-6zwkfzab	130	4	available	available	JJ
cord-313227-6zwkfzab	130	5	now	now	RB
cord-313227-6zwkfzab	130	6	to	to	TO
cord-313227-6zwkfzab	130	7	improve	improve	VB
cord-313227-6zwkfzab	130	8	the	the	DT
cord-313227-6zwkfzab	130	9	lung	lung	NN
cord-313227-6zwkfzab	130	10	injuries	injury	NNS
cord-313227-6zwkfzab	130	11	due	due	JJ
cord-313227-6zwkfzab	130	12	to	to	IN
cord-313227-6zwkfzab	130	13	the	the	DT
cord-313227-6zwkfzab	130	14	host	host	NN
cord-313227-6zwkfzab	130	15	reactions	reaction	NNS
cord-313227-6zwkfzab	130	16	and	and	CC
cord-313227-6zwkfzab	130	17	reduce	reduce	VB
cord-313227-6zwkfzab	130	18	the	the	DT
cord-313227-6zwkfzab	130	19	lethality	lethality	NN
cord-313227-6zwkfzab	130	20	of	of	IN
cord-313227-6zwkfzab	130	21	the	the	DT
cord-313227-6zwkfzab	130	22	disease	disease	NN
cord-313227-6zwkfzab	130	23	are	be	VBP
cord-313227-6zwkfzab	130	24	badly	badly	RB
cord-313227-6zwkfzab	130	25	needed	need	VBN
cord-313227-6zwkfzab	130	26	,	,	,
cord-313227-6zwkfzab	130	27	and	and	CC
cord-313227-6zwkfzab	130	28	some	some	DT
cord-313227-6zwkfzab	130	29	are	be	VBP
cord-313227-6zwkfzab	130	30	already	already	RB
cord-313227-6zwkfzab	130	31	in	in	IN
cord-313227-6zwkfzab	130	32	clinical	clinical	JJ
cord-313227-6zwkfzab	130	33	studies	study	NNS
cord-313227-6zwkfzab	130	34	.	.	.
cord-313227-6zwkfzab	131	1	Drugs	drug	NNS
cord-313227-6zwkfzab	131	2	targeting	target	VBG
cord-313227-6zwkfzab	131	3	multiple	multiple	JJ
cord-313227-6zwkfzab	131	4	cyto	cyto	NNS
cord-313227-6zwkfzab	131	5	/	/	SYM
cord-313227-6zwkfzab	131	6	chemokines	chemokine	NNS
cord-313227-6zwkfzab	131	7	involved	involve	VBN
cord-313227-6zwkfzab	131	8	in	in	IN
cord-313227-6zwkfzab	131	9	SARS	SARS	NNP
cord-313227-6zwkfzab	131	10	-	-	HYPH
cord-313227-6zwkfzab	131	11	COv-2	COv-2	VBN
cord-313227-6zwkfzab	131	12	IP	ip	NN
cord-313227-6zwkfzab	131	13	are	be	VBP
cord-313227-6zwkfzab	131	14	available	available	JJ
cord-313227-6zwkfzab	131	15	for	for	IN
cord-313227-6zwkfzab	131	16	trial	trial	NN
cord-313227-6zwkfzab	131	17	or	or	CC
cord-313227-6zwkfzab	131	18	for	for	IN
cord-313227-6zwkfzab	131	19	off	off	IN
cord-313227-6zwkfzab	131	20	-	-	HYPH
cord-313227-6zwkfzab	131	21	label	label	NN
cord-313227-6zwkfzab	131	22	use	use	NN
cord-313227-6zwkfzab	131	23	,	,	,
cord-313227-6zwkfzab	131	24	but	but	CC
cord-313227-6zwkfzab	131	25	close	close	JJ
cord-313227-6zwkfzab	131	26	attention	attention	NN
cord-313227-6zwkfzab	131	27	is	be	VBZ
cord-313227-6zwkfzab	131	28	needed	need	VBN
cord-313227-6zwkfzab	131	29	to	to	IN
cord-313227-6zwkfzab	131	30	the	the	DT
cord-313227-6zwkfzab	131	31	schedule	schedule	NN
cord-313227-6zwkfzab	131	32	of	of	IN
cord-313227-6zwkfzab	131	33	administration	administration	NN
cord-313227-6zwkfzab	131	34	,	,	,
cord-313227-6zwkfzab	131	35	considered	consider	VBD
cord-313227-6zwkfzab	131	36	the	the	DT
cord-313227-6zwkfzab	131	37	immunosuppressive	immunosuppressive	JJ
cord-313227-6zwkfzab	131	38	action	action	NN
cord-313227-6zwkfzab	131	39	of	of	IN
cord-313227-6zwkfzab	131	40	these	these	DT
cord-313227-6zwkfzab	131	41	drugs	drug	NNS
cord-313227-6zwkfzab	131	42	.	.	.
cord-313227-6zwkfzab	132	1	To	to	IN
cord-313227-6zwkfzab	132	2	this	this	DT
cord-313227-6zwkfzab	132	3	aim	aim	VB
cord-313227-6zwkfzab	132	4	rapid	rapid	JJ
cord-313227-6zwkfzab	132	5	identification	identification	NN
cord-313227-6zwkfzab	132	6	of	of	IN
cord-313227-6zwkfzab	132	7	prognostic	prognostic	JJ
cord-313227-6zwkfzab	132	8	factors	factor	NNS
cord-313227-6zwkfzab	132	9	in	in	IN
cord-313227-6zwkfzab	132	10	the	the	DT
cord-313227-6zwkfzab	132	11	peripheral	peripheral	JJ
cord-313227-6zwkfzab	132	12	immune	immune	NN
cord-313227-6zwkfzab	132	13	profile	profile	NN
cord-313227-6zwkfzab	132	14	may	may	MD
cord-313227-6zwkfzab	132	15	support	support	VB
cord-313227-6zwkfzab	132	16	therapeutic	therapeutic	JJ
cord-313227-6zwkfzab	132	17	approach	approach	NN
cord-313227-6zwkfzab	132	18	.	.	.
cord-313227-6zwkfzab	133	1	Careful	careful	JJ
cord-313227-6zwkfzab	133	2	clinical	clinical	JJ
cord-313227-6zwkfzab	133	3	studies	study	NNS
cord-313227-6zwkfzab	133	4	are	be	VBP
cord-313227-6zwkfzab	133	5	warranted	warrant	VBN
cord-313227-6zwkfzab	133	6	.	.	.
cord-313227-6zwkfzab	134	1	SS	SS	NNP
cord-313227-6zwkfzab	134	2	and	and	CC
cord-313227-6zwkfzab	134	3	RP	RP	NNP
cord-313227-6zwkfzab	134	4	both	both	DT
cord-313227-6zwkfzab	134	5	equally	equally	RB
cord-313227-6zwkfzab	134	6	contributed	contribute	VBD
cord-313227-6zwkfzab	134	7	in	in	IN
cord-313227-6zwkfzab	134	8	designing	design	VBG
cord-313227-6zwkfzab	134	9	and	and	CC
cord-313227-6zwkfzab	134	10	realizing	realize	VBG
cord-313227-6zwkfzab	134	11	the	the	DT
cord-313227-6zwkfzab	134	12	manuscript	manuscript	NN
cord-313227-6zwkfzab	134	13	.	.	.
cord-313227-6zwkfzab	135	1	The	the	DT
cord-313227-6zwkfzab	135	2	continuing	continue	VBG
cord-313227-6zwkfzab	135	3	2019-nCoV	2019-ncov	CD
cord-313227-6zwkfzab	135	4	epidemic	epidemic	NN
cord-313227-6zwkfzab	135	5	threat	threat	NN
cord-313227-6zwkfzab	135	6	of	of	IN
cord-313227-6zwkfzab	135	7	novel	novel	JJ
cord-313227-6zwkfzab	135	8	coronaviruses	coronaviruse	NNS
cord-313227-6zwkfzab	135	9	to	to	IN
cord-313227-6zwkfzab	135	10	global	global	JJ
cord-313227-6zwkfzab	135	11	health	health	NN
cord-313227-6zwkfzab	135	12	-The	-The	:
cord-313227-6zwkfzab	135	13	latest	late	JJS
cord-313227-6zwkfzab	135	14	2019	2019	CD
cord-313227-6zwkfzab	135	15	novel	novel	JJ
cord-313227-6zwkfzab	135	16	coronavirus	coronavirus	NN
cord-313227-6zwkfzab	135	17	outbreak	outbreak	NN
cord-313227-6zwkfzab	135	18	in	in	IN
cord-313227-6zwkfzab	135	19	Wuhan	Wuhan	NNP
cord-313227-6zwkfzab	135	20	,	,	,
cord-313227-6zwkfzab	135	21	China	China	NNP
cord-313227-6zwkfzab	135	22	Emerging	Emerging	NNP
cord-313227-6zwkfzab	135	23	coronaviruses	coronaviruse	NNS
cord-313227-6zwkfzab	135	24	:	:	:
cord-313227-6zwkfzab	135	25	genome	genome	NN
cord-313227-6zwkfzab	135	26	structure	structure	NN
cord-313227-6zwkfzab	135	27	,	,	,
cord-313227-6zwkfzab	135	28	replication	replication	NN
cord-313227-6zwkfzab	135	29	,	,	,
cord-313227-6zwkfzab	135	30	and	and	CC
cord-313227-6zwkfzab	135	31	pathogenesis	pathogenesis	NN
cord-313227-6zwkfzab	135	32	Severe	severe	JJ
cord-313227-6zwkfzab	135	33	acute	acute	JJ
cord-313227-6zwkfzab	135	34	respiratory	respiratory	JJ
cord-313227-6zwkfzab	135	35	syndrome	syndrome	NN
cord-313227-6zwkfzab	135	36	coronavirus	coronavirus	NN
cord-313227-6zwkfzab	135	37	2	2	CD
cord-313227-6zwkfzab	136	1	(	(	-LRB-
cord-313227-6zwkfzab	136	2	SARS	SARS	NNP
cord-313227-6zwkfzab	136	3	-	-	HYPH
cord-313227-6zwkfzab	136	4	CoV-2	CoV-2	NNP
cord-313227-6zwkfzab	136	5	)	)	-RRB-
cord-313227-6zwkfzab	136	6	and	and	CC
cord-313227-6zwkfzab	136	7	coronavirus	coronavirus	NN
cord-313227-6zwkfzab	136	8	disease-2019	disease-2019	NNP
cord-313227-6zwkfzab	136	9	(	(	-LRB-
cord-313227-6zwkfzab	136	10	COVID-19	COVID-19	NNP
cord-313227-6zwkfzab	136	11	)	)	-RRB-
cord-313227-6zwkfzab	136	12	:	:	:
cord-313227-6zwkfzab	137	1	the	the	DT
cord-313227-6zwkfzab	137	2	epidemic	epidemic	NN
cord-313227-6zwkfzab	137	3	and	and	CC
cord-313227-6zwkfzab	137	4	the	the	DT
cord-313227-6zwkfzab	137	5	challenges	challenge	NNS
cord-313227-6zwkfzab	137	6	Characteristics	characteristic	NNS
cord-313227-6zwkfzab	137	7	of	of	IN
cord-313227-6zwkfzab	137	8	and	and	CC
cord-313227-6zwkfzab	137	9	important	important	JJ
cord-313227-6zwkfzab	137	10	lessons	lesson	NNS
cord-313227-6zwkfzab	137	11	from	from	IN
cord-313227-6zwkfzab	137	12	the	the	DT
cord-313227-6zwkfzab	137	13	coronavirus	coronavirus	NN
cord-313227-6zwkfzab	137	14	disease	disease	NN
cord-313227-6zwkfzab	137	15	2019	2019	CD
cord-313227-6zwkfzab	137	16	(	(	-LRB-
cord-313227-6zwkfzab	137	17	COVID-19	COVID-19	NNP
cord-313227-6zwkfzab	137	18	)	)	-RRB-
cord-313227-6zwkfzab	137	19	outbreak	outbreak	NN
cord-313227-6zwkfzab	137	20	in	in	IN
cord-313227-6zwkfzab	137	21	China	China	NNP
cord-313227-6zwkfzab	137	22	:	:	:
cord-313227-6zwkfzab	137	23	summary	summary	NN
cord-313227-6zwkfzab	137	24	of	of	IN
cord-313227-6zwkfzab	137	25	a	a	DT
cord-313227-6zwkfzab	137	26	report	report	NN
cord-313227-6zwkfzab	137	27	of	of	IN
cord-313227-6zwkfzab	137	28	72314	72314	CD
cord-313227-6zwkfzab	137	29	cases	case	NNS
cord-313227-6zwkfzab	137	30	from	from	IN
cord-313227-6zwkfzab	137	31	the	the	DT
cord-313227-6zwkfzab	137	32	Chinese	chinese	JJ
cord-313227-6zwkfzab	137	33	center	center	NN
cord-313227-6zwkfzab	137	34	for	for	IN
cord-313227-6zwkfzab	137	35	disease	disease	NNP
cord-313227-6zwkfzab	137	36	control	control	NN
cord-313227-6zwkfzab	137	37	and	and	CC
cord-313227-6zwkfzab	138	1	prevention	prevention	NN
cord-313227-6zwkfzab	138	2	Angiotensinconverting	Angiotensinconverting	NNP
cord-313227-6zwkfzab	138	3	enzyme	enzyme	NN
cord-313227-6zwkfzab	138	4	2	2	CD
cord-313227-6zwkfzab	138	5	(	(	-LRB-
cord-313227-6zwkfzab	138	6	ACE2	ACE2	NNP
cord-313227-6zwkfzab	138	7	)	)	-RRB-
cord-313227-6zwkfzab	138	8	as	as	IN
cord-313227-6zwkfzab	138	9	a	a	DT
cord-313227-6zwkfzab	138	10	SARS	SARS	NNP
cord-313227-6zwkfzab	138	11	-	-	HYPH
cord-313227-6zwkfzab	138	12	CoV-2	CoV-2	NNP
cord-313227-6zwkfzab	138	13	receptor	receptor	NN
cord-313227-6zwkfzab	138	14	:	:	:
cord-313227-6zwkfzab	138	15	molecular	molecular	JJ
cord-313227-6zwkfzab	138	16	mechanisms	mechanism	NNS
cord-313227-6zwkfzab	138	17	and	and	CC
cord-313227-6zwkfzab	138	18	potential	potential	JJ
cord-313227-6zwkfzab	138	19	therapeutic	therapeutic	JJ
cord-313227-6zwkfzab	138	20	target	target	NN
cord-313227-6zwkfzab	138	21	COVID-19	covid-19	NN
cord-313227-6zwkfzab	138	22	:	:	:
cord-313227-6zwkfzab	138	23	consider	consider	VB
cord-313227-6zwkfzab	138	24	cytokine	cytokine	JJ
cord-313227-6zwkfzab	138	25	storm	storm	NN
cord-313227-6zwkfzab	138	26	syndromes	syndrome	NNS
cord-313227-6zwkfzab	138	27	and	and	CC
cord-313227-6zwkfzab	138	28	immunosuppression	immunosuppression	NN
cord-313227-6zwkfzab	138	29	Cytokine	cytokine	NN
cord-313227-6zwkfzab	138	30	storm	storm	NN
cord-313227-6zwkfzab	138	31	and	and	CC
cord-313227-6zwkfzab	138	32	sepsis	sepsis	NN
cord-313227-6zwkfzab	138	33	disease	disease	NN
cord-313227-6zwkfzab	138	34	pathogenesis	pathogenesis	NN
cord-313227-6zwkfzab	139	1	Diverse	diverse	JJ
cord-313227-6zwkfzab	139	2	macrophage	macrophage	NN
cord-313227-6zwkfzab	139	3	populations	population	NNS
cord-313227-6zwkfzab	139	4	mediate	mediate	VBP
cord-313227-6zwkfzab	139	5	acute	acute	JJ
cord-313227-6zwkfzab	139	6	lung	lung	NN
cord-313227-6zwkfzab	139	7	inflammation	inflammation	NN
cord-313227-6zwkfzab	139	8	and	and	CC
cord-313227-6zwkfzab	139	9	resolution	resolution	NN
cord-313227-6zwkfzab	139	10	Lipoxin	Lipoxin	NNP
cord-313227-6zwkfzab	139	11	A4	A4	NNP
cord-313227-6zwkfzab	139	12	receptor	receptor	NN
cord-313227-6zwkfzab	139	13	agonist	agonist	NN
cord-313227-6zwkfzab	140	1	BML-111	bml-111	NN
cord-313227-6zwkfzab	140	2	induces	induce	VBZ
cord-313227-6zwkfzab	140	3	autophagy	autophagy	NN
cord-313227-6zwkfzab	140	4	in	in	IN
cord-313227-6zwkfzab	140	5	alveolar	alveolar	JJ
cord-313227-6zwkfzab	140	6	macrophages	macrophage	NNS
cord-313227-6zwkfzab	140	7	and	and	CC
cord-313227-6zwkfzab	140	8	protects	protect	VBZ
cord-313227-6zwkfzab	140	9	from	from	IN
cord-313227-6zwkfzab	140	10	acute	acute	JJ
cord-313227-6zwkfzab	140	11	lung	lung	NN
cord-313227-6zwkfzab	140	12	injury	injury	NN
cord-313227-6zwkfzab	140	13	by	by	IN
cord-313227-6zwkfzab	140	14	activating	activate	VBG
cord-313227-6zwkfzab	140	15	MAPK	MAPK	NNP
cord-313227-6zwkfzab	140	16	signaling	signal	VBG
cord-313227-6zwkfzab	140	17	Effect	effect	NN
cord-313227-6zwkfzab	140	18	of	of	IN
cord-313227-6zwkfzab	140	19	TLR4	TLR4	NNP
cord-313227-6zwkfzab	140	20	/	/	SYM
cord-313227-6zwkfzab	140	21	MyD88	MyD88	NNS
cord-313227-6zwkfzab	141	1	signaling	signal	VBG
cord-313227-6zwkfzab	141	2	pathway	pathway	NN
cord-313227-6zwkfzab	141	3	on	on	IN
cord-313227-6zwkfzab	141	4	sepsis	sepsis	NN
cord-313227-6zwkfzab	141	5	-	-	HYPH
cord-313227-6zwkfzab	141	6	associated	associate	VBN
cord-313227-6zwkfzab	141	7	acute	acute	JJ
cord-313227-6zwkfzab	141	8	respiratory	respiratory	JJ
cord-313227-6zwkfzab	141	9	distress	distress	NN
cord-313227-6zwkfzab	141	10	syndrome	syndrome	NN
cord-313227-6zwkfzab	141	11	in	in	IN
cord-313227-6zwkfzab	141	12	rats	rat	NNS
cord-313227-6zwkfzab	141	13	,	,	,
cord-313227-6zwkfzab	141	14	via	via	IN
cord-313227-6zwkfzab	141	15	regulation	regulation	NN
cord-313227-6zwkfzab	141	16	of	of	IN
cord-313227-6zwkfzab	141	17	macrophage	macrophage	NN
cord-313227-6zwkfzab	141	18	activation	activation	NN
cord-313227-6zwkfzab	141	19	and	and	CC
cord-313227-6zwkfzab	141	20	inflammatory	inflammatory	JJ
cord-313227-6zwkfzab	141	21	response	response	NN
cord-313227-6zwkfzab	141	22	Protective	protective	JJ
cord-313227-6zwkfzab	141	23	and	and	CC
cord-313227-6zwkfzab	141	24	pathogenic	pathogenic	JJ
cord-313227-6zwkfzab	141	25	functions	function	NNS
cord-313227-6zwkfzab	141	26	of	of	IN
cord-313227-6zwkfzab	141	27	macrophage	macrophage	NN
cord-313227-6zwkfzab	141	28	subsets	subset	NNS
cord-313227-6zwkfzab	141	29	Exploring	explore	VBG
cord-313227-6zwkfzab	141	30	the	the	DT
cord-313227-6zwkfzab	141	31	full	full	JJ
cord-313227-6zwkfzab	141	32	spectrum	spectrum	NN
cord-313227-6zwkfzab	141	33	of	of	IN
cord-313227-6zwkfzab	141	34	macrophage	macrophage	NN
cord-313227-6zwkfzab	141	35	activation	activation	NN
cord-313227-6zwkfzab	141	36	Macrophages	macrophage	NNS
cord-313227-6zwkfzab	141	37	in	in	IN
cord-313227-6zwkfzab	141	38	tissue	tissue	NN
cord-313227-6zwkfzab	141	39	repair	repair	NN
cord-313227-6zwkfzab	141	40	,	,	,
cord-313227-6zwkfzab	141	41	regeneration	regeneration	NN
cord-313227-6zwkfzab	141	42	,	,	,
cord-313227-6zwkfzab	141	43	and	and	CC
cord-313227-6zwkfzab	141	44	fibrosis	fibrosis	NN
cord-313227-6zwkfzab	141	45	Pathogenic	pathogenic	JJ
cord-313227-6zwkfzab	141	46	human	human	JJ
cord-313227-6zwkfzab	141	47	coronavirus	coronavirus	NN
cord-313227-6zwkfzab	141	48	infections	infection	NNS
cord-313227-6zwkfzab	141	49	:	:	:
cord-313227-6zwkfzab	141	50	causes	cause	NNS
cord-313227-6zwkfzab	141	51	and	and	CC
cord-313227-6zwkfzab	141	52	consequences	consequence	NNS
cord-313227-6zwkfzab	141	53	of	of	IN
cord-313227-6zwkfzab	141	54	cytokine	cytokine	NN
cord-313227-6zwkfzab	141	55	storm	storm	NN
cord-313227-6zwkfzab	141	56	and	and	CC
cord-313227-6zwkfzab	141	57	immunopathology	immunopathology	NN
cord-313227-6zwkfzab	141	58	Plasma	plasma	NN
cord-313227-6zwkfzab	141	59	inflammatory	inflammatory	JJ
cord-313227-6zwkfzab	141	60	cytokines	cytokine	NNS
cord-313227-6zwkfzab	141	61	and	and	CC
cord-313227-6zwkfzab	141	62	chemokines	chemokine	NNS
cord-313227-6zwkfzab	141	63	in	in	IN
cord-313227-6zwkfzab	141	64	severe	severe	JJ
cord-313227-6zwkfzab	141	65	acute	acute	JJ
cord-313227-6zwkfzab	141	66	respiratory	respiratory	JJ
cord-313227-6zwkfzab	141	67	syndrome	syndrome	NN
cord-313227-6zwkfzab	141	68	MERS	MERS	NNP
cord-313227-6zwkfzab	141	69	-	-	HYPH
cord-313227-6zwkfzab	141	70	CoV	cov	NN
cord-313227-6zwkfzab	141	71	infection	infection	NN
cord-313227-6zwkfzab	141	72	in	in	IN
cord-313227-6zwkfzab	141	73	humans	human	NNS
cord-313227-6zwkfzab	141	74	is	be	VBZ
cord-313227-6zwkfzab	141	75	associated	associate	VBN
cord-313227-6zwkfzab	141	76	with	with	IN
cord-313227-6zwkfzab	141	77	a	a	DT
cord-313227-6zwkfzab	141	78	pro	pro	JJ
cord-313227-6zwkfzab	141	79	-	-	JJ
cord-313227-6zwkfzab	141	80	inflammatory	inflammatory	JJ
cord-313227-6zwkfzab	141	81	Th1	th1	NN
cord-313227-6zwkfzab	141	82	and	and	CC
cord-313227-6zwkfzab	141	83	Th17	Th17	NNP
cord-313227-6zwkfzab	141	84	cytokine	cytokine	NN
cord-313227-6zwkfzab	141	85	profile	profile	NN
cord-313227-6zwkfzab	141	86	MERS	MERS	NNP
cord-313227-6zwkfzab	141	87	-	-	HYPH
cord-313227-6zwkfzab	141	88	CoV	cov	NN
cord-313227-6zwkfzab	141	89	infection	infection	NN
cord-313227-6zwkfzab	141	90	is	be	VBZ
cord-313227-6zwkfzab	141	91	associated	associate	VBN
cord-313227-6zwkfzab	141	92	with	with	IN
cord-313227-6zwkfzab	141	93	downregulation	downregulation	NN
cord-313227-6zwkfzab	141	94	of	of	IN
cord-313227-6zwkfzab	141	95	genes	gene	NNS
cord-313227-6zwkfzab	141	96	encoding	encode	VBG
cord-313227-6zwkfzab	141	97	Th1	th1	NN
cord-313227-6zwkfzab	141	98	and	and	CC
cord-313227-6zwkfzab	141	99	Th2	Th2	NNP
cord-313227-6zwkfzab	141	100	cytokines	cytokine	NNS
cord-313227-6zwkfzab	141	101	/	/	SYM
cord-313227-6zwkfzab	141	102	chemokines	chemokine	NNS
cord-313227-6zwkfzab	141	103	and	and	CC
cord-313227-6zwkfzab	141	104	elevated	elevate	VBN
cord-313227-6zwkfzab	141	105	inflammatory	inflammatory	JJ
cord-313227-6zwkfzab	141	106	innate	innate	JJ
cord-313227-6zwkfzab	141	107	immune	immune	JJ
cord-313227-6zwkfzab	141	108	response	response	NN
cord-313227-6zwkfzab	141	109	in	in	IN
cord-313227-6zwkfzab	141	110	the	the	DT
cord-313227-6zwkfzab	141	111	lower	low	JJR
cord-313227-6zwkfzab	141	112	respiratory	respiratory	JJ
cord-313227-6zwkfzab	141	113	tract	tract	NN
cord-313227-6zwkfzab	141	114	Clinical	clinical	JJ
cord-313227-6zwkfzab	141	115	features	feature	NNS
cord-313227-6zwkfzab	141	116	of	of	IN
cord-313227-6zwkfzab	141	117	patients	patient	NNS
cord-313227-6zwkfzab	141	118	infected	infect	VBN
cord-313227-6zwkfzab	141	119	with	with	IN
cord-313227-6zwkfzab	141	120	2019	2019	CD
cord-313227-6zwkfzab	141	121	novel	novel	JJ
cord-313227-6zwkfzab	141	122	coronavirus	coronavirus	NN
cord-313227-6zwkfzab	141	123	in	in	IN
cord-313227-6zwkfzab	141	124	Wuhan	Wuhan	NNP
cord-313227-6zwkfzab	141	125	Inflammatory	Inflammatory	NNP
cord-313227-6zwkfzab	141	126	chemokines	chemokine	NNS
cord-313227-6zwkfzab	141	127	direct	direct	VBP
cord-313227-6zwkfzab	141	128	and	and	CC
cord-313227-6zwkfzab	141	129	restrict	restrict	VBP
cord-313227-6zwkfzab	141	130	leukocyte	leukocyte	NN
cord-313227-6zwkfzab	141	131	migration	migration	NN
cord-313227-6zwkfzab	141	132	within	within	IN
cord-313227-6zwkfzab	141	133	live	live	JJ
cord-313227-6zwkfzab	141	134	tissues	tissue	NNS
cord-313227-6zwkfzab	141	135	as	as	IN
cord-313227-6zwkfzab	141	136	glycan	glycan	NN
cord-313227-6zwkfzab	141	137	-	-	HYPH
cord-313227-6zwkfzab	141	138	bound	bind	VBN
cord-313227-6zwkfzab	141	139	gradients	gradient	NNS
cord-313227-6zwkfzab	141	140	Clinical	clinical	JJ
cord-313227-6zwkfzab	141	141	and	and	CC
cord-313227-6zwkfzab	141	142	biochemical	biochemical	JJ
cord-313227-6zwkfzab	141	143	indexes	index	NNS
cord-313227-6zwkfzab	141	144	from	from	IN
cord-313227-6zwkfzab	141	145	2019-nCoV	2019-ncov	CD
cord-313227-6zwkfzab	141	146	infected	infect	VBN
cord-313227-6zwkfzab	141	147	patients	patient	NNS
cord-313227-6zwkfzab	141	148	linked	link	VBN
cord-313227-6zwkfzab	141	149	to	to	IN
cord-313227-6zwkfzab	141	150	viral	viral	JJ
cord-313227-6zwkfzab	141	151	loads	load	NNS
cord-313227-6zwkfzab	141	152	and	and	CC
cord-313227-6zwkfzab	141	153	lung	lung	NN
cord-313227-6zwkfzab	141	154	injury	injury	NN
cord-313227-6zwkfzab	142	1	Antispike	Antispike	NNP
cord-313227-6zwkfzab	142	2	IgG	igg	NN
cord-313227-6zwkfzab	142	3	causes	cause	VBZ
cord-313227-6zwkfzab	142	4	severe	severe	JJ
cord-313227-6zwkfzab	142	5	acute	acute	JJ
cord-313227-6zwkfzab	142	6	lung	lung	NN
cord-313227-6zwkfzab	142	7	injury	injury	NN
cord-313227-6zwkfzab	142	8	by	by	IN
cord-313227-6zwkfzab	142	9	skewing	skew	VBG
cord-313227-6zwkfzab	142	10	macrophage	macrophage	NN
cord-313227-6zwkfzab	142	11	responses	response	NNS
cord-313227-6zwkfzab	142	12	during	during	IN
cord-313227-6zwkfzab	142	13	acute	acute	JJ
cord-313227-6zwkfzab	142	14	SARS	SARS	NNP
cord-313227-6zwkfzab	142	15	-	-	HYPH
cord-313227-6zwkfzab	142	16	CoV	CoV	NNP
cord-313227-6zwkfzab	142	17	infection	infection	NN
cord-313227-6zwkfzab	142	18	Antibody	Antibody	NNP
cord-313227-6zwkfzab	142	19	responses	response	NNS
cord-313227-6zwkfzab	142	20	against	against	IN
cord-313227-6zwkfzab	142	21	SARS	SARS	NNP
cord-313227-6zwkfzab	142	22	coronavirus	coronavirus	NN
cord-313227-6zwkfzab	142	23	are	be	VBP
cord-313227-6zwkfzab	142	24	correlated	correlate	VBN
cord-313227-6zwkfzab	142	25	with	with	IN
cord-313227-6zwkfzab	142	26	disease	disease	NN
cord-313227-6zwkfzab	142	27	outcome	outcome	NN
cord-313227-6zwkfzab	142	28	of	of	IN
cord-313227-6zwkfzab	142	29	infected	infected	JJ
cord-313227-6zwkfzab	142	30	individuals	individual	NNS
cord-313227-6zwkfzab	142	31	Severe	severe	JJ
cord-313227-6zwkfzab	142	32	pandemic	pandemic	NN
cord-313227-6zwkfzab	142	33	2009	2009	CD
cord-313227-6zwkfzab	142	34	H1N1	H1N1	NNP
cord-313227-6zwkfzab	142	35	influenza	influenza	NN
cord-313227-6zwkfzab	142	36	disease	disease	NN
cord-313227-6zwkfzab	142	37	due	due	JJ
cord-313227-6zwkfzab	142	38	to	to	IN
cord-313227-6zwkfzab	142	39	pathogenic	pathogenic	JJ
cord-313227-6zwkfzab	142	40	immune	immune	JJ
cord-313227-6zwkfzab	142	41	complexes	complex	NNS
cord-313227-6zwkfzab	143	1	High	high	JJ
cord-313227-6zwkfzab	143	2	titer	titer	NN
cord-313227-6zwkfzab	143	3	and	and	CC
cord-313227-6zwkfzab	143	4	avidity	avidity	NN
cord-313227-6zwkfzab	143	5	of	of	IN
cord-313227-6zwkfzab	143	6	nonneutralizing	nonneutralize	VBG
cord-313227-6zwkfzab	143	7	antibodies	antibody	NNS
cord-313227-6zwkfzab	143	8	against	against	IN
cord-313227-6zwkfzab	143	9	influenza	influenza	NN
cord-313227-6zwkfzab	143	10	vaccine	vaccine	NN
cord-313227-6zwkfzab	143	11	antigen	antigen	NN
cord-313227-6zwkfzab	143	12	are	be	VBP
cord-313227-6zwkfzab	143	13	associated	associate	VBN
cord-313227-6zwkfzab	143	14	with	with	IN
cord-313227-6zwkfzab	143	15	severe	severe	JJ
cord-313227-6zwkfzab	143	16	influenza	influenza	NN
cord-313227-6zwkfzab	143	17	Acute	acute	JJ
cord-313227-6zwkfzab	143	18	respiratory	respiratory	JJ
cord-313227-6zwkfzab	143	19	distress	distress	NN
cord-313227-6zwkfzab	143	20	syndrome	syndrome	NN
cord-313227-6zwkfzab	143	21	Clinical	clinical	JJ
cord-313227-6zwkfzab	143	22	course	course	NN
cord-313227-6zwkfzab	143	23	and	and	CC
cord-313227-6zwkfzab	143	24	risk	risk	NN
cord-313227-6zwkfzab	143	25	factors	factor	NNS
cord-313227-6zwkfzab	143	26	for	for	IN
cord-313227-6zwkfzab	143	27	mortality	mortality	NN
cord-313227-6zwkfzab	143	28	of	of	IN
cord-313227-6zwkfzab	143	29	adult	adult	NN
cord-313227-6zwkfzab	143	30	inpatients	inpatient	NNS
cord-313227-6zwkfzab	143	31	with	with	IN
cord-313227-6zwkfzab	143	32	COVID-19	COVID-19	NNP
cord-313227-6zwkfzab	143	33	in	in	IN
cord-313227-6zwkfzab	143	34	Wuhan	Wuhan	NNP
cord-313227-6zwkfzab	143	35	,	,	,
cord-313227-6zwkfzab	143	36	China	China	NNP
cord-313227-6zwkfzab	143	37	:	:	:
cord-313227-6zwkfzab	144	1	a	a	DT
cord-313227-6zwkfzab	144	2	retrospective	retrospective	JJ
cord-313227-6zwkfzab	144	3	cohort	cohort	NN
cord-313227-6zwkfzab	144	4	study	study	NN
cord-313227-6zwkfzab	144	5	Recent	recent	JJ
cord-313227-6zwkfzab	144	6	advances	advance	NNS
cord-313227-6zwkfzab	144	7	in	in	IN
cord-313227-6zwkfzab	144	8	the	the	DT
cord-313227-6zwkfzab	144	9	understanding	understanding	NN
cord-313227-6zwkfzab	144	10	and	and	CC
cord-313227-6zwkfzab	144	11	management	management	NN
cord-313227-6zwkfzab	144	12	of	of	IN
cord-313227-6zwkfzab	144	13	ARDS	ARDS	NNP
cord-313227-6zwkfzab	144	14	.	.	.
cord-313227-6zwkfzab	145	1	F1000Res	F1000Res	NNP
cord-313227-6zwkfzab	145	2	A	a	DT
cord-313227-6zwkfzab	145	3	trial	trial	NN
cord-313227-6zwkfzab	145	4	of	of	IN
cord-313227-6zwkfzab	145	5	lopinavirritonavir	lopinavirritonavir	NNS
cord-313227-6zwkfzab	145	6	in	in	IN
cord-313227-6zwkfzab	145	7	adults	adult	NNS
cord-313227-6zwkfzab	145	8	hospitalized	hospitalize	VBN
cord-313227-6zwkfzab	145	9	with	with	IN
cord-313227-6zwkfzab	145	10	severe	severe	JJ
cord-313227-6zwkfzab	145	11	Covid-19	Covid-19	NNP
cord-313227-6zwkfzab	145	12	Remdesivir	Remdesivir	NNP
cord-313227-6zwkfzab	145	13	and	and	CC
cord-313227-6zwkfzab	145	14	chloroquine	chloroquine	NN
cord-313227-6zwkfzab	145	15	effectively	effectively	RB
cord-313227-6zwkfzab	145	16	inhibit	inhibit	VBP
cord-313227-6zwkfzab	145	17	the	the	DT
cord-313227-6zwkfzab	145	18	recently	recently	RB
cord-313227-6zwkfzab	145	19	emerged	emerge	VBN
cord-313227-6zwkfzab	145	20	novel	novel	JJ
cord-313227-6zwkfzab	145	21	coronavirus	coronavirus	NN
cord-313227-6zwkfzab	145	22	(	(	-LRB-
cord-313227-6zwkfzab	145	23	2019-nCoV	2019-ncov	CD
cord-313227-6zwkfzab	145	24	)	)	-RRB-
cord-313227-6zwkfzab	145	25	in	in	IN
cord-313227-6zwkfzab	145	26	vitro	vitro	FW
cord-313227-6zwkfzab	145	27	Breakthrough	Breakthrough	NNP
cord-313227-6zwkfzab	145	28	:	:	:
cord-313227-6zwkfzab	145	29	chloroquine	chloroquine	NN
cord-313227-6zwkfzab	145	30	phosphate	phosphate	NN
cord-313227-6zwkfzab	145	31	has	have	VBZ
cord-313227-6zwkfzab	145	32	shown	show	VBN
cord-313227-6zwkfzab	145	33	apparent	apparent	JJ
cord-313227-6zwkfzab	145	34	efficacy	efficacy	NN
cord-313227-6zwkfzab	145	35	in	in	IN
cord-313227-6zwkfzab	145	36	treatment	treatment	NN
cord-313227-6zwkfzab	145	37	of	of	IN
cord-313227-6zwkfzab	145	38	COVID-19	covid-19	JJ
cord-313227-6zwkfzab	145	39	associated	associated	JJ
cord-313227-6zwkfzab	145	40	pneumonia	pneumonia	NN
cord-313227-6zwkfzab	145	41	in	in	IN
cord-313227-6zwkfzab	145	42	clinical	clinical	JJ
cord-313227-6zwkfzab	145	43	studies	study	NNS
cord-313227-6zwkfzab	146	1	Risk	risk	NN
cord-313227-6zwkfzab	146	2	factors	factor	NNS
cord-313227-6zwkfzab	146	3	associated	associate	VBN
cord-313227-6zwkfzab	146	4	with	with	IN
cord-313227-6zwkfzab	146	5	acute	acute	JJ
cord-313227-6zwkfzab	146	6	respiratory	respiratory	JJ
cord-313227-6zwkfzab	146	7	distress	distress	NN
cord-313227-6zwkfzab	146	8	syndrome	syndrome	NN
cord-313227-6zwkfzab	146	9	and	and	CC
cord-313227-6zwkfzab	146	10	death	death	NN
cord-313227-6zwkfzab	146	11	in	in	IN
cord-313227-6zwkfzab	146	12	patients	patient	NNS
cord-313227-6zwkfzab	146	13	with	with	IN
cord-313227-6zwkfzab	146	14	coronavirus	coronavirus	NN
cord-313227-6zwkfzab	146	15	disease	disease	NN
cord-313227-6zwkfzab	146	16	2019	2019	CD
cord-313227-6zwkfzab	146	17	pneumonia	pneumonia	NN
cord-313227-6zwkfzab	146	18	in	in	IN
cord-313227-6zwkfzab	146	19	Wuhan	Wuhan	NNP
cord-313227-6zwkfzab	146	20	,	,	,
cord-313227-6zwkfzab	146	21	China	China	NNP
cord-313227-6zwkfzab	146	22	Dexamethasone	Dexamethasone	NNP
cord-313227-6zwkfzab	146	23	treatment	treatment	NN
cord-313227-6zwkfzab	146	24	for	for	IN
cord-313227-6zwkfzab	146	25	the	the	DT
cord-313227-6zwkfzab	146	26	acute	acute	JJ
cord-313227-6zwkfzab	146	27	respiratory	respiratory	JJ
cord-313227-6zwkfzab	146	28	distress	distress	NN
cord-313227-6zwkfzab	146	29	syndrome	syndrome	NN
cord-313227-6zwkfzab	146	30	:	:	:
cord-313227-6zwkfzab	146	31	a	a	DT
cord-313227-6zwkfzab	146	32	multicentre	multicentre	NNP
cord-313227-6zwkfzab	146	33	,	,	,
cord-313227-6zwkfzab	146	34	randomised	randomised	JJ
cord-313227-6zwkfzab	146	35	controlled	control	VBN
cord-313227-6zwkfzab	146	36	trial	trial	NN
cord-313227-6zwkfzab	146	37	Successful	successful	JJ
cord-313227-6zwkfzab	146	38	treatment	treatment	NN
cord-313227-6zwkfzab	146	39	of	of	IN
cord-313227-6zwkfzab	146	40	cytokine	cytokine	NN
cord-313227-6zwkfzab	146	41	release	release	NN
cord-313227-6zwkfzab	146	42	syndrome	syndrome	NN
cord-313227-6zwkfzab	146	43	with	with	IN
cord-313227-6zwkfzab	146	44	IL-6	IL-6	NNP
cord-313227-6zwkfzab	146	45	blockade	blockade	NN
cord-313227-6zwkfzab	146	46	in	in	IN
cord-313227-6zwkfzab	146	47	a	a	DT
cord-313227-6zwkfzab	146	48	patient	patient	NN
cord-313227-6zwkfzab	146	49	transitioning	transition	VBG
cord-313227-6zwkfzab	146	50	from	from	IN
cord-313227-6zwkfzab	146	51	immune	immune	JJ
cord-313227-6zwkfzab	146	52	-	-	HYPH
cord-313227-6zwkfzab	146	53	checkpoint	checkpoint	NN
cord-313227-6zwkfzab	146	54	to	to	IN
cord-313227-6zwkfzab	146	55	MEK	MEK	NNP
cord-313227-6zwkfzab	146	56	/	/	SYM
cord-313227-6zwkfzab	146	57	BRAF	BRAF	NNP
cord-313227-6zwkfzab	146	58	inhibition	inhibition	NN
cord-313227-6zwkfzab	146	59	:	:	:
cord-313227-6zwkfzab	146	60	a	a	DT
cord-313227-6zwkfzab	146	61	case	case	NN
cord-313227-6zwkfzab	146	62	report	report	NN
cord-313227-6zwkfzab	146	63	and	and	CC
cord-313227-6zwkfzab	146	64	review	review	NN
cord-313227-6zwkfzab	146	65	of	of	IN
cord-313227-6zwkfzab	146	66	literature	literature	NN
cord-313227-6zwkfzab	146	67	Advances	advance	NNS
cord-313227-6zwkfzab	146	68	in	in	IN
cord-313227-6zwkfzab	146	69	the	the	DT
cord-313227-6zwkfzab	146	70	research	research	NN
cord-313227-6zwkfzab	146	71	of	of	IN
cord-313227-6zwkfzab	146	72	cytokine	cytokine	NN
cord-313227-6zwkfzab	146	73	storm	storm	NN
cord-313227-6zwkfzab	146	74	mechanism	mechanism	NN
cord-313227-6zwkfzab	146	75	induced	induce	VBN
cord-313227-6zwkfzab	146	76	by	by	IN
cord-313227-6zwkfzab	146	77	Corona	Corona	NNP
cord-313227-6zwkfzab	146	78	Virus	Virus	NNP
cord-313227-6zwkfzab	146	79	Disease	Disease	NNP
cord-313227-6zwkfzab	146	80	Effective	effective	JJ
cord-313227-6zwkfzab	146	81	treatment	treatment	NN
cord-313227-6zwkfzab	146	82	of	of	IN
cord-313227-6zwkfzab	146	83	severe	severe	JJ
cord-313227-6zwkfzab	146	84	COVID-19	covid-19	JJ
cord-313227-6zwkfzab	146	85	patients	patient	NNS
cord-313227-6zwkfzab	146	86	with	with	IN
cord-313227-6zwkfzab	146	87	tocilizumab	tocilizumab	NNP
cord-313227-6zwkfzab	146	88	Tocilizumab	Tocilizumab	NNP
cord-313227-6zwkfzab	146	89	,	,	,
cord-313227-6zwkfzab	146	90	an	an	DT
cord-313227-6zwkfzab	146	91	anti	anti	JJ
cord-313227-6zwkfzab	146	92	-	-	JJ
cord-313227-6zwkfzab	146	93	IL6	il6	JJ
cord-313227-6zwkfzab	146	94	receptor	receptor	NN
cord-313227-6zwkfzab	146	95	antibody	antibody	NN
cord-313227-6zwkfzab	146	96	,	,	,
cord-313227-6zwkfzab	146	97	to	to	TO
cord-313227-6zwkfzab	146	98	treat	treat	VB
cord-313227-6zwkfzab	146	99	Covid-19-related	covid-19-related	JJ
cord-313227-6zwkfzab	146	100	respiratory	respiratory	JJ
cord-313227-6zwkfzab	146	101	failure	failure	NN
cord-313227-6zwkfzab	146	102	:	:	:
cord-313227-6zwkfzab	146	103	a	a	DT
cord-313227-6zwkfzab	146	104	case	case	NN
cord-313227-6zwkfzab	146	105	report	report	NN
cord-313227-6zwkfzab	146	106	Targeting	target	VBG
cord-313227-6zwkfzab	146	107	the	the	DT
cord-313227-6zwkfzab	146	108	inflammatory	inflammatory	JJ
cord-313227-6zwkfzab	146	109	cascade	cascade	NN
cord-313227-6zwkfzab	146	110	with	with	IN
cord-313227-6zwkfzab	146	111	anakinra	anakinra	NNP
cord-313227-6zwkfzab	146	112	in	in	IN
cord-313227-6zwkfzab	146	113	moderate	moderate	JJ
cord-313227-6zwkfzab	146	114	to	to	TO
cord-313227-6zwkfzab	146	115	severe	severe	JJ
cord-313227-6zwkfzab	146	116	COVID-19	COVID-19	NNP
cord-313227-6zwkfzab	146	117	pneumonia	pneumonia	NN
cord-313227-6zwkfzab	146	118	:	:	:
cord-313227-6zwkfzab	146	119	case	case	NNP
cord-313227-6zwkfzab	146	120	series	series	NNP
cord-313227-6zwkfzab	146	121	novel	novel	NN
cord-313227-6zwkfzab	146	122	coronavirus	coronavirus	NN
cord-313227-6zwkfzab	146	123	(	(	-LRB-
cord-313227-6zwkfzab	146	124	COVID-19	covid-19	VB
cord-313227-6zwkfzab	146	125	)	)	-RRB-
cord-313227-6zwkfzab	146	126	with	with	IN
cord-313227-6zwkfzab	146	127	IL-6	IL-6	NNP
cord-313227-6zwkfzab	146	128	inhibitor	inhibitor	NN
cord-313227-6zwkfzab	146	129	:	:	:
cord-313227-6zwkfzab	147	1	are	be	VBP
cord-313227-6zwkfzab	147	2	we	-PRON-	PRP
cord-313227-6zwkfzab	147	3	already	already	RB
cord-313227-6zwkfzab	147	4	that	that	RB
cord-313227-6zwkfzab	147	5	far	far	RB
cord-313227-6zwkfzab	147	6	?	?	.
cord-313227-6zwkfzab	148	1	Anakinra	Anakinra	NNP
cord-313227-6zwkfzab	148	2	for	for	IN
cord-313227-6zwkfzab	148	3	the	the	DT
cord-313227-6zwkfzab	148	4	treatment	treatment	NN
cord-313227-6zwkfzab	148	5	of	of	IN
cord-313227-6zwkfzab	148	6	rheumatoid	rheumatoid	NNP
cord-313227-6zwkfzab	148	7	arthritis	arthritis	NN
cord-313227-6zwkfzab	148	8	:	:	:
cord-313227-6zwkfzab	148	9	a	a	DT
cord-313227-6zwkfzab	148	10	safety	safety	NN
cord-313227-6zwkfzab	148	11	evaluation	evaluation	NN
cord-313227-6zwkfzab	148	12	Emapalumab	Emapalumab	NNP
cord-313227-6zwkfzab	148	13	:	:	:
cord-313227-6zwkfzab	148	14	first	first	JJ
cord-313227-6zwkfzab	148	15	global	global	JJ
cord-313227-6zwkfzab	148	16	approval	approval	NN
cord-313227-6zwkfzab	148	17	Emapalumab	Emapalumab	NNP
cord-313227-6zwkfzab	148	18	in	in	IN
cord-313227-6zwkfzab	148	19	children	child	NNS
cord-313227-6zwkfzab	148	20	with	with	IN
cord-313227-6zwkfzab	148	21	primary	primary	JJ
cord-313227-6zwkfzab	148	22	hemophagocytic	hemophagocytic	JJ
cord-313227-6zwkfzab	148	23	lymphohistiocytosis	lymphohistiocytosis	NN
cord-313227-6zwkfzab	148	24	Occurrence	Occurrence	NNP
cord-313227-6zwkfzab	148	25	of	of	IN
cord-313227-6zwkfzab	148	26	SARS	SARS	NNP
cord-313227-6zwkfzab	148	27	-	-	HYPH
cord-313227-6zwkfzab	148	28	CoV-2	CoV-2	NNP
cord-313227-6zwkfzab	148	29	during	during	IN
cord-313227-6zwkfzab	148	30	mycophenolate	mycophenolate	NNP
cord-313227-6zwkfzab	148	31	mofetil	mofetil	NNP
cord-313227-6zwkfzab	148	32	treatment	treatment	NN
cord-313227-6zwkfzab	148	33	for	for	IN
cord-313227-6zwkfzab	148	34	pemphigus	pemphigus	NNP
cord-313227-6zwkfzab	148	35	Mycophenolic	Mycophenolic	NNP
cord-313227-6zwkfzab	148	36	acid	acid	NN
cord-313227-6zwkfzab	148	37	,	,	,
cord-313227-6zwkfzab	148	38	an	an	DT
cord-313227-6zwkfzab	148	39	immunomodulator	immunomodulator	NN
cord-313227-6zwkfzab	148	40	,	,	,
cord-313227-6zwkfzab	148	41	has	have	VBZ
cord-313227-6zwkfzab	148	42	potent	potent	JJ
cord-313227-6zwkfzab	148	43	and	and	CC
cord-313227-6zwkfzab	148	44	broad	broad	JJ
cord-313227-6zwkfzab	148	45	-	-	HYPH
cord-313227-6zwkfzab	148	46	spectrum	spectrum	NN
cord-313227-6zwkfzab	148	47	in	in	IN
cord-313227-6zwkfzab	148	48	vitro	vitro	FW
cord-313227-6zwkfzab	148	49	antiviral	antiviral	JJ
cord-313227-6zwkfzab	148	50	activity	activity	NN
cord-313227-6zwkfzab	148	51	against	against	IN
cord-313227-6zwkfzab	148	52	pandemic	pandemic	NN
cord-313227-6zwkfzab	148	53	,	,	,
cord-313227-6zwkfzab	148	54	seasonal	seasonal	JJ
cord-313227-6zwkfzab	148	55	and	and	CC
cord-313227-6zwkfzab	148	56	avian	avian	JJ
cord-313227-6zwkfzab	148	57	influenza	influenza	NN
cord-313227-6zwkfzab	148	58	viruses	virus	NNS
cord-313227-6zwkfzab	148	59	affecting	affect	VBG
cord-313227-6zwkfzab	148	60	humans	human	NNS
cord-313227-6zwkfzab	148	61	A	a	DT
cord-313227-6zwkfzab	148	62	single	single	JJ
cord-313227-6zwkfzab	148	63	-	-	HYPH
cord-313227-6zwkfzab	148	64	centre	centre	NN
cord-313227-6zwkfzab	148	65	retrospective	retrospective	JJ
cord-313227-6zwkfzab	148	66	study	study	NN
cord-313227-6zwkfzab	148	67	of	of	IN
cord-313227-6zwkfzab	148	68	the	the	DT
cord-313227-6zwkfzab	148	69	safety	safety	NN
cord-313227-6zwkfzab	148	70	and	and	CC
cord-313227-6zwkfzab	148	71	efficacy	efficacy	NN
cord-313227-6zwkfzab	148	72	of	of	IN
cord-313227-6zwkfzab	148	73	mycophenolate	mycophenolate	NNP
cord-313227-6zwkfzab	148	74	mofetil	mofetil	NNP
cord-313227-6zwkfzab	148	75	in	in	IN
cord-313227-6zwkfzab	148	76	children	child	NNS
cord-313227-6zwkfzab	148	77	and	and	CC
cord-313227-6zwkfzab	148	78	adolescents	adolescent	NNS
cord-313227-6zwkfzab	148	79	with	with	IN
cord-313227-6zwkfzab	148	80	nephrotic	nephrotic	JJ
cord-313227-6zwkfzab	148	81	syndrome	syndrome	NN
cord-313227-6zwkfzab	148	82	T	T	NNP
cord-313227-6zwkfzab	148	83	-	-	HYPH
cord-313227-6zwkfzab	148	84	helper-1-cell	helper-1-cell	NNP
cord-313227-6zwkfzab	148	85	cytokines	cytokine	NNS
cord-313227-6zwkfzab	148	86	drive	drive	VBP
cord-313227-6zwkfzab	148	87	cancer	cancer	NN
cord-313227-6zwkfzab	148	88	into	into	IN
cord-313227-6zwkfzab	148	89	senescence	senescence	NN
cord-313227-6zwkfzab	148	90	Regulation	regulation	NN
cord-313227-6zwkfzab	148	91	of	of	IN
cord-313227-6zwkfzab	148	92	proliferation	proliferation	NN
cord-313227-6zwkfzab	148	93	,	,	,
cord-313227-6zwkfzab	148	94	survival	survival	NN
cord-313227-6zwkfzab	148	95	and	and	CC
cord-313227-6zwkfzab	148	96	apoptosis	apoptosis	NN
cord-313227-6zwkfzab	148	97	by	by	IN
cord-313227-6zwkfzab	148	98	members	member	NNS
cord-313227-6zwkfzab	148	99	of	of	IN
cord-313227-6zwkfzab	148	100	the	the	DT
cord-313227-6zwkfzab	148	101	TNF	TNF	NNP
cord-313227-6zwkfzab	148	102	superfamily	superfamily	NN
cord-313227-6zwkfzab	148	103	Safety	Safety	NNP
cord-313227-6zwkfzab	148	104	and	and	CC
cord-313227-6zwkfzab	148	105	efficacy	efficacy	NN
cord-313227-6zwkfzab	148	106	of	of	IN
cord-313227-6zwkfzab	148	107	tumor	tumor	NN
cord-313227-6zwkfzab	148	108	necrosis	necrosis	NN
cord-313227-6zwkfzab	148	109	factor	factor	NN
cord-313227-6zwkfzab	148	110	antagonists	antagonist	NNS
cord-313227-6zwkfzab	148	111	in	in	IN
cord-313227-6zwkfzab	148	112	older	old	JJR
cord-313227-6zwkfzab	148	113	patients	patient	NNS
cord-313227-6zwkfzab	148	114	with	with	IN
cord-313227-6zwkfzab	148	115	ulcerative	ulcerative	JJ
cord-313227-6zwkfzab	148	116	colitis	colitis	NN
cord-313227-6zwkfzab	148	117	:	:	:
cord-313227-6zwkfzab	148	118	patient	patient	JJ
cord-313227-6zwkfzab	148	119	-	-	HYPH
cord-313227-6zwkfzab	148	120	level	level	NN
cord-313227-6zwkfzab	148	121	pooled	pool	VBN
cord-313227-6zwkfzab	148	122	analysis	analysis	NN
cord-313227-6zwkfzab	148	123	of	of	IN
cord-313227-6zwkfzab	148	124	data	datum	NNS
cord-313227-6zwkfzab	148	125	from	from	IN
cord-313227-6zwkfzab	148	126	randomized	randomized	JJ
cord-313227-6zwkfzab	148	127	trials	trial	NNS
cord-313227-6zwkfzab	148	128	NF	nf	NN
cord-313227-6zwkfzab	148	129	-	-	HYPH
cord-313227-6zwkfzab	148	130	kappaB	kappaB	NNP
cord-313227-6zwkfzab	148	131	and	and	CC
cord-313227-6zwkfzab	148	132	the	the	DT
cord-313227-6zwkfzab	148	133	link	link	NN
cord-313227-6zwkfzab	148	134	between	between	IN
cord-313227-6zwkfzab	148	135	inflammation	inflammation	NN
cord-313227-6zwkfzab	148	136	and	and	CC
cord-313227-6zwkfzab	148	137	cancer	cancer	NN
cord-313227-6zwkfzab	149	1	Early	early	JJ
cord-313227-6zwkfzab	149	2	steps	step	NNS
cord-313227-6zwkfzab	149	3	in	in	IN
cord-313227-6zwkfzab	149	4	herpes	herpes	NN
cord-313227-6zwkfzab	149	5	simplex	simplex	NNP
cord-313227-6zwkfzab	149	6	virus	virus	NN
cord-313227-6zwkfzab	149	7	infection	infection	NN
cord-313227-6zwkfzab	149	8	blocked	block	VBN
cord-313227-6zwkfzab	149	9	by	by	IN
cord-313227-6zwkfzab	149	10	a	a	DT
cord-313227-6zwkfzab	149	11	proteasome	proteasome	VBN
cord-313227-6zwkfzab	149	12	inhibitor	inhibitor	NN
cord-313227-6zwkfzab	150	1	The	the	DT
cord-313227-6zwkfzab	150	2	VR23	VR23	NNP
cord-313227-6zwkfzab	150	3	antitumor	antitumor	NN
cord-313227-6zwkfzab	150	4	compound	compound	NN
cord-313227-6zwkfzab	150	5	also	also	RB
cord-313227-6zwkfzab	150	6	shows	show	VBZ
cord-313227-6zwkfzab	150	7	strong	strong	JJ
cord-313227-6zwkfzab	150	8	anti	anti	JJ
cord-313227-6zwkfzab	150	9	-	-	JJ
cord-313227-6zwkfzab	150	10	inflammatory	inflammatory	JJ
cord-313227-6zwkfzab	150	11	effects	effect	NNS
cord-313227-6zwkfzab	150	12	in	in	IN
cord-313227-6zwkfzab	150	13	a	a	DT
cord-313227-6zwkfzab	150	14	human	human	JJ
cord-313227-6zwkfzab	150	15	rheumatoid	rheumatoid	NN
cord-313227-6zwkfzab	150	16	arthritis	arthritis	NN
cord-313227-6zwkfzab	150	17	cell	cell	NN
cord-313227-6zwkfzab	150	18	model	model	NN
cord-313227-6zwkfzab	150	19	and	and	CC
cord-313227-6zwkfzab	150	20	acute	acute	JJ
cord-313227-6zwkfzab	150	21	lung	lung	NN
cord-313227-6zwkfzab	150	22	inflammation	inflammation	NN
cord-313227-6zwkfzab	150	23	in	in	IN
cord-313227-6zwkfzab	150	24	mice	mouse	NNS
cord-313227-6zwkfzab	151	1	A	a	DT
cord-313227-6zwkfzab	151	2	practical	practical	JJ
cord-313227-6zwkfzab	151	3	review	review	NN
cord-313227-6zwkfzab	151	4	of	of	IN
cord-313227-6zwkfzab	151	5	proteasome	proteasome	VBN
cord-313227-6zwkfzab	151	6	pharmacology	pharmacology	NN
cord-313227-6zwkfzab	151	7	Neurological	Neurological	NNP
cord-313227-6zwkfzab	151	8	monitoring	monitoring	NN
cord-313227-6zwkfzab	151	9	reduces	reduce	VBZ
cord-313227-6zwkfzab	151	10	the	the	DT
cord-313227-6zwkfzab	151	11	incidence	incidence	NN
cord-313227-6zwkfzab	151	12	of	of	IN
cord-313227-6zwkfzab	151	13	bortezomib	bortezomib	NNP
cord-313227-6zwkfzab	151	14	-	-	HYPH
cord-313227-6zwkfzab	151	15	induced	induce	VBN
cord-313227-6zwkfzab	151	16	peripheral	peripheral	JJ
cord-313227-6zwkfzab	151	17	neuropathy	neuropathy	NN
cord-313227-6zwkfzab	151	18	in	in	IN
cord-313227-6zwkfzab	151	19	multiple	multiple	JJ
cord-313227-6zwkfzab	151	20	myeloma	myeloma	NN
cord-313227-6zwkfzab	151	21	patients	patient	NNS
cord-313227-6zwkfzab	151	22	Regulation	Regulation	NNP
cord-313227-6zwkfzab	151	23	of	of	IN
cord-313227-6zwkfzab	151	24	poly(ADP	poly(ADP	NNP
cord-313227-6zwkfzab	151	25	-	-	HYPH
cord-313227-6zwkfzab	151	26	Ribose	Ribose	NNP
cord-313227-6zwkfzab	151	27	)	)	-RRB-
cord-313227-6zwkfzab	151	28	polymerase	polymerase	NN
cord-313227-6zwkfzab	151	29	1	1	CD
cord-313227-6zwkfzab	151	30	functions	function	NNS
cord-313227-6zwkfzab	151	31	by	by	IN
cord-313227-6zwkfzab	151	32	post	post	JJ
cord-313227-6zwkfzab	151	33	-	-	JJ
cord-313227-6zwkfzab	151	34	translational	translational	JJ
cord-313227-6zwkfzab	151	35	modifications	modification	NNS
cord-313227-6zwkfzab	152	1	Interferon	interferon	NN
cord-313227-6zwkfzab	152	2	-	-	HYPH
cord-313227-6zwkfzab	152	3	stimulated	stimulate	VBN
cord-313227-6zwkfzab	152	4	genes	gene	NNS
cord-313227-6zwkfzab	152	5	as	as	IN
cord-313227-6zwkfzab	152	6	enhancers	enhancer	NNS
cord-313227-6zwkfzab	152	7	of	of	IN
cord-313227-6zwkfzab	152	8	antiviral	antiviral	JJ
cord-313227-6zwkfzab	152	9	innate	innate	JJ
cord-313227-6zwkfzab	152	10	immune	immune	NN
cord-313227-6zwkfzab	152	11	signaling	signaling	NN
cord-313227-6zwkfzab	153	1	ADP	ADP	NNP
cord-313227-6zwkfzab	153	2	-	-	HYPH
cord-313227-6zwkfzab	153	3	ribosyltransferase	ribosyltransferase	NNP
cord-313227-6zwkfzab	153	4	PARP11	parp11	NN
cord-313227-6zwkfzab	153	5	modulates	modulate	VBZ
cord-313227-6zwkfzab	153	6	the	the	DT
cord-313227-6zwkfzab	153	7	interferon	interferon	NN
cord-313227-6zwkfzab	153	8	antiviral	antiviral	JJ
cord-313227-6zwkfzab	153	9	response	response	NN
cord-313227-6zwkfzab	153	10	by	by	IN
cord-313227-6zwkfzab	153	11	mono	mono	NN
cord-313227-6zwkfzab	153	12	-	-	HYPH
cord-313227-6zwkfzab	153	13	ADPribosylating	adpribosylate	VBG
cord-313227-6zwkfzab	153	14	the	the	DT
cord-313227-6zwkfzab	153	15	ubiquitin	ubiquitin	JJ
cord-313227-6zwkfzab	153	16	E3	e3	NN
cord-313227-6zwkfzab	153	17	ligase	ligase	NN
cord-313227-6zwkfzab	153	18	beta	beta	NN
cord-313227-6zwkfzab	153	19	-	-	HYPH
cord-313227-6zwkfzab	153	20	TrCP	trcp	NN
cord-313227-6zwkfzab	153	21	Antiviral	antiviral	JJ
cord-313227-6zwkfzab	153	22	activities	activity	NNS
cord-313227-6zwkfzab	153	23	of	of	IN
cord-313227-6zwkfzab	153	24	type	type	NN
cord-313227-6zwkfzab	154	1	I	-PRON-	PRP
cord-313227-6zwkfzab	154	2	interferons	interferon	NNS
cord-313227-6zwkfzab	154	3	to	to	IN
cord-313227-6zwkfzab	154	4	SARS	SARS	NNP
cord-313227-6zwkfzab	154	5	-	-	HYPH
cord-313227-6zwkfzab	154	6	CoV-2	CoV-2	NNP
cord-313227-6zwkfzab	154	7	infection	infection	NN
cord-313227-6zwkfzab	155	1	PARP12	PARP12	NNP
cord-313227-6zwkfzab	155	2	suppresses	suppress	VBZ
cord-313227-6zwkfzab	155	3	Zika	Zika	NNP
cord-313227-6zwkfzab	155	4	virus	virus	NN
cord-313227-6zwkfzab	155	5	infection	infection	NN
cord-313227-6zwkfzab	155	6	through	through	IN
cord-313227-6zwkfzab	155	7	PARP	PARP	NNP
cord-313227-6zwkfzab	155	8	-	-	HYPH
cord-313227-6zwkfzab	155	9	dependent	dependent	JJ
cord-313227-6zwkfzab	155	10	degradation	degradation	NN
cord-313227-6zwkfzab	155	11	of	of	IN
cord-313227-6zwkfzab	155	12	NS1	ns1	NN
cord-313227-6zwkfzab	155	13	and	and	CC
cord-313227-6zwkfzab	155	14	NS3	ns3	RB
cord-313227-6zwkfzab	155	15	viral	viral	JJ
cord-313227-6zwkfzab	155	16	proteins	protein	NNS
cord-313227-6zwkfzab	155	17	Exploring	explore	VBG
cord-313227-6zwkfzab	155	18	and	and	CC
cord-313227-6zwkfzab	155	19	comparing	compare	VBG
cord-313227-6zwkfzab	155	20	adverse	adverse	JJ
cord-313227-6zwkfzab	155	21	events	event	NNS
cord-313227-6zwkfzab	155	22	between	between	IN
cord-313227-6zwkfzab	155	23	PARP	PARP	NNP
cord-313227-6zwkfzab	155	24	inhibitors	inhibitor	NNS
cord-313227-6zwkfzab	156	1	An	an	DT
cord-313227-6zwkfzab	156	2	overview	overview	NN
cord-313227-6zwkfzab	156	3	on	on	IN
cord-313227-6zwkfzab	156	4	medicinal	medicinal	JJ
cord-313227-6zwkfzab	156	5	perspective	perspective	NN
cord-313227-6zwkfzab	156	6	of	of	IN
cord-313227-6zwkfzab	156	7	thiazolidine-2,4-dione	thiazolidine-2,4-dione	NNP
cord-313227-6zwkfzab	156	8	:	:	:
cord-313227-6zwkfzab	156	9	a	a	DT
cord-313227-6zwkfzab	156	10	remarkable	remarkable	JJ
cord-313227-6zwkfzab	156	11	scaffold	scaffold	NN
cord-313227-6zwkfzab	156	12	in	in	IN
cord-313227-6zwkfzab	156	13	the	the	DT
cord-313227-6zwkfzab	156	14	treatment	treatment	NN
cord-313227-6zwkfzab	156	15	of	of	IN
cord-313227-6zwkfzab	156	16	type	type	NN
cord-313227-6zwkfzab	156	17	2	2	CD
cord-313227-6zwkfzab	156	18	diabetes	diabete	VBZ
cord-313227-6zwkfzab	156	19	TNF	tnf	NN
cord-313227-6zwkfzab	156	20	-	-	HYPH
cord-313227-6zwkfzab	156	21	alpha	alpha	NN
cord-313227-6zwkfzab	156	22	and	and	CC
cord-313227-6zwkfzab	156	23	inflammatory	inflammatory	JJ
cord-313227-6zwkfzab	156	24	cytokines	cytokine	NNS
cord-313227-6zwkfzab	156	25	and	and	CC
cord-313227-6zwkfzab	156	26	risk	risk	NN
cord-313227-6zwkfzab	156	27	of	of	IN
cord-313227-6zwkfzab	156	28	type	type	NN
cord-313227-6zwkfzab	156	29	2	2	CD
cord-313227-6zwkfzab	156	30	diabetes	diabetes	NN
cord-313227-6zwkfzab	156	31	:	:	:
cord-313227-6zwkfzab	156	32	a	a	DT
cord-313227-6zwkfzab	156	33	systematic	systematic	JJ
cord-313227-6zwkfzab	156	34	review	review	NN
cord-313227-6zwkfzab	156	35	and	and	CC
cord-313227-6zwkfzab	156	36	meta	meta	NNP
cord-313227-6zwkfzab	156	37	-	-	HYPH
cord-313227-6zwkfzab	156	38	analysis	analysis	NN
cord-313227-6zwkfzab	156	39	Selective	selective	JJ
cord-313227-6zwkfzab	156	40	insulin	insulin	NN
cord-313227-6zwkfzab	156	41	resistance	resistance	NN
cord-313227-6zwkfzab	156	42	and	and	CC
cord-313227-6zwkfzab	156	43	the	the	DT
cord-313227-6zwkfzab	156	44	development	development	NN
cord-313227-6zwkfzab	156	45	of	of	IN
cord-313227-6zwkfzab	156	46	cardiovascular	cardiovascular	JJ
cord-313227-6zwkfzab	156	47	diseases	disease	NNS
cord-313227-6zwkfzab	156	48	in	in	IN
cord-313227-6zwkfzab	156	49	diabetes	diabetes	NN
cord-313227-6zwkfzab	156	50	:	:	:
cord-313227-6zwkfzab	156	51	the	the	DT
cord-313227-6zwkfzab	156	52	2015	2015	CD
cord-313227-6zwkfzab	156	53	edwin	edwin	NNP
cord-313227-6zwkfzab	156	54	bierman	bierman	NNP
cord-313227-6zwkfzab	156	55	award	award	NNP
cord-313227-6zwkfzab	156	56	lecture	lecture	NN
cord-313227-6zwkfzab	156	57	Can	Can	MD
cord-313227-6zwkfzab	156	58	pioglitazone	pioglitazone	NN
cord-313227-6zwkfzab	156	59	be	be	VB
cord-313227-6zwkfzab	156	60	potentially	potentially	RB
cord-313227-6zwkfzab	156	61	useful	useful	JJ
cord-313227-6zwkfzab	156	62	therapeutically	therapeutically	RB
cord-313227-6zwkfzab	156	63	in	in	IN
cord-313227-6zwkfzab	156	64	treating	treat	VBG
cord-313227-6zwkfzab	156	65	patients	patient	NNS
cord-313227-6zwkfzab	156	66	with	with	IN
cord-313227-6zwkfzab	156	67	COVID-19	covid-19	NN
cord-313227-6zwkfzab	156	68	?	?	.
cord-313227-6zwkfzab	157	1	Med	Med	NNP
cord-313227-6zwkfzab	157	2	Hypotheses	Hypotheses	NNP
cord-313227-6zwkfzab	157	3	Pioglitazone	Pioglitazone	NNP
cord-313227-6zwkfzab	157	4	,	,	,
cord-313227-6zwkfzab	157	5	a	a	DT
cord-313227-6zwkfzab	157	6	peroxisome	peroxisome	NN
cord-313227-6zwkfzab	157	7	proliferator	proliferator	NN
cord-313227-6zwkfzab	157	8	-	-	HYPH
cord-313227-6zwkfzab	157	9	activated	activate	VBN
cord-313227-6zwkfzab	157	10	receptor	receptor	NN
cord-313227-6zwkfzab	157	11	gamma	gamma	NN
cord-313227-6zwkfzab	157	12	ligand	ligand	NN
cord-313227-6zwkfzab	157	13	,	,	,
cord-313227-6zwkfzab	157	14	suppresses	suppress	VBZ
cord-313227-6zwkfzab	157	15	bleomycin	bleomycin	NN
cord-313227-6zwkfzab	157	16	-	-	HYPH
cord-313227-6zwkfzab	157	17	induced	induce	VBN
cord-313227-6zwkfzab	157	18	acute	acute	JJ
cord-313227-6zwkfzab	157	19	lung	lung	NN
cord-313227-6zwkfzab	157	20	injury	injury	NN
cord-313227-6zwkfzab	157	21	and	and	CC
cord-313227-6zwkfzab	158	1	fibrosis	fibrosis	NN
cord-313227-6zwkfzab	158	2	CXCR4	CXCR4	NNP
cord-313227-6zwkfzab	158	3	knockdown	knockdown	NN
cord-313227-6zwkfzab	158	4	prevents	prevent	VBZ
cord-313227-6zwkfzab	158	5	inflammatory	inflammatory	JJ
cord-313227-6zwkfzab	158	6	cytokine	cytokine	JJ
cord-313227-6zwkfzab	158	7	expression	expression	NN
cord-313227-6zwkfzab	158	8	in	in	IN
cord-313227-6zwkfzab	158	9	macrophages	macrophage	NNS
cord-313227-6zwkfzab	158	10	by	by	IN
cord-313227-6zwkfzab	158	11	suppressing	suppress	VBG
cord-313227-6zwkfzab	158	12	activation	activation	NN
cord-313227-6zwkfzab	158	13	of	of	IN
cord-313227-6zwkfzab	158	14	MAPK	MAPK	NNP
cord-313227-6zwkfzab	158	15	and	and	CC
cord-313227-6zwkfzab	158	16	NF	NF	NNP
cord-313227-6zwkfzab	158	17	-	-	HYPH
cord-313227-6zwkfzab	158	18	kappaB	kappaB	NNP
cord-313227-6zwkfzab	158	19	signaling	signal	VBG
cord-313227-6zwkfzab	158	20	pathways	pathway	NNS
cord-313227-6zwkfzab	159	1	CXCR4	CXCR4	NNP
cord-313227-6zwkfzab	159	2	inhibitor	inhibitor	NN
cord-313227-6zwkfzab	159	3	attenuates	attenuate	VBZ
cord-313227-6zwkfzab	159	4	ovalbumin	ovalbumin	RB
cord-313227-6zwkfzab	159	5	-	-	HYPH
cord-313227-6zwkfzab	159	6	induced	induce	VBN
cord-313227-6zwkfzab	159	7	airway	airway	JJ
cord-313227-6zwkfzab	159	8	inflammation	inflammation	NN
cord-313227-6zwkfzab	159	9	and	and	CC
cord-313227-6zwkfzab	159	10	hyperresponsiveness	hyperresponsiveness	NN
cord-313227-6zwkfzab	159	11	by	by	IN
cord-313227-6zwkfzab	159	12	inhibiting	inhibit	VBG
cord-313227-6zwkfzab	159	13	Th17	th17	CD
cord-313227-6zwkfzab	159	14	and	and	CC
cord-313227-6zwkfzab	159	15	Tc17	tc17	JJ
cord-313227-6zwkfzab	159	16	cell	cell	NN
cord-313227-6zwkfzab	159	17	immune	immune	NN
cord-313227-6zwkfzab	159	18	response	response	NN
cord-313227-6zwkfzab	159	19	Plerixafor	Plerixafor	NNP
cord-313227-6zwkfzab	159	20	enables	enable	VBZ
cord-313227-6zwkfzab	159	21	safe	safe	JJ
cord-313227-6zwkfzab	159	22	,	,	,
cord-313227-6zwkfzab	159	23	rapid	rapid	JJ
cord-313227-6zwkfzab	159	24	,	,	,
cord-313227-6zwkfzab	159	25	efficient	efficient	JJ
cord-313227-6zwkfzab	159	26	mobilization	mobilization	NN
cord-313227-6zwkfzab	159	27	of	of	IN
cord-313227-6zwkfzab	159	28	hematopoietic	hematopoietic	JJ
cord-313227-6zwkfzab	159	29	stem	stem	NN
cord-313227-6zwkfzab	159	30	cells	cell	NNS
cord-313227-6zwkfzab	159	31	in	in	IN
cord-313227-6zwkfzab	159	32	sickle	sickle	NN
cord-313227-6zwkfzab	159	33	cell	cell	NN
cord-313227-6zwkfzab	159	34	disease	disease	NN
cord-313227-6zwkfzab	159	35	patients	patient	NNS
cord-313227-6zwkfzab	159	36	after	after	IN
cord-313227-6zwkfzab	159	37	exchange	exchange	NN
cord-313227-6zwkfzab	159	38	transfusion	transfusion	NN
cord-313227-6zwkfzab	159	39	Dissecting	dissect	VBG
cord-313227-6zwkfzab	159	40	influenza	influenza	NN
cord-313227-6zwkfzab	159	41	virus	virus	NN
cord-313227-6zwkfzab	159	42	pathogenesis	pathogenesis	NN
cord-313227-6zwkfzab	159	43	uncovers	uncover	VBZ
cord-313227-6zwkfzab	159	44	a	a	DT
cord-313227-6zwkfzab	159	45	novel	novel	JJ
cord-313227-6zwkfzab	159	46	chemical	chemical	NN
cord-313227-6zwkfzab	159	47	approach	approach	NN
cord-313227-6zwkfzab	159	48	to	to	TO
cord-313227-6zwkfzab	159	49	combat	combat	VB
cord-313227-6zwkfzab	159	50	the	the	DT
cord-313227-6zwkfzab	159	51	infection	infection	NN
cord-313227-6zwkfzab	159	52	COVID-19	covid-19	CD
cord-313227-6zwkfzab	159	53	infection	infection	NN
cord-313227-6zwkfzab	159	54	in	in	IN
cord-313227-6zwkfzab	159	55	a	a	DT
cord-313227-6zwkfzab	159	56	patient	patient	NN
cord-313227-6zwkfzab	159	57	with	with	IN
cord-313227-6zwkfzab	159	58	multiple	multiple	JJ
cord-313227-6zwkfzab	159	59	sclerosis	sclerosis	NN
cord-313227-6zwkfzab	159	60	treated	treat	VBN
cord-313227-6zwkfzab	159	61	with	with	IN
cord-313227-6zwkfzab	159	62	fingolimod	fingolimod	NNP
cord-313227-6zwkfzab	159	63	Benefitrisk	Benefitrisk	NNP
cord-313227-6zwkfzab	159	64	profile	profile	NN
cord-313227-6zwkfzab	159	65	of	of	IN
cord-313227-6zwkfzab	159	66	sphingosine-1-phosphate	sphingosine-1-phosphate	JJ
cord-313227-6zwkfzab	159	67	receptor	receptor	NN
cord-313227-6zwkfzab	159	68	modulators	modulator	NNS
cord-313227-6zwkfzab	159	69	in	in	IN
cord-313227-6zwkfzab	159	70	relapsing	relapse	VBG
cord-313227-6zwkfzab	159	71	and	and	CC
cord-313227-6zwkfzab	159	72	secondary	secondary	JJ
cord-313227-6zwkfzab	159	73	progressive	progressive	JJ
cord-313227-6zwkfzab	159	74	multiple	multiple	JJ
cord-313227-6zwkfzab	159	75	sclerosis	sclerosis	NN
cord-313227-6zwkfzab	160	1	The	the	DT
cord-313227-6zwkfzab	160	2	authors	author	NNS
cord-313227-6zwkfzab	160	3	declare	declare	VBP
cord-313227-6zwkfzab	160	4	that	that	IN
cord-313227-6zwkfzab	160	5	the	the	DT
cord-313227-6zwkfzab	160	6	research	research	NN
cord-313227-6zwkfzab	160	7	was	be	VBD
cord-313227-6zwkfzab	160	8	conducted	conduct	VBN
cord-313227-6zwkfzab	160	9	in	in	IN
cord-313227-6zwkfzab	160	10	the	the	DT
cord-313227-6zwkfzab	160	11	absence	absence	NN
cord-313227-6zwkfzab	160	12	of	of	IN
cord-313227-6zwkfzab	160	13	any	any	DT
cord-313227-6zwkfzab	160	14	commercial	commercial	JJ
cord-313227-6zwkfzab	160	15	or	or	CC
cord-313227-6zwkfzab	160	16	financial	financial	JJ
cord-313227-6zwkfzab	160	17	relationships	relationship	NNS
cord-313227-6zwkfzab	160	18	that	that	WDT
cord-313227-6zwkfzab	160	19	could	could	MD
cord-313227-6zwkfzab	160	20	be	be	VB
cord-313227-6zwkfzab	160	21	construed	construe	VBN
cord-313227-6zwkfzab	160	22	as	as	IN
cord-313227-6zwkfzab	160	23	a	a	DT
cord-313227-6zwkfzab	160	24	potential	potential	JJ
cord-313227-6zwkfzab	160	25	conflict	conflict	NN
cord-313227-6zwkfzab	160	26	of	of	IN
cord-313227-6zwkfzab	160	27	interest	interest	NN
cord-313227-6zwkfzab	160	28	.	.	.
cord-313227-6zwkfzab	161	1	Copyright	copyright	NN
cord-313227-6zwkfzab	161	2	©	©	NNP
cord-313227-6zwkfzab	161	3	2020	2020	CD
cord-313227-6zwkfzab	161	4	Scala	Scala	NNP
cord-313227-6zwkfzab	161	5	and	and	CC
cord-313227-6zwkfzab	161	6	Pacelli	Pacelli	NNP
cord-313227-6zwkfzab	161	7	.	.	.
cord-313227-6zwkfzab	162	1	This	this	DT
cord-313227-6zwkfzab	162	2	is	be	VBZ
cord-313227-6zwkfzab	162	3	an	an	DT
cord-313227-6zwkfzab	162	4	open	open	JJ
cord-313227-6zwkfzab	162	5	-	-	HYPH
cord-313227-6zwkfzab	162	6	access	access	NN
cord-313227-6zwkfzab	162	7	article	article	NN
cord-313227-6zwkfzab	162	8	distributed	distribute	VBN
cord-313227-6zwkfzab	162	9	under	under	IN
cord-313227-6zwkfzab	162	10	the	the	DT
cord-313227-6zwkfzab	162	11	terms	term	NNS
cord-313227-6zwkfzab	162	12	of	of	IN
cord-313227-6zwkfzab	162	13	the	the	DT
cord-313227-6zwkfzab	162	14	Creative	Creative	NNP
cord-313227-6zwkfzab	162	15	Commons	Commons	NNP
cord-313227-6zwkfzab	162	16	Attribution	Attribution	NNP
cord-313227-6zwkfzab	162	17	License	License	NNP
cord-313227-6zwkfzab	162	18	(	(	-LRB-
cord-313227-6zwkfzab	162	19	CC	CC	NNP
cord-313227-6zwkfzab	162	20	BY	BY	NNP
cord-313227-6zwkfzab	162	21	)	)	-RRB-
cord-313227-6zwkfzab	162	22	.	.	.
cord-313227-6zwkfzab	163	1	The	the	DT
cord-313227-6zwkfzab	163	2	use	use	NN
cord-313227-6zwkfzab	163	3	,	,	,
cord-313227-6zwkfzab	163	4	distribution	distribution	NN
cord-313227-6zwkfzab	163	5	or	or	CC
cord-313227-6zwkfzab	163	6	reproduction	reproduction	NN
cord-313227-6zwkfzab	163	7	in	in	IN
cord-313227-6zwkfzab	163	8	other	other	JJ
cord-313227-6zwkfzab	163	9	forums	forum	NNS
cord-313227-6zwkfzab	163	10	is	be	VBZ
cord-313227-6zwkfzab	163	11	permitted	permit	VBN
cord-313227-6zwkfzab	163	12	,	,	,
cord-313227-6zwkfzab	163	13	provided	provide	VBD
cord-313227-6zwkfzab	163	14	the	the	DT
cord-313227-6zwkfzab	163	15	original	original	JJ
cord-313227-6zwkfzab	163	16	author(s	author(s	NNP
cord-313227-6zwkfzab	163	17	)	)	-RRB-
cord-313227-6zwkfzab	163	18	and	and	CC
cord-313227-6zwkfzab	163	19	the	the	DT
cord-313227-6zwkfzab	163	20	copyright	copyright	NN
cord-313227-6zwkfzab	163	21	owner(s	owner(s	NNP
cord-313227-6zwkfzab	163	22	)	)	-RRB-
cord-313227-6zwkfzab	163	23	are	be	VBP
cord-313227-6zwkfzab	163	24	credited	credit	VBN
cord-313227-6zwkfzab	163	25	and	and	CC
cord-313227-6zwkfzab	163	26	that	that	IN
cord-313227-6zwkfzab	163	27	the	the	DT
cord-313227-6zwkfzab	163	28	original	original	JJ
cord-313227-6zwkfzab	163	29	publication	publication	NN
cord-313227-6zwkfzab	163	30	in	in	IN
cord-313227-6zwkfzab	163	31	this	this	DT
cord-313227-6zwkfzab	163	32	journal	journal	NN
cord-313227-6zwkfzab	163	33	is	be	VBZ
cord-313227-6zwkfzab	163	34	cited	cite	VBN
cord-313227-6zwkfzab	163	35	,	,	,
cord-313227-6zwkfzab	163	36	in	in	IN
cord-313227-6zwkfzab	163	37	accordance	accordance	NN
cord-313227-6zwkfzab	163	38	with	with	IN
cord-313227-6zwkfzab	163	39	accepted	accepted	JJ
cord-313227-6zwkfzab	163	40	academic	academic	JJ
cord-313227-6zwkfzab	163	41	practice	practice	NN
cord-313227-6zwkfzab	163	42	.	.	.
cord-313227-6zwkfzab	164	1	No	no	DT
cord-313227-6zwkfzab	164	2	use	use	NN
cord-313227-6zwkfzab	164	3	,	,	,
cord-313227-6zwkfzab	164	4	distribution	distribution	NN
cord-313227-6zwkfzab	164	5	or	or	CC
cord-313227-6zwkfzab	164	6	reproduction	reproduction	NN
cord-313227-6zwkfzab	164	7	is	be	VBZ
cord-313227-6zwkfzab	164	8	permitted	permit	VBN
cord-313227-6zwkfzab	164	9	which	which	WDT
cord-313227-6zwkfzab	164	10	does	do	VBZ
cord-313227-6zwkfzab	164	11	not	not	RB
cord-313227-6zwkfzab	164	12	comply	comply	VB
cord-313227-6zwkfzab	164	13	with	with	IN
cord-313227-6zwkfzab	164	14	these	these	DT
cord-313227-6zwkfzab	164	15	terms	term	NNS
cord-313227-6zwkfzab	164	16	.	.	.